5month DHIS

01.
2 - Reproductive and Maternal Health | Hospital, Health center, Clinic | Monthly (Hamle 2014)
S.No Activity
RMH Reproductive and Maternal Health

MAT_CAR Total number of new and repeat acceptors by age
MAT_CAR_A
Contraceptive new acceptors by age
MAT_CAR_Ag
10 - 14 years
MAT_CAR_Ag
15 - 19 years
MAT_CAR_Ag
20 - 24 years
MAT_CAR_Ag
25 - 29 years
MAT_CAR_Ag
30 - 49 years
MAT_CAR_A
Contraceptive repeat acceptors by age
MAT_CAR_Ag
10 - 14 years
MAT_CAR_Ag
15 - 19 years
MAT_CAR_Ag
20 - 24 years
MAT_CAR_Ag
25 - 29 years
MAT_CAR_Ag
30 - 49 years
MAT_CAR_M
Total new and repeat acceptors, disaggregated by method
MAT_CAR_M
Contraceptive new acceptors by method
MAT_CAR_Mt
Oral contraceptives
MAT_CAR_Mt
Injectables
MAT_CAR_Mt
Implants
MAT_CAR_Mt
IUCD
MAT_CAR_Mt
Vasectomy
MAT_CAR_Mt
Tubal ligation
MAT_CAR_Mt
Others
MAT_CAR_M
Contraceptive repeat acceptors by method
MAT_CAR_Mt
Oral contraceptives
MAT_CAR_Mt
Injectables
MAT_CAR_Mt
Implants
MAT_CAR_Mt
IUCD
MAT_CAR_Mt
Vasectomy
MAT_CAR_Mt
Tubal ligation
MAT_CAR_Mt
Others
RMH_FP_IPImmediate Postpartum Contraceptive Acceptance (IPPFP)

MAT_IPPCATotal PPFP 聽acceptors,聽disaggregated by age
MAT_IPPCAR
10 - 14 years
MAT_IPPCAR
15 - 19 years
MAT_IPPCAR
20 - 24 years
MAT_IPPCAR
25 - 29 years
MAT_IPPCAR
30 - 49 years
RMH_FP_L Premature Removal of Long term family planning methods (PRLAFP)

MAT_LAFPPTotal number of premature removal of LAFP within 6 month insertion
MAT_LAFPPR
Implants
MAT_LAFPPR
IUCD
MAT_LAFPPR
Others
MAT_TLAFPTotal LAFP removal in the reporting period
MAT_ANC1 Antenatal Care (ANC) coverage 鈥

MAT_ANC1_Total Number of pregnant women that received antenatal care 鈥
MAT_ANC1_G
<= 12 weeks
MAT_ANC1_G
> 12 and <=16 weeks
MAT_ANC1_G
> 16 weeks
MAT_ANC1_Number of pregnant women that received antenatal care 鈥
MAT_ANC1_M
10 - 14 years
MAT_ANC1_M
15 - 19 years
MAT_ANC1_M
>= 20 years
MAT_ANC4 Antenatal care (ANC) coverage 鈥

MAT_ANC4+Total number of pregnant women that received four or more antenatal care contacts by Maternal Age
MAT_ANC4+_
10 - 14 years
MAT_ANC4+_
15 - 19 years
MAT_ANC4+_
>= 20 years
MAT_ANC4+Total number of pregnant women that received four or more antenatal care contacts by gestational week
MAT_ANC4+_
<= 30 weeks
MAT_ANC4+_
> 30 weeks
MAT_ANC8 Antenatal Care (ANC) coverage 鈥

MAT_ANC8+Number of pregnant women that received antenatal care 鈥
RMH_ANC_Pregnant women attending antenatal care tested for syphilis

MAT_SYPH.Total Number of pregnant women tested for syphilis
MAT_SYPH.1
Reactive
MAT_SYPH.1
Non-Reactive
MAT_SYPH.R
Total Number of pregnant women treated for syphilis
MAT_Hepa Total Number of Pregnant women attending antenatal care tested for hepatitis B
MAT_Hepa. Reactive
MAT_Hepa. Non-Reactive
MAT_Prp.1. Total Number of pregnant women who were received prophylaxis for HBV
RMH_L&D_ Births attended by skilled health personnel

L&D_SBA.1.Total number of births attended by skilled health personnel
MAT_PPH.1Total number of women who developed postpartum hemorrhage (PPH)
MAT_PPH.1.Home delivery
MAT_PPH.1.Facility delivery
MAT_UTER Percentage women who received uterotonics in the first one minute after delivery
MAT_UTER.Total number of women who received uterotonics in the first one minute after delivery
MAT_UTER.1
oxytocin
MAT_UTER.1
mesoprostol
MAT_UTER.1
ergometrin
MAT_UTER.1
Other uterotonics
MAT_SBR Still birth rate
MAT_SBR.SNumber of still births
MAT_SBR.LB
Number of Live births
B&D_Ntfc
MAT_B&D_IB
Number of Institutional birth notifications given
MAT_B&D_ID
Number of Institutional death notifications given
MAT_EPNC.Early postnatal care coverage

MAT_EPNC.Number of postnatal visits within 7 days of delivery
MAT_EPNC.1
24Hrs (1day)
MAT_EPNC.1
25 - 48 hrs (1 - 2 days)
MAT_EPNC.1
49 - 72 hrs (2 - 3 days)
MAT_EPNC.1
73 hrs - 7 days (4 - 7 days)
RMH_L&D_ Caesarean section

MAT_CS.1. Number of women having given birth by caesarean section
MAT_CAC Number of women receiving comprehensive abortion care services dis aggregated by maternal age
MAT_CAC_ Number of safe abortions performed
MAT_CAC_S10 - 14 years
MAT_CAC_S>= 30 years
MAT_CAC_ Number of post abortion/emergency care
MAT_CAC_P10 - 14 years
MAT_CAC_P>= 30 years
MAT_CAC.Tr
Number of women receiving comprehensive abortion care disaggregated by trimester
MAT_CAC.Tr.
First trimester(<12 Weeks)
Second Trimester (鈮
MAT_CAC.Tr.
MAT_CAC.MNumber of women receiving post abortion care family planning methods disaggregated by Methods
MAT_CAC.MA
Oral contraceptives
MAT_CAC.MA
Injectables
MAT_CAC.MA
Implants
MAT_CAC.MA
IUCD
MAT_CAC.MA
Vasectomy
MAT_CAC.MA
Tubal ligation
MAT_CAC.MA
Others
MAT_OFC_INumber of obstetric fistula cases identified by Age
MAT_OFC_Id
10 - 14 years
MAT_OFC_Id
15 - 19 years
MAT_OFC_Id
20 - 24 years
MAT_OFC_Id
25 - 29 years
MAT_OFC_Id
>= 30 years
MAT_OFC_TNumber of obstetric fistula cases treated by Age
MAT_OFC_Tr
10 - 14 years
MAT_OFC_Tr
15 - 19 years
MAT_OFC_Tr
20 - 24 years
MAT_OFC_Tr
25 - 29 years
MAT_OFC_Tr
>= 30 years
MAT_IMD Proportion of maternal death(institutional)

MAT_IMD.1.Number of maternal deaths in health facility
MAT_TngP_Total number of teenage girls tested positive for pregnancy
MAT_TngP_T
10 - 14 years
MAT_TngP_T
15 - 19 years
MAT_Tngtst.Total number of women tested positive for pregnancy
02 - PMTCT | Hospital, Health center, Clinic | Monthly (Hamle 2014)
S.No Activity
RMCH__PMT
Does health facility provide Monthly PMTCT service?
MTCT PMTCT
MTCT_TST Pregnant and lactating women who were tested for HIV and know their results
MTCT_TST.1
Number of Pregnant women tested and know their HIV result during pregnancy
03 - EPI | Hospital, Health center, Health post, Clinic | Monthly (Hamle 2014)
S.No Activity
EPI Expanded Program on Immunization (EPI)
EPI_HepBDNumber of Live births who receive a HepB-Birth dose(BD)
EPI_HepBD.Within 24 hours after birth
EPI_HepBD.Within 24 to 14 days after birth
EPI_BCG1. Number of children under one year of age who have received BCG vaccine
EPI_DPT1.1.Number of children under one year of age who have received first dose of pentavalent vaccine
EPI_DPT3.1.Number of children under one year of age who have received third dose of pentavalent vaccine
EPI_OPV1.1Number of children under one year of age who have received first dose of polio vaccine
EPI_OPV3.1Number of children under one year of age who have received third dose of Polio vaccine
EPI_PCV1.1Number of children under one year of age who have received first dose of pneumococcal vaccine
EPI_PCV3.1Number of children under one year of age who have received third dose of pneumococcal vaccine
EPI_IPV.1. Number of children under one year of age who have received one dose of inactivated polio vaccine
EPI_Rota1.1Number of children under one year of age who have received first dose of Rotavirus vaccine
EPI_Rota2.1Number of children under one year of age who have received 2nd dose of Rotavirus vaccine
EPI_MCV1.1Number of children under one year of age who have received first dose of measles vaccine
EPI_FI.1. Number of children received all vaccine doses before 1st birthday
EPI_MCV2 Measles dose coverage
EPI_MCV2.1Number of children (15-23 ) months of age who have received second dose of measles vaccine
EPI_PAB Proportion of under one children protected against Neonatal Tetanus(PAB)
EPI_PAB.1. Number of infants whose mothers had protective doses of TD against NNT (PAB)
EPI_HPV1 HPV 1 (Human Papilloma Virus vaccine (1st dose) Immunization coverage (14 years old girls)
EPI_HPV1.1Number of girls 14 year of age who have received first dose of human papilloma virus vaccine
EPI_HPV2 HPV 2 (Human Papilloma Virus vaccine (2nd dose) Immunization coverage (14 years old girls)
EPI_HPV2.1Number of girls 14 years of age who have received second dose of human papillomavirus vaccine in 6 month interval from the fir
EPI_TD TD Vaccination
EPI_TD1.1. women who have received TD1 vaccination
EPI_VWR Vaccine wastage rate
HepatitisB -Birth dose(BD) wastage rate
EPI_VWR_Hep
HepB-Birth doses given (all ages)
EPI_VWR_Hep
HepB-Birth doses opened
EPI_VWR_He
HepB-Birth doses damaged
EPI_VWR_Hep
HepB-Birth doses expired
BCG Vaccine wastage rate
EPI_VWR_BC
BCG doses given (all ages)
EPI_VWR_BBCG doses opened
EPI_VWR_BBCG doses damaged
EPI_VWR_BC
BCG doses expired
Penta Vaccine wastage rate
EPI_VWR_Pe
Pentavalent (DPT-HepB-Hib) doses given (all ages)
EPI_VWR_Pe
Pentavalent (DPT-HepB-Hib) doses opened
EPI_VWR_Pe
Pentavalent (DPT-HepB-Hib) doses damaged
EPI_VWR_Pe
Pentavalent (DPT-HepB-Hib) doses expired
PCV Vaccine wastage rate
EPI_VWR_PC
Pneumococcal conjugated vaccine doses given
EPI_VWR_PPneumococcal conjugated vaccine doses opened
EPI_VWR_PPneumococcal conjugated vaccine doses damaged
EPI_VWR_PC
Pneumococcal conjugated vaccine doses expired
Rota Vaccine wastage rate
EPI_VWR_RT
Rota doses give (all ages)
EPI_VWR_RT
Rota doses opened
EPI_VWR_RRota doses damaged
EPI_VWR_RT
Rota doses expired
Polio Vaccine wastage rate
EPI_VWR_PV
Polio doses given (all ages)
EPI_VWR_PPolio doses opened
EPI_VWR_PPolio doses damaged
EPI_VWR_PV
Polio doses expired
Measles Vaccine wastage rate
EPI_VWR_MC
Measles doses given (all ages)
EPI_VWR_MMeasles doses opened
EPI_VWR_MMeasles doses damaged
EPI_VWR_MC
Measles doses expired
TD Vaccine wastage rate
EPI_VWR_TD
TD doses given (all ages)
EPI_VWR_TTD doses opened
EPI_VWR_TTD doses damaged
EPI_VWR_TD
TD doses expired
IPV Vaccine wastage rate
EPI_VWR_IPIPV doses given
EPI_VWR_IPIPV doses opened
04.2 - Neonatal and Child Health | Health center, Hospital and clinic | Monthly (Hamle 2014)
S.No Activity
CH Child Health
CH_IND Institutional neonatal death
CH_IND. 1 Number of neonatal deaths in the first 24 hrs of life
CH_IND. 2 Number of neonatal deaths between 1 -7 days of life
CH_TX_PNEUnder-five children with pneumonia received antibiotic treatment
CH_TX_PNENumber of under 5 children treated for pneumonia
CH_TX_SYI.Number of sick young infants 0-2 months treated for Critical illness
CH_TX_SYI.1
Treated for Very Severe Diseases
CH_TX_SYI.1
Treated for Local bacterial infection ( LBI)
CH_TX_SYI.1
Treated for Pneumonia
CH_TX_DIAChildren treated with Zinc and ORS for diarrhea
CH_TX_DIAR
Treated by ORS and zinc
CH_TX_DIAR
Treated by ORS only
CH_KMC Low birth weight or premature newborns for whom KMC was initiated after delivery
CH_KMC.1. Total number of newborns weighing <2000gm and/or premature newborns for which KMC initiated
CH_KMC.2. Total number of newborns weighing <2000gm and/or premature
CH_ASPH Asphyxiated neonates who were resuscitated (with bag & mask) and survived
CH_ASPH.1.Number of neonates resuscitated and survived
CH_ASPH.2.Total number of neonates resuscitated
Does the facility provides NICU Service?
CH_TX_NICTreatment outcome of neonates admitted to NICU
CH_TX_NICTotal neonates admitted to NICU
CH_TX_NICTotal neonates discharged from NICU
CH_TX_NICU
Recovered
CH_TX_NICU
Dead
CH_TX_NICU
Transferred
CH_TX_NICU
Others( Absconded, Left against medical advice…….)
CH_CHX Newborns that received at least one dose of CHX to the cord on the first day after birth
CH_CHX.1. Number of Newborns that received at least one dose of CHX to the cord on the first day after birth
CH_CHDM Children aged 0 to 59 months Assessed for developmental milestone
CH_CHDM. 0 to 24 months
CH_CHDMSChildren aged 0 to 59 months Assessed for developmental milestone and there status
CH_CHDMS.Suspected Developmental Delay
CH_CHDMS.Developmental Delay
CH_CHDMS.No Developmental Delay
05.2 - Nutrition | Hospital, Health center | Monthly (Hamle 2014)
S.No Activity
NUT Nutrition
NUT_LBW Percentage of live births that weigh less than 2,500gm out of the total live births weighed
NUT_GMP. Number of live-born babies with birth weight less than 2,500 gm
NUT_LBW.2.Total number of live births weighed
NUT_GMP Proportion of < 2 year children who have participated in growth monitoring and promotion (GMP)
NTR_GMP.1Number of children less than 2 yr weighted during GMP session
NTR_GMP.1.0 - 5 months
NTR_GMP.1.6 - 23 months
NUT_GMP.MNumber of weights recorded with moderate malnutrition, by age (Z-score between -2 and -3)
NUT_GMP.MM
0 - 5 months
NUT_GMP.MM
6 - 23 months
NUT_GMP_ Number of weights recorded with severe malnutrition, by age (Z-score below (-3)
NUT_GMP_S
0 - 5 months
NUT_GMP_S
6 - 23 months
NCH_NTR_ Children aged 6-59 months who received vitamin A supplementation
NUT_VITA Total number of children aged 6-59 months who received Vitamin A supplementation dis aggregated by a
NUT_VITA. 6 - 11 months
NUT_VITA.2Total number of children aged 6-59 months who received Vitamin A supplementation dis aggregated by d
NUT_VITA.2.First dose
NUT_VITA.2.Second dose
NUT_DeW Proportion of children 24-59 months de-wormed
NUT_DeW.1Total number of children aged 24 - 59 months dewormed
NUT_DeW.1.First dose
NUT_DeW.1.Second dose
NUT_DeW.2Number of pregnant women De-wormed
NUT_IFA Proportion of pregnant women received iron and folic acid (IFA) supplements at least 90 plus
NUT_IFA.1 Total number of Pregnant women received IFA at least 90 plus
NUT_IFA.1. 10 - 14 years
NUT_IFA.1. >= 20 years
NUT_PreSMProportion of Pregnant and lactating women (PLW) screened for malnutrition
NUT_PreSMTotal number of PLW screened for acute malnutrition by MUAC status
NUT_PreSMN
MUAC < 23 cm
NUT_PreSMN
MUAC >= 23 cm
NUT_PreSMTotal number of PLW screened for acute malnutrition By maternal status:
NUT_PreSMN
Pregnant
NUT_PreSMN
lactating
NUT_U5SM Children aged <5 yrs screened for acute malnutrition
NUT_U5SM Total Number of children < 5 yr screened for acute malnutrition
NUT_U5SMN
0 - 5 months
NUT_U5SMN
6 - 23 months
NUT_U5SMN
24 - 59 Months
NUT_U5SMN
Number of <5yr children screened and have moderate acute malnutrition
NUT_U5SMN
0 - 5 months
NUT_U5SMN
6 - 23 months
NUT_U5SMN
24 - 59 Months
NUT_U5SMN
Number of <5yr children screened and have severe acute malnutrition
NUT_U5SMN.
0 - 5 months
NUT_U5SMN.
6 - 23 months
NUT_U5SMN.
24 - 59 Months
NUT_TX-U5Admission and treatment outcome for management of severe acute malnutrition in children under 5 yrs fo
NUT_TX-U5Total SAM at the beginning of the month
NUT_TX-U50 - 5 months
NUT_TX-U524 - 59 Months
NUT_TX-U5Total number of children with SAM admitted to SC during the reporting period(new and re-admision)
NUT_TX-U5Number of children stablized
NUT_TX-U5M
0 - 5 months
NUT_TX-U5M
6 - 23 months
NUT_TX-U5M
24 - 59 Months
NUT_TX-U5Number of children cured
NUT_TX-U5M
0 - 5 months
NUT_TX-U5M
6 - 23 months
NUT_TX-U5M
24 - 59 Months
NUT_TX-U5Number of children died
NUT_TX-U5M
0 - 5 months
NUT_TX-U5M
6 - 23 months
NUT_TX-U5M
24 - 59 Months
NUT_TX-U5Number of children transferred out
NUT_TX-U5Number of children defaulted
NUT_TX-U5Number of children -non-respondent
NUT_TX-U5Number of children Medical transfer
NUT_TX-U5Number of children unknown status
NUT_TX-U5Number of children who exit from severe acute malnutrition treatment during the reporting period by age(SC)
NUT_TX-U5M
0 - 5 months
NUT_TX-U5M
6 - 23 months
NUT_TX-U5M
24 - 59 Months
NUT_TX-U5Admission and treatment outcome for management of severe acute malnutrition in children under 6-59 M
NUT_TX-U5Total SAM at the beginning of the month for OTP
NUT_TX-U5OTP_Number of children stabilized
NUT_TX-U5OTP_Number of children cured
NUT_TX-U5OTP_Number of children died
NUT_TX-U5OTP_Number of children transferred out
NUT_TX-U5OTP_Number of children defaulted
NUT_TX-U5OTP_Number of children -non-respondent
NUT_TX-U5OTP_Number of children Medical transfer
NUT_TX-U5OTP_Number of children unknown status
NUT_TX-U5Total number of children with SAM admitted to OTP during the reporting period
NUT_TX-U5Number of children who exit from severe acute malnutrition treatment during the reporting period(OTP)
NUT_TX-U5Admission and treatment outcome for management of MAM for childern 6-59 months
NUT_TX-U5Total MAM at the beginning of the month
NUT_TX-U5Total number of children with MAM admitted to OTP during the reporting period
NUT_TX-U5MAM_Number of children stabilized
NUT_TX-U5MAM_Number of children cured
NUT_TX-U5MAM_Number of children died
NUT_TX-U5MAM_Number of children transferred out
NUT_TX-U5MAM_Number of children defaulted
NUT_TX-U5M
MAM_Number of children -non-respondent
NUT_TX-U5MAM_Number of children Medical transfer
NUT_TX-U5MAM_Number of children unknown status
NUT_TX-U5Number of children who exit from MAM treatment during the reporting period
NUT_Adl&YAdolescent and Youth Nutrition Service
NUT_Adl&Yo
Total number of Adolescent girls Aged 14-19 years screened for malnutrition
NUT_Adl&YAdolescent and Youth Aged 10-19 screened for nutrition-Normal
NUT_Adl&Yo10 - 14 years, Male
NUT_Adl&Yo10 - 14 years, Female
NUT_Adl&YAdolescent and Youth Aged 10-19 screened for nutrition-underweight
NUT_Adl&YAdolescent and Youth Aged 10-19 screened for nutrition-overweight
06 - HIV | Hospital, Health center, Clinic | Monthly (Hamle 2014)
S.No Activity
HIV HIV Prevention and Control
HIV_HTS_T Clients receiving HIV test results (at VCT)
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
10 - 14 years, Female
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_T Clients testing positive for HIV (at VCT)
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_T Clients receiving HIV test results (at PITC)
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TS
Clients testing positive for HIV (at PITC)
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HCT_PHCT by population group
HIV_HTS_T HIV testing service - HTS who received result by population group
HIV_HTS_T HIV testing service - HTS who tested positive by population group
HIV_TST_PO
Female comercial Sex workers : Received result
HIV_HTS_TS
Female comercial Sex workers :Positive
HIV_HTS_TS
Long distance drivers: Received result
HIV_HTS_TS
Long distance drivers :Positive
HIV_HTS_TS
Mobile/Daily Laborers: Received result
HIV_HTS_TS
Mobile/Daily Laborers: Positive
HIV_HTS_TS
OVC of PLHIV :Received result
HIV_HTS_TS
OVC of PLHIV: Positive
HIV_HTS_TS
Children of PLHIV: Received result
HIV_HTS_TS
Children of PLHIV: Positive
HIV_HTS_TS
Prisoners :Received result
HIV_HTS_TS
Prisoners : Positive
HIV_HTS_TS
Partners of PLHIV: Received result
HIV_HTS_TS
Partners of PLHIV: Positive
HIV_HTS_TS
Other MARPs:Received result
HIV_HTS_TS
Other MARPs: Positive
HIV_HTS_TS
General population: Received result
HIV_HTS_TS
General population: Positive
HIV_HTS_T Number of individuals who were identified and tested using Index testing services and received their resul
HIV_HTS_T Number of index cases offered
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TS
Number of contacts elicited
HIV_HTS_TS
< 15 years, Male
HIV_HTS_TS
< 15 years, Female
HIV_HTS_TS
>= 15 years, Male
HIV_HTS_TS
>= 15 years, Female
HIV_HTS_TS
Number of contacts tested
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_T Number of contacts by test result (Positive)
HIV_HTS_TS
New positive
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TS
Known positive
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_T Number of Individual HIV self test KIT distribued
HIV_HTS_T Directly assisted
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_T Unassisted
HIV_HTS_TS
Male
HIV_HTS_TS
Female
HIV_HIV_TreDoes health facility provide Monthly PMTCT / ART Treatment Service?
HIV_TX_CUNumber of adults and children who are currently on ART by age, sex and regimen category
HIV_TX_CUNumber of children (<15) who are currently on ART
HIV_TX_CU Children聽currently on ART aged <1 yr
HIV_TX_CU Children currently on ART aged <1 yr on First line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CU Children currently on ART aged <1 yr on Second line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren currently on ART aged <1 yr on Third line regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CU Children聽currently on ART aged 1-4 yr
HIV_TX_CU Children currently on ART aged 1-4 yr on First line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CU Children currently on ART aged 1-4 yr on Second-line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren currently on ART aged 1-4 yr on Third line regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CU Children聽currently on ART aged 5-9 yr
HIV_TX_CU Children聽currently on ART aged 5-9 yr on First line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CU Children聽currently on ART aged 5-9 yr on Second line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CU Children聽currently on ART aged 5-9 yr on Third line regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CU Children聽 currently on ART aged 10-14 year
HIV_TX_CU Children聽 currently on ART aged 10-14 year on First line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CU Children currently on ART aged 10-14 year on Second line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren currently on ART aged 10-14 years on Third line regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUNumber of adults who are currently on ART (>=15)
HIV_TX_CUAdult currently on ART aged 15-19
HIV_TX_CU Adult currently on ART aged 15-19 on First line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CU Adult currently on ART aged 15-19 on Second-line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUAdult currently on ART aged 15-19 on Third line regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CU Adult currently on ART aged 20-24 on Second-line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CU Adult currently on ART aged 25-29 on Second line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUAdult currently on ART aged 50+
Adult currently on ART aged 50+ on First line聽 regimen by sex
HIV_TX_CUR
HIV_TX_CUR
Male
HIV_TX_CUR
Female
Adult currently on ART aged 50+ on Second line聽 regimen by sex
HIV_TX_CUR
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Adult currently on ART aged 50+ on Third line regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUCurrently on ART by pregnancy status
HIV_TX_CUPregnant
HIV_TX_CUNon pregnant
HIV_TX_CUNumber of children (<19) who are currently on ART by regimen type
HIV_TX_CUChildren currently on ART aged <1 yr by regimen type
HIV_TX_CU Children currently on ART aged <1 yr on First line聽 regimen by regimen type
HIV_TX_CU4f=AZT + 3TC + LPV/r
HIV_TX_CU4g=ABC + 3TC + LPV/r
HIV_TX_CU4j= ABC +3TC + DTG
HIV_TX_CU4k= AZT + 3TC + DTG
HIV_TX_CU4h=other first line
HIV_TX_CUChildren currently on ART aged <1 yr on second line regimen by regimen type
HIV_TX_CUR
5e=ABC + 3TC + LPV/r
HIV_TX_CUR
5f=AZT + 3TC + LPV/r
HIV_TX_CUR
5m = ABC + 3TC + DTG
HIV_TX_CUR
5n= AZT + 3TC + DTG
HIV_TX_CUR
5j=other secondline
HIV_TX_CUChildren currently on ART aged <1 yr on Third line regimen by regimen type
HIV_TX_CUR
6c=DRV/r+DTG+AZT+3TC
HIV_TX_CUR
6f= DRV/r + DTG + ABC + 3TC
HIV_TX_CUR
6e=Other thirdline regimen
HIV_TX_CUChildren currently on ART aged 1-4 yr by regimen type
HIV_TX_CU 聽Children currently on ART aged 1-4 yr on First line regimen by regimen type
HIV_TX_CUR
4d = AZT+3TC+EFV
HIV_TX_CUR
HIV_TX_CUR
4g=ABC + 3TC + LPV/r
HIV_TX_CUR
4j= ABC +3TC + DTG
HIV_TX_CUR
4k= AZT + 3TC + DTG
HIV_TX_CUR
4L= ABC + 3TC + EFV
HIV_TX_CUR
4h=other first line
HIV_TX_CUChildren currently on ART aged 1-4 yr on Second-line regimen by regimen type
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CUR
5h=ABC + 3TC + EFV
HIV_TX_CUR
HIV_TX_CUR
5n= AZT + 3TC + DTG
HIV_TX_CUR
5j=other secondline
HIV_TX_CUChildren currently on ART aged 1-4 yr on Third Line regimen by regimen type
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CUR
6g= DRV/r +ABC+3TC+ EFV
HIV_TX_CUR
6h= DRV/r +AZT+3TC+EFV
HIV_TX_CUR
HIV_TX_CUChildren currently on ART aged 5-9 yr on by regimen type

HIV_TX_CUChildren currently on ART aged 5-9 yr on First line regimen by regimen type
HIV_TX_CUR
4d = AZT+3TC+EFV
HIV_TX_CUR
4e= TDF+3TC+EFV
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CUR
4i= TDF + 3TC + DTG
HIV_TX_CUR
4j= ABC +3TC + DTG
HIV_TX_CUR
4k= AZT + 3TC + DTG
HIV_TX_CUR
4L= ABC + 3TC + EFV
HIV_TX_CUR
4h=other first line
HIV_TX_CUChildren currently on ART aged 5-9 yr on Second line regimen by regimen type
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CUR
5g= TDF + 3TC + EFV
HIV_TX_CUR
5h=ABC + 3TC + EFV
HIV_TX_CUR
5i=TDF + 3TC+ LPV/r
HIV_TX_CUR
HIV_TX_CUR
5n= AZT + 3TC + DTG
HIV_TX_CUR
5o= TDF + 3TC + DTG
HIV_TX_CUR
5j=other secondline
HIV_TX_CUR
HIV_TX_CUR
6d=DRV/r+DTG+TDF+3TC
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CUChildren currently on ART aged 10-14 year by regimen type
HIV_TX_CU Children currently on ART aged 10-14 year on 聽First line regimen by regimen type
HIV_TX_CUR
4d = AZT+3TC+EFV
HIV_TX_CUR
4e= TDF+3TC+EFV
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CUR
4i= TDF + 3TC + DTG
HIV_TX_CUR
4j= ABC +3TC + DTG
HIV_TX_CUR
4k= AZT + 3TC + DTG
HIV_TX_CUR
4L= ABC + 3TC + EFV
HIV_TX_CUR
4h=other first line
HIV_TX_CUChildren currently on ART aged 10-14 year on Second line regimen by regimen type
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CUR
5g= TDF + 3TC + EFV
HIV_TX_CUR
5h=ABC + 3TC + EFV
HIV_TX_CUR
5i=TDF + 3TC+ LPV/r
HIV_TX_CUR
HIV_TX_CUR
5n= AZT + 3TC + DTG
HIV_TX_CUR
5o= TDF + 3TC + DTG
HIV_TX_CUR
5j=other secondline
HIV_TX_CUChildren currently on ART aged 10-14 year on Third Line regimen by regimen type
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CUAdult currently on ART aged 15-19 by regimen type
HIV_TX_CU Adult currently on ART aged 15-19 on聽First line regimen by regimen type
HIV_TX_CUR
1d = AZT-3TC-EFV
HIV_TX_CUR
1e = TDF-3TC-EFV
HIV_TX_CUR
1g= ABC + 3TC + EFV
HIV_TX_CUR
1j=TDF + 3TC + DTG
HIV_TX_CUR
1k= AZT +3TC +DTG
HIV_TX_CUR
1i = Other specify
HIV_TX_CUAdult currently on ART aged 15-19 on Second line regimen by regimen type
HIV_TX_CUR
2e= AZT+3TC+LPV/r
HIV_TX_CUR
2f=AZT+3TC+ATV/r
HIV_TX_CUR
2g= TDF-3TC-LPV/r
HIV_TX_CUR
2h =TDF-3TC-ATV/r
HIV_TX_CUR
2i = ABC + 3TC + LPV/r
HIV_TX_CUR
2j = TDF + 3TC + DTG
HIV_TX_CUR
2k = AZT + 3TC + DTG
HIV_TX_CUR
2l=other secondline
HIV_TX_CUAdult currently on ART aged 15-19 on Third Line regimen by regimen type
HIV_TX_CUR
3a=DRV/r+DTG+AZT/3TC
HIV_TX_CUR
3b=DRV/r+DTG+TDF/3TC
HIV_TX_CUR
3c=DRV/r+ABC+3TC+DTG
HIV_TX_CUR
3e= DRV/r+TDF+3TC+EFV
HIV_TX_CUR
3f= DRV/r+AZT+3TC +EFV
HIV_TX_CUR
3d=Other thirdline
HIV_TX_CUAdults >=20 years currently on ART by regimen type
HIV_TX_CU Adults >=20 years currently on First line聽 regimen by regimen type
HIV_TX_CUR
1d = AZT-3TC-EFV, Male
HIV_TX_CUR
1d = AZT-3TC-EFV, Female - pregnant
HIV_TX_CUR
1d = AZT-3TC-EFV, Female - non-pregnant
HIV_TX_CUR
1e = TDF-3TC-EFV, Male
HIV_TX_CUR
1e = TDF-3TC-EFV, Female - pregnant
HIV_TX_CUR
1e = TDF-3TC-EFV, Female - non-pregnant
HIV_TX_CUR
1g= ABC + 3TC + EFV, Male
HIV_TX_CUR
1g= ABC + 3TC + EFV, Female - pregnant
HIV_TX_CUR
1g= ABC + 3TC + EFV, Female - non-pregnant
HIV_TX_CUR
1j=TDF + 3TC + DTG, Male
HIV_TX_CUR
1j=TDF + 3TC + DTG, Female - pregnant
HIV_TX_CUR
1j=TDF + 3TC + DTG, Female - non-pregnant
HIV_TX_CUR
1k= AZT +3TC +DTG, Male
HIV_TX_CUR
1k= AZT +3TC +DTG, Female - pregnant
HIV_TX_CUR
1k= AZT +3TC +DTG, Female - non-pregnant
HIV_TX_CUR
1i = Other specify, Male
HIV_TX_CUR
1i = Other specify, Female - pregnant
HIV_TX_CUR
1i = Other specify, Female - non-pregnant
HIV_TX_CU 聽Adults >=20 years currently on Second line regimen by regimen type
HIV_TX_CUR
2e= AZT+3TC+LPV/r, Male
HIV_TX_CUR
2e= AZT+3TC+LPV/r, Female - pregnant
HIV_TX_CUR
2e= AZT+3TC+LPV/r, Female - non-pregnant
HIV_TX_CUR
2f=AZT+3TC+ATV/r, Male
HIV_TX_CUR
2f=AZT+3TC+ATV/r, Female - pregnant
HIV_TX_CUR
2f=AZT+3TC+ATV/r, Female - non-pregnant
HIV_TX_CUR
2g= TDF-3TC-LPV/r, Male
HIV_TX_CUR
2g= TDF-3TC-LPV/r, Female - pregnant
HIV_TX_CUR
2g= TDF-3TC-LPV/r, Female - non-pregnant
HIV_TX_CUR
2h =TDF-3TC-ATV/r, Male
HIV_TX_CUR
2h =TDF-3TC-ATV/r, Female - pregnant
HIV_TX_CUR
2h =TDF-3TC-ATV/r, Female - non-pregnant
HIV_TX_CUR
2i = ABC + 3TC + LPV/r, Male
HIV_TX_CUR
2i = ABC + 3TC + LPV/r, Female - pregnant
HIV_TX_CUR
2i = ABC + 3TC + LPV/r, Female - non-pregnant
HIV_TX_CUR
2j = TDF + 3TC + DTG, Male
HIV_TX_CUR
2j = TDF + 3TC + DTG, Female - pregnant
HIV_TX_CUR
2j = TDF + 3TC + DTG, Female - non-pregnant
HIV_TX_CUR
2k = AZT + 3TC + DTG, Male
HIV_TX_CUR
2k = AZT + 3TC + DTG, Female - pregnant
HIV_TX_CUR
2k = AZT + 3TC + DTG, Female - non-pregnant
HIV_TX_CUR
2l=other secondline, Male
HIV_TX_CUR
2l=other secondline, Female - pregnant
HIV_TX_CUR
2l=other secondline, Female - non-pregnant
HIV_TX_CUAdults >=20 years currently on Third Line regimen by regimen type
HIV_TX_CUR
3a=DRV/r+DTG+AZT/3TC, Male
HIV_TX_CUR
3a=DRV/r+DTG+AZT/3TC, Female - pregnant
HIV_TX_CUR
3a=DRV/r+DTG+AZT/3TC, Female - non-pregnant
HIV_TX_CUR
3b=DRV/r+DTG+TDF/3TC, Male
HIV_TX_CUR
3b=DRV/r+DTG+TDF/3TC, Female - pregnant
HIV_TX_CUR
3b=DRV/r+DTG+TDF/3TC, Female - non-pregnant
HIV_TX_CUR
3c=DRV/r+ABC+3TC+DTG, Male
HIV_TX_CUR
3c=DRV/r+ABC+3TC+DTG, Female - pregnant
HIV_TX_CUR
3c=DRV/r+ABC+3TC+DTG, Female - non-pregnant
HIV_TX_CUR
3e= DRV/r+TDF+3TC+EFV, Male
HIV_TX_CUR
3e= DRV/r+TDF+3TC+EFV, Female - pregnant
HIV_TX_CUR
3e= DRV/r+TDF+3TC+EFV, Female - non-pregnant
HIV_TX_CUR
3f= DRV/r+AZT+3TC +EFV, Male
HIV_TX_CUR
3f= DRV/r+AZT+3TC +EFV, Female - pregnant
HIV_TX_CUR
3f= DRV/r+AZT+3TC +EFV, Female - non-pregnant
HIV_TX_CUR
3d=Other thirdline, Male
HIV_TX_CUR
3d=Other thirdline, Female - pregnant
HIV_TX_CUR
3d=Other thirdline, Female - non-pregnant
HIV_TX_NE Number of adults and children with HIV infection newly started on ART
HIV_TX_NEW
< 1 year, Male
HIV_TX_NEW
< 1 year, Female - non-pregnant
HIV_TX_NEW
1 - 4 years, Male
HIV_TX_NEW
1 - 4 years, Female - non-pregnant
HIV_TX_NEW
5 - 9 years, Male
HIV_TX_NEW
HIV_TX_NEW
10 - 14 years, Male
HIV_TX_NEW
HIV_TX_NEW
15 - 19 years, Male
HIV_TX_NEW
15 - 19 years, Female - pregnant
HIV_TX_NEW
HIV_TX_NEW
20 - 24 years, Male
HIV_TX_NEW
HIV_TX_NEW
HIV_TX_NEW
25 - 29 years, Male
HIV_TX_NEW
HIV_TX_NEW
HIV_TX_NEW
30 - 34 years, Male
HIV_TX_NEW
HIV_TX_NEW
HIV_TX_NEW
35 - 39 years, Male
HIV_TX_NEW
HIV_TX_NEW
HIV_TX_NEW
40 - 44 years, Male
HIV_TX_NEW
HIV_TX_NEW
HIV_TX_NEW
45 - 49 years, Male
HIV_TX_NEW
HIV_TX_NEW
HIV_TX_NEW
>= 50 years, Male
HIV_TX_NEW
>= 50 years, Female - non-pregnant
HIV_ART_RART retention rate (Percentage of adult and children on ART treatment after 12 month of initation of ARV t
HIV_ART_RNumber of adults and children who are still on treatment at 12 months after initiating ART
HIV_ART_RE
< 1 year, Male
HIV_ART_RE
HIV_ART_RE
1 - 4 years, Male
HIV_ART_RE
HIV_ART_RE
5 - 9 years, Male
HIV_ART_RE
HIV_ART_RE
10 - 14 years, Male
HIV_ART_RE
HIV_ART_RE
15 - 19 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
20 - 24 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
25 - 29 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
30 - 34 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
35 - 39 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
40 - 44 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
45 - 49 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
>= 50 years, Male
HIV_ART_RE
HIV_ART_RNumber of persons on ART in the original cohort including those transferred in, minus those transferred out (net curren
HIV_ART_RE
< 1 year, Male
HIV_ART_RE
HIV_ART_RE
1 - 4 years, Male
HIV_ART_RE
HIV_ART_RE
5 - 9 years, Male
HIV_ART_RE
HIV_ART_RE
10 - 14 years, Male
HIV_ART_RE
HIV_ART_RE
15 - 19 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
20 - 24 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
25 - 29 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
30 - 34 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
35 - 39 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
40 - 44 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
45 - 49 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
>= 50 years, Male
HIV_ART_RE
HIV_ART_NLinkage outcome of of newly identified Hiv positive individuals in the reporting period
HIV_ART_NLinked to care and treatment
HIV_ART_NKnown on ART
HIV_ART_NLost to follow up art
HIV_ART_NReferred to other facility
HIV_ART_NDied
HIV_ART_NOthers
HIV_TX_PV Viral load Suppression (Percentage of ART clients with a suppressed viral load among those with a viral lo
HIV_TX_PV Number of adult and pediatric ART patients for whom viral load test result received in the reporting period
HIV_TX_PVL< 1 year, Male
HIV_TX_PVL< 1 year, Female - non-pregnant
HIV_TX_PVL1 - 4 years, Male
HIV_TX_PVL1 - 4 years, Female - non-pregnant
HIV_TX_PVL15 - 19 years, Female - pregnant
HIV_TX_PVL>= 50 years, Male
HIV_TX_PVL>= 50 years, Female - non-pregnant
HIV_TX_PV Total number of adult and paediatric ART patients with an undetectable viral load(<50 copies/ml) in the reporting period
HIV_TX_PVL< 1 year, Male
HIV_TX_PVL< 1 year, Female - non-pregnant
HIV_TX_PVL>= 50 years, Male
HIV_TX_PVL>= 50 years, Female - non-pregnant
HIV_TX_DS Total number of adult and paediatric ART patients with low level viremia (50 -1000 copies/ml) in the reporting period
HIV_TX_DSD
< 1 year, Male
HIV_TX_DSD
HIV_TX_DSD
1 - 4 years, Male
HIV_TX_DSD
HIV_TX_DSD
5 - 9 years, Male
HIV_TX_DSD
HIV_TX_DSD
10 - 14 years, Male
HIV_TX_DSD
HIV_TX_DSD
15 - 19 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
20 - 24 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
25 - 29 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
30 - 34 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
35 - 39 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
40 - 44 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
45 - 49 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
>= 50 years, Male
HIV_TX_DSD
HIV_TX_DS Proportion of PLHIV currently on differentiated service Delivery model (DSD)
HIV_TX_3M Total number of clients on 3MMD
HIV_TX_3MM
< 1 year, Male
HIV_TX_3MM
< 1 year, Female
HIV_TX_3MM
1 - 4 years, Male
HIV_TX_3MM
1 - 4 years, Female
HIV_TX_3MM
5 - 9 years, Male
HIV_TX_3MM
5 - 9 years, Female
HIV_TX_3MM
10 - 14 years, Male
HIV_TX_3MM
HIV_TX_3MM
15 - 19 years, Male
HIV_TX_3MM
HIV_TX_3MM
20 - 24 years, Male
HIV_TX_3MM
HIV_TX_3MM
25 - 49 years, Male
HIV_TX_3MM
HIV_TX_3MM
>= 50 years, Male
HIV_TX_3MM
>= 50 years, Female
HIV_TX_AS Total number of clients on ASM(6MMD)
HIV_TX_ASM
15 - 19 years, Male
HIV_TX_ASM
HIV_TX_ASM
20 - 24 years, Male
HIV_TX_ASM
HIV_TX_ASM
25 - 49 years, Male
HIV_TX_ASM
HIV_TX_ASM
>= 50 years, Male
HIV_TX_ASM
>= 50 years, Female
HIV_TX_FT Total number of clients on FTAR
HIV_TX_FTA15 - 19 years, Male
HIV_TX_FTA15 - 19 years, Female
HIV_TX_FTA>= 50 years, Male
HIV_TX_FTA>= 50 years, Female
HIV_TX_CATotal number of clients on CAG
HIV_TX_CAG
15 - 19 years, Male
HIV_TX_CAG
HIV_TX_CAG
20 - 24 years, Male
HIV_TX_CAG
HIV_TX_CAG
25 - 49 years, Male
HIV_TX_CAG
HIV_TX_CAG
>= 50 years, Male
HIV_TX_CAG
>= 50 years, Female
HIV_TX_PC Total number of clients on PCAD
HIV_TX_PCA
15 - 19 years, Male
HIV_TX_PCA
HIV_TX_PCA
20 - 24 years, Male
HIV_TX_PCA
HIV_TX_PCA
25 - 49 years, Male
HIV_TX_PCA
HIV_TX_PCA
>= 50 years, Male
HIV_TX_PCA
>= 50 years, Female
.
HIV_TX_Adol
Total number of clients on Adolescent DSD
HIV_TX_KP Total number of clients on KP DSD
HIV_TX_MCTotal number of clients on MCH DSD
HIV_TX_ othe
Total number of clients on other types of DSD
HIV_TX_AHTotal number of clients on "Advanced HIV Disease Care Model"
HIV_TX_AHD
< 1 year, Male
HIV_TX_AHD
< 1 year, Female
HIV_TX_AHD
1 - 4 years, Male
HIV_TX_AHD
1 - 4 years, Female
HIV_TX_AHD
5 - 9 years, Male
HIV_TX_AHD
5 - 9 years, Female
HIV_TX_AHD
10 - 14 years, Male
HIV_TX_AHD
HIV_TX_AHD
15 - 19 years, Male
HIV_TX_AHD
HIV_TX_AHD
20 - 24 years, Male
HIV_TX_AHD
HIV_TX_AHD
25 - 49 years, Male
HIV_TX_AHD
HIV_TX_AHD
>= 50 years, Male
HIV_TX_AHD
>= 50 years, Female
HIV_ART_I Number of ART Clients that interrupted Treatment
HIV_ART_I Number of ART Clients Interrupted treatment by outcome
HIV_ART_I Lost after treatemnt < 3month
HIV_ART_IN< 15 years, Male
HIV_ART_IN< 15 years, Female
HIV_ART_IN>= 15 years, Male
HIV_ART_IN>= 15 years, Female
HIV_ART_I Lost after treatemnt > 3month
HIV_ART_INTransferred out
HIV_ART_INRefused (stopped) treatement
HIV_ART_INDied
HIV_ART_RNumber of ART clients restarted ARV treatment in the reporting period
HIV_ART_RE
< 15 years, Male
HIV_ART_RE
< 15 years, Female
HIV_ART_RE
>= 15 years, Male
HIV_ART_RE
>= 15 years, Female
HIV_PrEP Number of individuals receiving Pre-Exposure Prophylaxis
HIV_PrEP.1 PrEP (New Number of individuals who were newly enrolled on PrEP)
HIV_PrEP.1 By age and Sex
HIV_PrEP.1.15 - 19 years, Male
HIV_PrEP.1.15 - 19 years, Female
HIV_PrEP.1.>= 50 years, Male
HIV_PrEP.1.>= 50 years, Female
HIV_PrEP.1.By Client Category
HIV_PrEP.1.Discordant Couple
HIV_PrEP.1.Female sex worker[FSW]
HIV_PrEP.1 PrEP Curr (Number of individuals that received oral PrEP during the reporting period)
HIV_PrEP_ By age and Sex
HIV_PrEP_C15 - 19 years, Male
HIV_PrEP_C15 - 19 years, Female
HIV_PrEP_C>= 50 years, Male
HIV_PrEP_C>= 50 years, Female
HIV_PrEP_ By Client Category
HIV_PrEP_CDiscordant Couple
HIV_PrEP_CFemale sex worker[FSW]
HIV_PEP Number of persons provided with post-exposure prophylaxis (PEP) for risk of HIV infection by exposure type
HIV_PEP. 1 Occupational
HIV_PEP. 2 Sexual violence
HIV_PEP. 3 Other Non occupational
HIV_PLHIV_Proportion of clinically undernourished People Living with HIV (PLHIV) who received therapeutic or supplementary food
HIV_PLHIV_Number of PLHIV who were assessed/screened for malnutrition
HIV_PLHIV_T
< 15 years, Male
HIV_PLHIV_T
< 15 years, Female
HIV_PLHIV_T
>= 15 years, Male
HIV_PLHIV_T
>= 15 years, Female
HIV_PLHIV Number of PLHIV that were nutritionally assessed and found to be clinically undernourished (disaggregated by Age, Sex
HIV_PLHIV Total MAM
HIV_PLHIV_< 15 years, Male
HIV_PLHIV_< 15 years, Female
HIV_PLHIV_>= 15 years, Male
HIV_PLHIV_>= 15 years, Female
HIV_PLHIV Total SAM
HIV_PLHIV Clinically undernourished PLHIV who received therapeutic or supplementary food (disaggregated by age, sex and pregn
HIV_PLHIV_Total MAM who received therapeutic or supplementary food
HIV_PLHIV_< 15 years, Female - pregnant
HIV_PLHIV_< 15 years, Female - non-pregnant
HIV_PLHIV_>= 15 years, Female - pregnant
HIV_PLHIV_>= 15 years, Female - non-pregnant
HIV_PLHIV_Total SAM who received therapeutic or supplementary food
HIV_STI_S Proportion of STI cases tested for HIV
HIV_STI_SCNumber of STI cases tested for HIV
HIV_STI_SCMale
HIV_STI_SCFemale
HIV_STI_S Number of STI cases tested positive for HIV
HIV_STI_SCMale
HIV_STI_SCFemale
HIV_STI_S Total number of STI cases, by syndrome
HIV_STI_SYUrethral discharge
HIV_STI_SYPersistent urethral discharge
HIV_STI_SYScrotal swelling
HIV_STI_SYVaginal discharge
HIV_STI_SYPID (pelvic inflammatory disease)
HIV_STI_SYNon vesicular genital ulcer disease (NVGUD)
HIV_STI_SYVesicular genital ulcer disease (VGUD)
HIV_STI_SYInguinal bubo
HIV_STI_SYNeonatal conjunctivitis
HIV_STI_SYNeonatal herpes
HIV_ART_F Number of non-pregnant women living with HIV on ART aged 15-49 reporting the use of any method of modern family pl
HIV_ART_FP
10 - 14 years
HIV_ART_FP
15 - 19 years
HIV_ART_FP
20 - 24 years
HIV_ART_FP
25 - 29 years
HIV_ART_FP
30 - 49 years
HIV_ART_F Number of non-pregnant women living with HIV on ART aged 15-49 reporting the use of any method of modern family pl
HIV_ART_FP
Oral contraceptives
HIV_ART_FP
Injectables
HIV_ART_FP
Implants
HIV_ART_FP
IUCD
HIV_ART_FP
Others
HIV_TB_SCProportion of patients enrolled in HIV care who were screened for TB (FD)
HIV_TB.1 Number of NEWLY Enrolled ART clients who were screened for TB during the reporting period
HIV_TB.1. 1 < 15 years, Male
HIV_TB.1. 2 < 15 years, Female
HIV_TB.1. 3 >= 15 years, Male
HIV_TB.1. 4 >= 15 years, Female
HIV_TB_SCScreened Positive for TB
HIV_TB_SCR
< 15 years, Male
HIV_TB_SCR
< 15 years, Female
HIV_TB_SCR
>= 15 years, Male
HIV_TB_SCR
>= 15 years, Female
HIV_TB_SCNumber of PLHIVs PREVIOUSLY on ART and screened for TB
HIV_TB_SCR
< 15 years, Male
HIV_TB_SCR
< 15 years, Female
HIV_TB_SCR
>= 15 years, Male
HIV_TB_SCR
>= 15 years, Female
HIV_TB_SCR
< 15 years, Male
HIV_TB_SCR
< 15 years, Female
HIV_TB_SCR
>= 15 years, Male
HIV_TB_SCR
>= 15 years, Female
HIV_ART_TP
Number of ART patients who started on a standard course of TB Preventive Treatment (TPT) in the reporting period
HIV_TB_TP Patients on 6H
HIV_TB_TPT< 15 years, Male
HIV_TB_TPT< 15 years, Female
HIV_TB_TPT>= 15 years, Male
HIV_TB_TPT>= 15 years, Female
HIV_ART_T Patients on 3HP
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_T Patients on 3HR
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_T Number of ART patients who were initiated on any course of TPT 12 months before the reporting period
HIV_TPT Patients on 6H 12 months prior to the reporting period
HIV_TPT. 1 < 15 years, Male
HIV_TPT. 2 < 15 years, Female
HIV_TPT. 3 >= 15 years, Male
HIV_TPT. 4 >= 15 years, Female
HIV_ART_TP
Patients on 3HP 12 months prior to the reporting period
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_TP
Patients on 3HR 12 months prior to the reporting period
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_T Number of ART patients who started TPT 12 months prior to the reproting period that completed a full course of therapy
HIV_ART_TP
Patients who completed 6H
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_TP
Patients who completed 3HP
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_TP
Patients who completed 3HR
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_CXCA_Cervical Cancer screening by type of test
HIV_CXCA_Screened by VIA
HIV_CXCA_Screened by HPV DNA
HIV_CXCA_VIA Screening Result
HIV_CXCA_Normal cervix:
HIV_CXCA_S
15 - 19 years
HIV_CXCA_S
20 - 24 years
HIV_CXCA_S
25 - 29 years
HIV_CXCA_S
30 - 49 years
07 - TB/Leprosy | Hospital, Health center, clinic | Monthly (Hamle 2014)
S.No Activity
TB_COMM Proportion of all forms of TB cases notified and treated from community referral
TB_TX_PTBNumber of all forms of TB (New and Relapse) cases that were notified and treated during the reporting period
TB Number of bacteriologically confirmed New Pulmonary TB cases detected and enrolled in the reporting period by age
TB. 1 0 - 4 years, Male
TB. 2 0 - 4 years, Female
TB. 19 >=65 yr, Male
TB. 20 >=65 yr, Female
TB_TX_PTBNumber of clinically diagnosed New pulmonary TB cases detected and enrolled in the reporting period by age and se
TB_TX_PTB.0 - 4 years, Male
TB_TX_PTB.0 - 4 years, Female
TB_TX_PTB.>=65 yr, Male
TB_TX_PTB.>=65 yr, Female
TB_TX_EPTNumber of clinically diagnosed and bacteriological confirmed new EPTB cases detected and enrolled in the reporting
TB_TX_EPTB
0 - 4 years, Male
TB_TX_EPTB
0 - 4 years, Female
TB_TX_EPTB
5 - 9 years, Male
TB_TX_EPTB
5 - 9 years, Female
TB_TX_EPTB
10 - 14 years, Male
TB_TX_EPTB
TB_TX_EPTB
15 - 19 years, Male
TB_TX_EPTB
TB_TX_EPTB
20 - 24 years, Male
TB_TX_EPTB
TB_TX_EPTB
25 - 34 years, Male
TB_TX_EPTB
TB_TX_EPTB
35 - 44 years, Male
TB_TX_EPTB
TB_TX_EPTB
45 - 54 years, Male
TB_TX_EPTB
TB_TX_EPTB
55 - 64 years, Male
TB_TX_EPTB
TB_TX_EPTB
>=65 yr, Male
TB_TX_EPTB
>=65 yr, Female
TB_TX_RTBNumber of all RELAPSE TB cases detected and enrolled in the reporting period
TB_TX_RTB.0 - 4 years, Male
TB_TX_RTB.0 - 4 years, Female
TB_TX_RTB.>=65 yr, Male
TB_TX_RTB.>=65 yr, Female
TB_RET Tuberculosis Re-treatment
TB_RET. 1 Treatment after Relapse (R), Male
TB_RET. 2 Treatment after Relapse (R), Female
TB_RET. 3 Failed, Male
TB_RET. 4 Failed, Female
TB_RET. 5 Lost to follow-up, Male
TB_RET. 6 Lost to follow-up, Female
TB_RET. 7 Other previously treated (unknown & undocumented treatment outcome) (O), Male
TB_RET. 8 Other previously treated (unknown & undocumented treatment outcome) (O), Female
TB_KEY_PONumber of notified TB cases from key affected population group during the reporting period
TB_KEY_POP
Health care workers including HEWs
TB_KEY_POP
Diabetes
TB_KEY_POP
Homeless
TB_KEY_POP
Refugee
TB_KEY_POP
Prisoners
TB_KEY_POP
Miners
TB_KEY_POP
Congregated Settings
TB_KEY_POP
TB Contacts
TB_KEY_POP
Other key affected population
CDC_TB_R TB Treatment-outcome
TB_TX_OUTTotal number of bacteriologically confirmed new Pulmonary TB cases enrolled in cohort (PTB+) in the same month of the previou
TB_CR_PTB.
Treatment outcome of cohort of new PTB+ bacteriologically confirmed TB cases
TB_CR_PTB.
Completed
TB_CR_PTB.
Cured
TB_CR_PTB.
Lost to follow-up
TB_CR_PTB.
Dead
TB_CR_PTB.
Failed
TB_CR_PTB.
Not evaluated
TB_CR_PTB.
Moved to DR TB Register
TB_CR_PNTB
Total number of new clinically diagnosed pulmonary TB cases enrolled in the cohort (P/Neg) in the same month of the previous E
TB_CR_PNTB
Treatment outcome of cohort of clinically diagnosed pulmonary TB cases(P/Neg)
TB_CR_PNTB
Completed
TB_CR_PNTB
Lost to follow-up
TB_CR_PNTB
Deaths
TB_CR_PNTB
Failed
TB_CR_PNTB
TB_CR_PNTB
Not evaluated
TB_CR_EPTB
Total number of new EPTB cases enrolled in the cohort (EPTB) in the same month of previous EFY
TB_CR_EPTB
Treatment outcome of cohort of new extra pulmonary TB (EPTB)cases
TB_CR_EPTB
Completed
TB_CR_EPTB
Lost to follow-up
TB_CR_EPTB
Deaths
TB_CR_EPTB
Failed
TB_CR_EPTB
TB_CR_EPTB
Not evaluated
TB_CR_RTB.
Total number of all Relapse cases enrolled in the cohort in the same month of previous EFY
TB_CR_RTB.
Treatment outcome of cohort of all Relapse cases
TB_CR_RTB.
Completed
TB_CR_RTB.
Cured
TB_CR_RTB.
Lost to follow-up
TB_CR_RTB.
Dead
TB_CR_RTB.
Failed
TB_CR_RTB.
Not evaluated
TB_CR_RTB.
TB_COMM. Number of all forms TB cases detected and registered on TB unit register who are initially referred by the community
TB_CBTSR.1
Number of cohort TB patients (all forms) who were successfully treated (cured plus completed treatment) who received support f
TB_CBTSR.2
Total number of patients who started TB treatment in same reporting month of pervious year and who received any form of treatm
TB_DX_PRIV
Number of TB cases (all forms) notified in public health facilities with initial referral by PPM sites for TB diagnosis or initiation of T
TB_CI Contact investigation coverage
TB_CI.1.1 Total number of contacts with index bacteriologically confirmed drug susceptible TB cases during the reporting Month
TB_CI.1.1. 10 - 4 years
TB_CI.1.1. 25 - 14 years
TB_CI.1.1. 3>= 15 years
TB_CI.1.2 Total number of contacts with index bacteriologically confirmed DR-TB cases during the reporting Month
TB_CI.1.2. 10 - 4 years
TB_CI.1.2. 25 - 14 years
TB_CI.1.2. 3>= 15 years
TB_CI_SCR.Contacts of drug susceptible TB cases screened for TB
TB_CI_SCR.1
0 - 4 years
TB_CI_SCR.1
5 - 14 years
TB_CI_SCR.1
>= 15 years
TB_CI_SCR.Contacts of drug Resistant TB cases screened for TB
TB_CI_SCR.2
0 - 4 years
TB_CI_SCR.2
5 - 14 years
TB_CI_SCR.2
>= 15 years
TB_CI_SCRNumber of contacts with index bacteriologically confirmed TB (drug susceptible) cases screened negative for TB in the
TB_CI_SCR_
0 - 4 years
TB_CI_SCR_
5 - 14 years
TB_CI_SCR_
>= 15 years
TB_TPT TB Preventive Therapy (TPT) Coverage
TB_TPT Number of contacts screened negative for TB and others eligible and put on TB Preventive Therapy (TPT) in the reportin
TB_TPT. 1 0 - 4 years
TB_TPT. 3 >= 15 years
TB_TPT.1.4 By Regimen Type
TB_TPT.1.4.3HP
TB_TPT.1.4.3RH
TB_TPT.1.4.6H
TB_TPT.2.1 Number of cohort of individuals started TPT 12 months prior to the reporting period by Age Group
TB_TPT.2.1.0 - 4 years
TB_TPT.2.1.>= 15 years
TB_TPT.2.5 By Regimen Type
TB_TPT.2.5.3HP
TB_TPT.2.5.3RH
TB_TPT.2.5.6H
TB_TPT.3 TPT completion rate
TB_IPT.3 Number of cohort of individuals that completed TPT treatment among those who started 12 months prior to the reportin
TB_IPT.3. 1 0 - 4 years
TB_IPT.3. 2 5 - 14 years
TB_IPT.3. 3 >= 15 years
TB_IPT.3.4 By Regimen Type
TB_IPT.3.4. 3HP
TB_IPT.3.4. 3RH
TB_IPT.3.4. 6H
TB_TST-WHNumber of new and relapse bacteriologically confirmed pulmonary TB patients initially tested using a WHO recommend
TB_TST-WHO
0 - 4 years, Male
TB_TST-WHO
0 - 4 years, Female
TB_TST-WHO
5 - 14 years, Male
TB_TST-WHO
TB_TST-WHO
>= 15 years, Male
TB_TST-WHO
>= 15 years, Female
TB_DST.1 Number of notified bacteriologically confirmed TB cases evaluated for drug susceptibility testing according to national
TB_DST.1. 1New
TB_DST.1. 2Previously treated including relapse
TB_DST.1. 3Unknown treatment History
TB_DST.2 Number of TB cases with drug susceptibility testing result for at least rifampicin during the reporting period
TB_DST.2. 1New
TB_DST.2. 2Previously treated including relapse
TB_DST.2. 3Unknown treatment History
TB_DR_DR.Number of DR TB cases detected (Hr, RR Only, MDR- TB , Pre XDR and XDR TB cases)
TB_DR_DR Number of Hr-TB TB cases
TB_DR_DR.< 15 years, Male
TB_DR_DR.< 15 years, Female
TB_DR_DR.>= 15 years, Male
TB_DR_DR.>= 15 years, Female
TB_DR_DR.Total Number of confirmed RR only TB cases
TB_DR_DR.7
< 15 years, Male
TB_DR_DR.7
< 15 years, Female
TB_DR_DR.7
>= 15 years, Male
TB_DR_DR.7
>= 15 years, Female
TB_DR_DR.Total number of confirmed MDR TB cases
TB_DR_DR.1
< 15 years, Male
TB_DR_DR.1
< 15 years, Female
TB_DR_DR.1
>= 15 years, Male
TB_DR_DR.1
>= 15 years, Female
TB_DR_DR.Total number of confirmed Pre-XDR TB cases
TB_DR_DR.1
< 15 years, Male
TB_DR_DR.1
< 15 years, Female
TB_DR_DR.1
>= 15 years, Male
TB_DR_DR.1
>= 15 years, Female
TB_DR_DR.Total number of confirmed XDR- TB cases
TB_DR_DR.2
< 15 years, Male
TB_DR_DR.2
< 15 years, Female
TB_DR_DR.2
>= 15 years, Male
TB_DR_DR.2
>= 15 years, Female
Is the health facility a DR TB Treatment initiating center?
TB_DR_TX DR TB treatment coverage
TB_DR_TX Number of Hr-TB put on Hr-TB regimen by HIV status
TB_DR_TX. Positive
TB_DR_TX. Negative
TB_DR_TX. Unknown
TB_DR_TX. By Registration Group
TB_DR_TX.5New
TB_DR_TX.5Previously treated with first line drug
TB_DR_TX.5Previously treated with second line drug
TB_DR_TX.5Unknown
TB_DR_DSTDR TB cases put on second line treatment by regimen type
TB_DR_DST.
Shorter regimen
TB_DR_DST.
Longer regimen
TB_DR_DST.
Individualized Regimen
TB_DR_DSTDR TB cases put on second line treatment by HIV status
TB_DR_DST.
Positive
TB_DR_DST.
Negative
TB_DR_DST.
Unknown
TB_DR_DSTDR TB cases put on second line treatment by registration group
TB_DR_DST.
New
TB_DR_DST.
Previously treated with first line drug
TB_DR_DST.
Previously treated with second line drug
TB_DR_DST.
Unknown
TB_DR_DSTDR TB cases put on second line treatment by diagnosis type
TB_DR_DST.
Bacterologically confirmed Pulmonary DR TB cases
TB_DR_DST.
Bacterologically confirmed EPTB DR TB cases
TB_DR_DST.
Clinically Diagnosed DR TB cases
TB_DR_DSTRR/MDR-TB cases with DST result at least for fluoroquinolone during the reporting month
TB_DR_DST.
with susceptibility result
TB_DR_DST.
with resistant strain
TB_DR_DST.
whom Susceptibility result unknown
TB_DR_CTXDR TB Treatment Interim result for cohort of patient registered the same month of the previous year (12 month earlier)
TB_DR_CTXTotal Number of聽 cohort聽 DR-TB cases initiated on second-line anti-TB the same month of the previous year (12 mont
TB_DR_CTX.
Short term regimen
TB_DR_CTX.
Long term
TB_DR_CTXNumber of cohort DR-TB cases started short term second-line anti-TB treatment regimen the same month of the previou
TB_DR_CTX.
Positive culture result at 6 month
TB_DR_CTX.
Negative culture result at 6 month
TB_DR_CTX.
Died within six months of treatment
TB_DR_CTX.
Lost to follow up within six months of treatment
TB_DR_CTX.
Not evaluated at six month of treatment
TB_DR_CTXNumber of聽 cohort DR-TB cases started聽 long term second-line anti-TB treatment regimen the same month of the prev
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_TxOTotal number of cohort DR-TB cases started on short term second-line anti-TB treatment regimen 24 months earlier.
TB_DR_TxO.Cured
TB_DR_TxO.Completed
TB_DR_TxO.Died
TB_DR_TxO.Failed
TB_DR_TxO.Lost to follow-up
TB_DR_TxO.Not evaluated
TB_DR_CTX.
Total number of cohort DR-TB cases started on long term second-line anti-TB treatment regimen 24 months earlier.
TB_DR_CTX.
Cured
TB_DR_CTX.
Completed
TB_DR_CTX.
Died
TB_DR_CTX.
Failed
TB_DR_CTX.
Lost to follow-up
TB_DR_CTX.
Not evaluated
TB_DR_CTX.
Total number of cohort DR-TB cases started on long term( standardized and individualized) second-line anti-TB treatme
TB_DR_CTX.
Cured
TB_DR_CTX.
Completed
TB_DR_CTX.
Died
TB_DR_CTX.
Failed
TB_DR_CTX.
Lost to follow-up
TB_DR_CTX.
Not evaluated
TB_DR_NUTNumber of drug susceptible TB cases screened for Malnutrition during the reporting period
TB_DR_NUT.
Normal
TB_DR_NUT.
MAM
TB_DR_NUT.
SAM
TB_MN Number of DR TB cases enrolled to second line drugs screened for Malnutrition during the reporting period
TB_MN. 1 Normal
TB_MN. 2 MAM
TB_MN. 3 SAM
TBHIV Total number of new and relapse TB patients registered during the reporting period having a documented HIV positive t
TBHIV. 1 < 15 years, Male
TBHIV. 2 < 15 years, Female
TBHIV. 3 >= 15 years, Male
TBHIV. 4 >= 15 years, Female
TB_HIV_N Total number of new and relapse TB patients registered during the reporting period having a documented HIV negative
TB_HIV_N. < 15 years, Male
TB_HIV_N. < 15 years, Female
TB_HIV_N. >= 15 years, Male
TB_HIV_N. >= 15 years, Female
TB_ART.1 Total number of HIV-positive new and relapse TB patients who are already on ART
TB_ART.1. 10 - 4 years, Male
TB_ART.1. 20 - 4 years, Female
TB_ART.1. 5>= 15 years, Male
TB_ART.1. 6>= 15 years, Female
TB_NEW_AR
Total number of newly tested HIV positive TB patients who began ART during the reporting month
TB_NEW_ART
0 - 4 years, Male
TB_NEW_ART
0 - 4 years, Female
TB_NEW_ART
5 - 14 years, Male
TB_NEW_ART
TB_NEW_ART
>= 15 years, Male
TB_NEW_ART
>= 15 years, Female
LEP_NOT_1All new leprosy cases detected (MB+PB)
LEP_NOT_.1New Leprosy cases detected(PB)
LEP_NOT_.1.
< 15 years, Male
LEP_NOT_.1.
< 15 years, Female
LEP_NOT_.1.
>= 15 years, Male
LEP_NOT_.1.
>= 15 years, Female
LEP_NOT_.1New Leprosy cases detected(MB)
LEP_NOT_.1.
< 15 years, Male
LEP_NOT_.1.
< 15 years, Female
LEP_NOT_.1.
>= 15 years, Male
LEP_NOT_.1.
>= 15 years, Female
LEP_NOT_.1.
Total relapse Leprosy cases detected
LEP_NOT_.1.
Total retreatment cases other than relapse
LCS Leprosy contact screening
LEP_CSCR.Total number of household contacts of leprosy cases registered in the reporting period
LEP_CSCR.2
Total number of household contacts of leprosy patients that are screened for Leprosy in the reporting period
LEP_CSCR.3
Total number of household contacts diagnosed with Leprosy cases in the reporting month
LEP_DIS.1 New leprosy cases with Grade II disability (MB+PB)
LEP_DIS.1. < 15 years, Male
LEP_DIS.1. < 15 years, Female
LEP_DIS.1. >= 15 years, Male
LEP_DIS.1. >= 15 years, Female
LEP_TX.r Leprosy Treatment Completion Rate
LEP_TX.r. Result of new leprosy cohort cases registered during 16-18 months prior to this reporting period
LEP_TX.2. Registered cohort of MB cases
LEP_TX.3. Treatment completed MB cases
LEP_TX.4. Registered cohort of PB cases
LEP_TX.5. Treatment completed PB cases
TB_LB TB_Total Number of AFB tests performed by Method
TB_LB. 1 Ziehl-Neelsen based AFB Microscopy
TB_LB. 2 Fluorescent based AFB Microscopy
TB_LB_AFBTB_Total Number of AFB tested positive by Method
TB_LB_AFB.Ziehl-Neelsen based AFB Microscopy
TB_LB_AFB.Fluorescent based AFB Microscopy
08.2 - Malaria, NTD, NCD | Hospital, Health center, Clinic | Monthly (Hamle 2014)
S.No Activity
MAL Total number of slides or RDT performed for malaria diagnosis
MAL. 1 < 5 years, Male
MAL. 2 < 5 years, Female
MAL. 3 5 - 14 years, Male
MAL. 4 5 - 14 years, Female
MAL. 5 >= 15 years, Male
MAL. 6 >= 15 years, Female
MAL_POS.1Total number of slides or RDT Positive
MAL_POS.1.< 5 years, Male
MAL_POS.1.< 5 years, Female
MAL_POS.1.5 - 14 years, Male
MAL_POS.1.5 - 14 years, Female
MAL_POS.1.>= 15 years, Male
MAL_POS.1.>= 15 years, Female
Mal_Travel. Malaria with Travel History
Is the woreda elimination district?
Mal_Noti. Case notified to PHCU for further investigation (Elimination Districts)
MAL_FULL.1Number of index cases investigated and classified (Elimination Ditricts)
MAL_FULL.2Number of secondary cases during investigation (Elimination Ditricts)
MAL_FOCI.1Number of foci investigated and classified (Elimination Ditricts)
NTD. Does the facility provide leishmaniasis treatment?
Number of visceral Leishmaniasis (VL) cases treated
NTD_VL.1 Number of visceral leishmaniasis patients treated by age and sex
NTD_VL.1. 1< 5 years, Male
NTD_VL.1. 2< 5 years, Female
NTD_VL.1. 35 - 14 years, Male
NTD_VL.1. 45 - 14 years, Female
NTD_VL.1. 5>= 15 years, Male
NTD_VL.1. 6>= 15 years, Female
NTD_VL.2 Number of visceral leishmaniasis patients treated by treatment type
NTD_VL.2. 1Primary visceral leishmaniasis
NTD_VL.2. 2Relapse visceral leishmaniasis
NTD_VL.2. 3Post Kala-azar dermal leishmaniasis (PKDL)
NTD_VL.3 Number of visceral leishmaniasis patients treated by treatment outcome
NTD_VL.3. 1Cured
NTD_VL.3. 2Defaulted
NTD_VL.3. 3Failed
NTD_VL.3. 4Dead
NTD_VL.3. 5Referred
NTD_VL.4 Number of visceral leishmaniasis patients treated by HIV test result status
NTD_VL.4. 1Positive
NTD_VL.4. 2Negative
Number of cutaneous Leishmaniasis (CL) cases treated
NTD_CL.1 Number of cutaneous leishmaniasis treated by age and sex
NTD_CL.1. 1< 5 years, Male
NTD_CL.1. 2< 5 years, Female
NTD_CL.1. 35 - 14 years, Male
NTD_CL.1. 45 - 14 years, Female
NTD_CL.1. 5>= 15 years, Male
NTD_CL.1. 6>= 15 years, Female
NTD_CL.2 Number of cutaneous leishmaniasis patients treated by type
NTD_CL.2. 1Primary cutaneous leishmaniasis
NTD_CL.2. 2Relapse cutaneous leishmaniasis
NTD_CL.3 Number of cutaneous leishmaniasis patients treated by treatment outcome
NTD_CL.3. 1Cured
NTD_CL.3. 2Defaulted
NTD_CL.3. 3Failed
NTD_CL.3. 4Dead
NTD_CL.3. 5Referred
NTD_TT.1 Number of people with TT who received corrective TT surgery
NTD_TT.1. 1< 15 years, Male
NTD_TT.1. 2< 15 years, Female
NTD_TT.1. 3>= 15 years, Male
NTD_TT.1. 4>= 15 years, Female
NTD_HYD Number of hydrocele cases operated (due to lymphatic filariasis)
NTD_HYD. 1< 15 years, Male
NTD_HYD. 2>= 15 years, Male
NTD_POD Number of lymph edema cases managed (podoconosis and lymphatic filariasis)
NTD_POD. 1< 15 years, Male
NTD_POD. 2< 15 years, Female
NTD_POD. 3>= 15 years, Male
NTD_POD. 4>= 15 years, Female
NCT_HTN Hypertension
NCT_HTN Number of Individuals screened for hypertension
NCT_HTN. 118 - 29 years, Male
NCT_HTN. 218 - 29 years, Female
NCT_HTN. 7>=70 years, Male
NCT_HTN. 8>=70 years, Female
NCD_HTNDX
Number of Individuals screened for hypertension by result of screening
NCD_HTNDX.
Raised BP
NCD_HTNDX.
Normal BP
NCD_HTNDX
Hypertensive patients enrolled to care by Type of Treatment
NCD_HTNDX.
Healthy life style counciling (HLC) only
NCD_HTNDX.
Pharmacological management and HLC
NCD_HTNDX
Hypertensive patients enrolled to care by age and sex
NCD_HTNDX.
18 - 29 years, Male
NCD_HTNDX.
NCD_HTNDX.
30 - 39 years, Male
NCD_HTNDX.
NCD_HTNDX.
40 - 69 years, Male
NCD_HTNDX.
NCD_HTNDX.
>=70 years, Male
NCD_HTNDX.
>=70 years, Female
NCD_HTNDX
Hypertensive patients by timing of enrollment
NCD_HTNDX.
Newly enrolled to care
NCD_HTNDX.
Previously in care
NCD_HTNTX
Total number of cohort hypertensive patients enrolled to care six month prior to the reporting month
NCD_HTNT Treatment outcome for cohort of patient registered for hypertension treatment six months prior to the rep
NCD_HTNTX
Controlled
NCD_HTNTX
Uncontrolled
NCD_HTNTX
Lost to follow-up
NCD_HTNTX
Died
NCD_HTNTX
Transferred out
NCD_HTNTX
Not evaluated
CVD Cardio vascular diseases
CVD Number of individuals in high CVD risk by type of risk category :
CVD. 1 Lab based risk category ( >=20%)
CVD. 2 Non-Lab based category (>=10%)
NCD_CVD.2Number of individuals in high CVD risk by Age Catagory:
NCD_CVD.2.40 - 59 Years, Male
NCD_CVD.2.40 - 59 Years, Female
NCD_CVD.3Number of patients with high CVD risk who received treatment by type of treatment:
NCD_CVD.3.With Statin
NCD_CVD.3.Without Statin
NCD_CVD.4patients with high CVD risk who received treatment by Age Catagory:
DM Diabetes mellitus
NCD_DMDX.Individuals screened for Diabetes Mellitus by age and sex
NCD_DMDX.1
< 40 years, Male
NCD_DMDX.1
< 40 years, Female
NCD_DMDX.1
>= 40 years, Male
NCD_DMDX.1
>= 40 years, Female
NCD_DMDX.Number of Individuals screened for Diabetes Mellitus by result of screening
NCD_DMDX.1
Raised blood sugar
NCD_DMDX.1
Normal blood sugar
NCD_DMDX.Diabetic patients enrolled to care by types of Diabete
NCD_DMDX.2
Type I
NCD_DMDX.2
Type II
NCD_DMDX.2
Gestational DM
NCD_DMDX.Diabetic patients enrolled to care by type of treatment
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.Diabetic patients enrolled to care by age and sex
NCD_DMDX.2
< 15 years, Male
NCD_DMDX.2
< 15 years, Female
NCD_DMDX.2
15 - 29 years, Male
NCD_DMDX.2
NCD_DMDX.2
30 - 39 years, Male
NCD_DMDX.2
NCD_DMDX.2
>= 40 years, Male
NCD_DMDX.2
>= 40 years, Female
NCD_DMDX.Diabetic patients by Timing of enrollment
NCD_DMDX.2
NCD_DMDX.2
Previously in care
NCD_DMTXSix-monthly control of diabetes among individuals treated for diabetes
NCD_DMTX.Total number of cohort of hypertensive pateints registered for diabetes treatment six months prior to the reporting period
NCD_DMTXTreatment outcome for cohort of patient registered for diabetes treatment six months prior to the reporting period
NCD_DMTX.Controlled
NCD_DMTX.Uncontrolled
NCD_DMTX.Lost to follow-up
NCD_DMTX.Died
NCD_DMTX.Transferred out
NCD_DMTX.Not evaluated
NCD_DMTX.Treatment outcome for cohort of patient registered for diabetes treatment six months prior to the reporting period by ag
NCD_DMTX.2
< 15 years, Male
NCD_DMTX.2
< 15 years, Female
NCD_DMTX.2
15 - 29 years, Male
NCD_DMTX.2
NCD_DMTX.2
30 - 39 years, Male
NCD_DMTX.2
NCD_DMTX.2
>= 40 years, Male
NCD_DMTX.2
>= 40 years, Female
NCD_CV_SC
Women age 30-49 years who have been screened for cervical Ca by screening type
NCD_CV_SCR
Screened by VIA
NCD_CV_SCR
Screened by HPV DNA
NCD_CV_SCR
Women age 30-49 years who have been screened for cervical Ca VIA screening result
NCD_CV_SCR
Negative
09.2 - Medical services | Health center | Monthly (Hamle 2014)
S.No Activity
MS Number of outpatient visits
MS. 1 < 5 years, Male
MS. 2 < 5 years, Female
MS. 3 5 - 10 years, Male
MS. 4 5 - 10 years, Female
MS. 13 >= 66 years, Male
MS. 14 >= 66 years, Female
MS_OPD_Nu
Number of health insurance beneficiaries that visited HF in the reporting period
MS_BOR Bed occupancy rate
MS_IPD_BOR
Total length of stay (in days) in the reporting period
MS_IPD_BOR
Total Number of beds in the reporting period
MS_ALOS Average length of stay
MS_ALS.1. Total length of stay (in days) during discharge
MS_ALS.2. Number of inpatient discharges
MS_LaBT Essential laboratorial tests available
MS_LaBT.1.Monthly score of essential laboratorial tests of the facility
MS_RoR Referral-out rate
MS_RoR.1 Number of people referred to other health facility
MS_RoR.1. Emergency referral
MS_RoR.1. Non-emergency referral
MS_AMBU Ambulance service utilization for referral service
MS_NumRI Total number of referral-ins
MS_NumRI. Emergency referral
MS_NumRI. Non-emergency referral
MS_AMBU.1Number of clients that came to health facility using ambulance
MS_AMBU.1.
Pre-facility
MS_AMBU.1.
Between facility
MS_AMBURAmbulance service response rate
MS_AMBURTotal number of Ambulance dispatched - by technician
MS_AMBUR1
With Emergency Medical Technicians (EMT)
MS_AMBUR1
Without Emergency Medical Technicians (EMT)
MS_AMBURe
Total number of ambulance requests made during the reporting period
MS_AMBURTotal number of Ambulance dispatched in the reporting period - by Case
MS_AMBUR2
Labor & Obstetrics Emergency
MS_AMBUR2
Road Traffic Accident
MS_AMBUR2
Trauma
MS_AMBUR2
Burn & Poisoning
MS_AMBUR2
Others
MS_EMERGEmergency unit mortality
MS_EMERGFacility emergency department mortality rate
MS_EMERGTotal death in the emergency unit
MS_EMERG_
< 15 years, < 24 hours, Male
MS_EMERG_
< 15 years, < 24 hours, Female
MS_EMERG_
< 15 years, >= 24 hours, Male
MS_EMERG_
< 15 years, >= 24 hours, Female
MS_EMERG_
>= 15 years, < 24 hours, Male
MS_EMERG_
>= 15 years, < 24 hours, Female
MS_EMERG_
>= 15 years, >= 24 hours, Male
MS_EMERG_
>= 15 years, >= 24 hours, Female
MS_EMERGEmergency attendance with more than 24 hours stay
MS_NumEMTotal number of emergency unit attendance during the reporting period
MS_EMERG2
Emergency attendance with more than 24 hours stay
MS_EMERG_
Total number of emergency room discharges
MS_IPD_AR.Number of inpatient admissions
HSQI_IPD_IInpatient mortality rate
MS_IPIMR.1Total number of inpatient death in the reporting period
MS_IPIMR.1.< 24 hours
MS_IPIMR.1.>= 24 hours
Proportion of blood units utilized from blood bank service
MS_UBDR.1Total units of blood received from NBTS & regional blood banks
MS_UBDT.1Total number of units of blood transfused
MS_UBDT.1.direct family replacement
MS_UBDT.1.from blood bank
MS_SATIR.1Number of serious adverse transfusion incidents and reactions occurred
MS_RTI.1 Number of road traffic injury cases dis aggregated by accident type
MS_RTI.1. 1Vehicle occupant
MS_RTI.1. 2Motor cyclist
MS_RTI.1. 3Pedestrian
MS_RTI.1. 4Others
PMS Improve access to pharmaceuticals & medical devices & their rational & proper use
PMS. Medroxyprogesterone Injection
PMS_AVAIL.Pentavalent vaccine
PMS_AVAIL.Magnesium Sulphate injection
PMS_AVAIL.Oxytocine inj
PMS_AVAIL.Gentamycin injection
PMS_AVAIL.ORS+/- Zinc sulphate
PMS_AVAIL.Amoxcillin dispersable/suspension/capsule
PMS_AVAIL.Iron + folic acid
PMS_AVAIL.Albendazole/Mebendazole tablet/suspension
PMS_AVAIL.TTC eye ointment
PMS_AVAIL.RHZE/RH
PMS_AVAIL.TDF/3TC/DTG
PMS_AVAIL.Co-trimoxazole 240mg/5ml suspension
PMS_AVAIL.Arthmeter + Lumfanthrine tablet
PMS_AVAIL.Amlodipine tablet
PMS_AVAIL.Frusamide tablets
PMS_AVAIL.Metformin tablet
PMS_AVAIL.Normal Saline 0.9%
PMS_AVAIL.40% glucose
PMS_AVAIL.Adrenaline injection
PMS_AVAIL.Tetanus Anti Toxin (TAT) injection
PMS_AVAIL.Omeprazole capsule
PMS_AVAIL.Metronidazole capsule
PMS_AVAIL.Ciprofloxcaxillin tablet
PMS_AVAIL.Hydralizine injection
PMS_ABIOTPercentage of encounters with an antibiotic prescribed
PMS_ABIOTINumber of encounter with one or more antibiotics
PMS_ABIOTITotal number of encounters
PMS_FILL10MS_Number of clients who received 100% of prescribed drugs
PMS_FILL10Total number of clients who received prescriptions
PMS_FSML Percentage of medicines prescribed from the facility’s medicines list
PMS_MPFML
Total number of medicines prescribed from Health facility medicine list
PMS_MP_Nu
Total number of medicine prescribed
EIDM_LQASProportion of health facilities that conduct reporting consistency check using LQAS
EIDM_LQASProportion of health facilities that conduct reporting consistency check using LQAS
EBDM. Did the HF conduct LQAS for service report?
DQ_DA.1.1. LQAS first score for service report
DQ_DA.1.2. LQAS last score for service report
DQ_DA2. Did the HF conduct LQAS for OPD report?
DQ_DA.2.1. LQAS first score for OPD report
DQ_DA.2.2. LQAS last score for OPD report
DQ_DA3. Did the HF conduct LQAS for IPD report?
DQ_DA.3.1. LQAS first score for IPD report
DQ_DA.3.1. LQAS last score for IPD report
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
750 363 416 470 425 365 2789

256 173 266 158 127 87 1067
1 1
13 1 8 15 7 6 50
20 36 22 44 18 20 160
35 79 62 44 26 46 292
188 57 174 55 76 14 564
494 190 150 312 298 278 1722
5 5
13 21 34
26 43 8 63 22 64 226
267 44 75 104 72 124 686
201 103 67 132 204 64 771
739 363 416 470 425 365 2778
253 173 266 158 127 87 1064
70 35 6 3 24 10 148
114 135 195 125 62 77 708
69 3 65 29 41 207
1 1
486 190 150 312 298 278 1714

147 14 2 8 35 7 213
283 176 142 256 249 234 1340
56 6 35 13 37 147
13 1 14
5 1 4 4 28 42
2 2
1 2 3
1 2 4 28 35
2 2
6 6 2 8 22
58 86 97 80 81 63 465
32 48 30 69 24 203
5 18 2 9 34
21 38 97 32 10 30 228
58 86 97 80 81 63 465
2 11 8 21 11 53
56 86 86 72 60 52 412
48 60 95 24 54 28 309
10 10
8 6 11 5 30
30 60 95 18 43 23 269
38 60 95 24 54 28 299
10 35 23 68
28 25 95 24 54 5 231
97 97
51 86 97 80 81 63 458
51 86 97 80 81 63 458
63 63
97 80 81 258
1 1
97 80 80 257
48 71 74 101 74 70 438
48 71 74 101 74 70 438
48 71 74 101 74 70 438
9.9 14.3 24.2

1 1 2
48 71 74 100 74 69 436
48 71 74 100 74 69 436
48 71 74 101 74 70 438
48 71 74 101 74 70 438
3 3
10 5 14 3 32
6 5 6 1 18
1 1
3 3 2 1 9
2 2 2 6
1 1 2
4 8 2 14
2 1 3
1 1
2 1 3
1 6 7
15 5 14 3 37
15 5 14 3 37
10 5 9 24
9 9
10 10
5 5
13 5 18
1 1
13 4 17
3 85 71 15 174
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
0 0 0 1 0 1 2
58 86 79 80 81 63 447
58 86 79 80 81 63 447
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
101 101
101 101
242 74 95 145 66 73 695

85 78 96 142 81 112 594
83 75 96 134 81 111 580
85 78 96 142 81 112 594
83 75 96 134 81 111 580
94 78 96 142 81 112 603
83 75 96 134 81 111 580
83 75 96 134 81 111 580
85 78 96 142 81 112 594
83 75 96 134 81 111 580
83 75 96 134 81 111 580
83 75 96 134 81 111 580
160 75 96 128 74 100 633
83 75 133 134 81 111 617
7 7
6 month interval from the first dose
58 106 13 42 84 63 366
54 62 21 44 50 80 311
2 46 21 52 121
3 1 11 15
16.4 18 13.6 18.5 42.8 39.2 148.5

138 82 95 145 83 73 616
165 100 110 178 145 120 818
4 0 0 0 0 0 4
265 228 288 405 244 334 1764
276 228 288 405 244 334 1775
13.4 4.2 4 2.4 7.6 3.5 35.1

266 228 288 405 244 334 1765
307 238 300 415 264 346 1870
4.4 0 0 0 0 0 4.4
172 153 192 276 163 223 1179
180 153 192 276 163 223 1187
15 5 7.1 10 17.3 14.8 69.2

238 228 288 405 244 341 1744
280 240 310 450 295 400 1975
2.8 7.3 4 6.9 21.9 13.7 56.6

172 153 192 270 168 233 1188
177 165 200 290 195 270 1297
10 10
10 10
3.8 8.5 7.8 7.1 0 4.7 31.9
125 236 166 130 130 143 930
130 258 180 140 130 150 988
18.3 11.8 12.7 10.7 21 20.7 95.2

85 75 96 134 83 111 584
104 85 110 150 105 140 694
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
6 106 98 71 48 329
96 24 3 8 131
8 1 9
13 2 7 22
96 3 1 100
114 46 46 204 175 98 683
114 46 46 204 175 98 683
46 18 27 38 1 130
7 1 8
7 1 8
7 1 8
0 0 0 0 0 0
71 74 145
71 74 145
78 187 106 371
50 122 23 195
28 65 83 176
187 1187 1374
1 1
186 1187 1373
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
48 71 74 100 74 70 437
1472 1917 1465 1697 1948 870 9369

106 53 97 61 132 203 652
1366 1864 1368 1636 1816 667 8717
5 4 5 6 10 30
5 4 5 6 10 30
2 1 2 2 5 12
2 1 2 2 5 12
223 552 1457 452 245 365 3294

81 149 32 132 110 112 616
142 403 1425 320 135 253 2678
223 552 1457 452 245 365 3294
223 552 1457 452 155 305 3144
90 60 150
95 139 182 186 54 235 891
95 132 174 130 54 175 760
7 8 56 60 131
28 60 557 24 10 32 711
86 96 80 81 101 444
8 21 11 40
86 96 72 60 90 404
834 211 261 162 487 521 2476

1 6 2 4 1 14
834 210 255 160 483 520 2462
834 211 216 159 361 518 2299
734 193 115 134 269 277 1722
100 18 101 25 92 241 577
1270 679 1104 323 2001 3137 8514

50 50
50 99 161 52 571 668 1601
1220 580 943 271 1380 2469 6863
991 3 3 11 3 6 1017
760 2 3 1 766
231 3 3 9 5 251
41 2 5 10 3 9 70
8 8
1 2 2 5 10
40 5 2 1 4 52
2 37 39
2 37 39
2 2
2 2
2 2
2 2
riod by age(SC)
2 5 6 37 9 59
2 5 2 8 17
1 1 2
5 6 3 9 23
5 6 8 19
5 6 11
3 3 6
5 3 8
1 1
5 3 8
244 105 349

244 29 273
68 68
73 4 77
47 6 53
56 19 75
75 75
22 22
35 35
13 13
5 5
1 1
1 1
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
353 62 298 288 1001
2 2
1 1
7 22 29
32 6 12 50
9 2 86 97
70 3 93 166
18 3 85 106
17 5 22
2 2
131 5 88 224
4 4
62 2 64
6 6
14 3 200 217
5 5
2 2
1 1
3 3
95 95
353 62 298 193 906
1 1
0 0 0 1 0 1 2
2 2
2 2
10 10
10 10
4 4
4 4
18 18
18 18
47 47
47 47
49 49
49 49
36 36
36 36
12 12
12 12
14 14
14 14
7 7
7 7
2 2
2 2
10 10
9 9
1 1
4 4
4 4
172 172
72 72
7 7
93 93
8 8
4 4
1 1
1 1
2 2
1 1
1 1
transferred out (net current cohort) 191 191
1 1
1 1
8 8
2 2
2 2
1 1
2 2
7 7
11 11
16 16
29 29
14 14
35 35
12 12
24 24
5 5
7 7
4 4
10 10
1 1
1 1
orting period
ml) in the reporting period 12 12
2 2
3 3
1 1
4 4
1 1
1 1
in the reporting period
110 110
7 7
3 3
2 2
8 8
1 1
2 2
1 1
3 3
27 27
44 44
5 5
7 7
91 91
7 7
9 9
29 29
35 35
4 4
7 7
6 6
6 6
y exposure type
utic or supplementary food
disaggregated by Age, Sex and Pregnancy)
ated by age, sex and pregnancy status)
6 6
5 5
1 1
6 6
2 2
3 3
1 1
method of modern family planning by age 54 54
3 3
9 9
42 42
method of modern family planning by method 54 54
52 52
2 2
1 1
1 1
44 44
5 5
7 7
16 16
16 16
n the reporting period

1 1
1 1
ted a full course of therapy

57 4 61
57 4 61
57 4 61
1 1
3 3
57 57
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
reporting period 60.8 12.2 73

reporting period by age 2 1 3
1 1
1 1
1 1
ng period by age and se 2 2
1 1
1 1
enrolled in the reporting 1 1
1 1
e same month of the previous EFY
ame month of the previous EFY

y the community
ment) who received support for treatment adherence by HEWs during in the same month of previous EFY
o received any form of treatment adherence support from Health extension workers
TB diagnosis or initiation of TB treatment. in the reporting month
uring the reporting Month by age
ned negative for TB in the reporting period
herapy (TPT) in the reporting period by Age Group

onths prior to the reporting period by Age Group
using a WHO recommended rapid tests (GeneXpert and others) at the time of TB diagnosis by age and sex
ting according to national policy during the reporting month
porting period
0 0 0 0 0 0 0
(12 month earlier)

he previous year (12 month earlier)
same month of the previous year (12 month earlier)

he same month of the previous year (12 month earlier)
men 24 months earlier.
men 24 months earlier.
econd-line anti-TB treatment regimen 36 months earlier.
porting period
documented HIV positive test result
documented HIV negative test result

2 2
1 1
1 1
2 2 4
1 1 2
1 1 2
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
21 10 26 1030 246 336 1669
98 15 41 154
2 1 125 8 28 164
2 5 146 32 33 218
4 9 233 11 37 294
7 7 8 223 100 86 431
6 3 3 205 80 111 408
2 5 166 35 8 216
10 1 11
15 1 16
1 31 15 1 48
1 2 29 32
2 40 17 4 63
1 41 3 1 46
7 1 4 2 10 5 29
0 0 0 0 0 0 0
53 327 62 162 604
30 30
40 40
12 58 25 16 111
17 60 7 84
9 65 30 59 163
13 67 5 80 165
2 2 2 6
5 5
53 327 62 162 604
3 1 2 11 17
50 326 60 151 587
3 1 2 11 1153 1170
3 1 1090 1094
2 11 63 76
3 1 2 11 17
1 1
3 2 5 10
6 6
3 1 62 11 77
3 1 11 15
62 62
1 3 1 3 6 14
1 3 1 3 166 174
1 3 1 3 166 174
1 48 49
11 11
9 9
16 16
1 12 13
1 48 49
1 20 21
28 28
1 48 49
1 48 49
2 1 68 71
2 48 50
1 20 21
79 1 20 100
6 6
15 3 18
20 6 26
35 5 40
9 9
1 1
1 1
1 1
the reporting period 1 1 2 79 83

the reporting period 1 1 2 79 83
1 1 2 79 83
the reporting period by age and sex 1 1
1 1
57 183 240
57 183 240
57 183 240
57 183 240
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
3745 2809 4233 7500 5897 3827 28011
100 199 212 346 1202 339 2398
434 484 273 679 1147 534 3551
89 70 140 316 305 143 1063
369 176 129 539 619 205 2037
182 144 500 332 224 343 1725
106 333 195 692 250 307 1883
117 162 90 637 290 210 1506
216 214 151 1015 519 239 2354
305 235 89 783 383 184 1979

53 67 124 545 232 279 1300
41 432 149 588 240 287 1737
1504 135 1021 233 94 231 3218

1524 1200 1225 5422 2352 3000 14723
22 27 16 65
22 3 4 29
22 27 16 65
22 12 10 44
0 0 0 0 100 0 100
25 12 47 17 41 142
22 8 43 4 30 107
3 4 4 13 11 35
25 12 47 84
22 8 43 73
3 4 4 11
25 12 47 41 125
25 12 47 41 125
25 12 47 41 125
25 12 47 41 125
29 12 51 41 133
25 12 47 41 125
22 8 47 41 118
3 4 7
30 30
91 30 121
22 12 10 44
1 2 3
1 1
1 1 2
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 0 1 1 1 1 5
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 0 0 0 1 1 3
1 1 1 1 1 1 6
1 1 1 0 1 1 5
1 1 1 0 1 1 5
1 1 1 0 1 1 5
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 0 1 0 1 1 4
1 0 1 1 1 1 5
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 0 1 1 1 1 5
59 100 56.5 109.3 324.8
23 1291 1520 3061 5895
39 1291 2690 2800 6820
1493 1291 5775 2352 3061 13972
1493 1291 5775 2352 3061 13972
100 100 100 100 100 500
1493 1291 5775 7500 3061 19120
1493 1291 5775 7500 3061 19120
6 6 6 7 12 8 45
93.3 92 91.7 91.9 89.2 93.8 551.9
95 93.3 95 93.8 94.2 93.8 565.1
6 1 6 3 12 3 31
95 95 94.2 73.3 90.8 92.5 540.8
93.3 95 92.5 90 94.2 93.3 558.3
1 0 1 0 1 0 3
95 95 95 285
95 95 95 285
01.2 - Reproductive and Maternal Health | Hospital, Health center, Clinic | Monthly (Nehase 2014)
S.No Activity
MAT_CAR Total number of new and repeat acceptors by age
MAT_CAR_A
MAT_CAR_Ag
10 - 14 years
MAT_CAR_Ag
15 - 19 years
MAT_CAR_Ag
20 - 24 years
MAT_CAR_Ag
25 - 29 years
MAT_CAR_Ag
30 - 49 years
MAT_CAR_A
MAT_CAR_Ag
10 - 14 years
MAT_CAR_Ag
15 - 19 years
MAT_CAR_Ag
20 - 24 years
MAT_CAR_Ag
25 - 29 years
MAT_CAR_Ag
30 - 49 years
MAT_CAR_Total new and repeat acceptors, disaggregated by method
MAT_CAR_M
MAT_CAR_Mt
Oral contraceptives
MAT_CAR_Mt
Injectables
MAT_CAR_Mt
Implants
MAT_CAR_Mt
IUCD
MAT_CAR_Mt
Vasectomy
MAT_CAR_Mt
Tubal ligation
MAT_CAR_Mt
Others
MAT_CAR_M
MAT_CAR_Mt
Oral contraceptives
MAT_CAR_Mt
Injectables
MAT_CAR_Mt
Implants
MAT_CAR_Mt
IUCD
MAT_CAR_Mt
Vasectomy
MAT_CAR_Mt
Tubal ligation
MAT_CAR_Mt
Others

MAT_IPPCATotal PPFP 聽acceptors,聽disaggregated by age
MAT_IPPCA10 - 14 years

MAT_LAFPP
Total number of premature removal of LAFP within 6 month insertion
MAT_LAFPPR
Implants
MAT_LAFPPR
IUCD
MAT_LAFPPR
Others
MAT_TLAFPTotal LAFP removal in the reporting period
MAT_ANC1Antenatal Care (ANC) coverage 鈥

Total Number of pregnant women that received antenatal care 鈥
MAT_ANC1_
MAT_ANC1_
<= 12 weeks
MAT_ANC1_
> 12 and <=16 weeks
MAT_ANC1_
> 16 weeks
Number of pregnant women that received antenatal care 鈥
MAT_ANC1_
MAT_ANC1_
10 - 14 years
MAT_ANC1_
15 - 19 years
MAT_ANC1_
>= 20 years
MAT_ANC4Antenatal care (ANC) coverage 鈥

MAT_ANC4+
Total number of pregnant women that received four or more antenatal care contacts by Maternal Age
MAT_ANC4+
10 - 14 years
MAT_ANC4+
15 - 19 years
MAT_ANC4+
>= 20 years
MAT_ANC4+
Total number of pregnant women that received four or more antenatal care contacts by gestational wee
MAT_ANC4+
<= 30 weeks
MAT_ANC4+
> 30 weeks

MAT_ANC8+
MAT_SYPH.Total Number of pregnant women tested for syphilis
MAT_SYPH.1
Reactive
MAT_SYPH.1
Non-Reactive
MAT_SYPH.Total Number of pregnant women treated for syphilis
MAT_Hepa Total Number of Pregnant women attending antenatal care tested for hepatitis B
MAT_Hepa. Reactive
MAT_Hepa. Non-Reactive
MAT_Prp.1.Total Number of pregnant women who were received prophylaxis for HBV
RMH_L&D_Births attended by skilled health personnel

L&D_SBA.1.Total number of births attended by skilled health personnel
MAT_PPH.1Total number of women who developed postpartum hemorrhage (PPH)
MAT_PPH.1.Facility delivery
MAT_UTERPercentage women who received uterotonics in the first one minute after delivery
MAT_UTER.Total number of women who received uterotonics in the first one minute after delivery
MAT_UTER.1
oxytocin
MAT_UTER.1
mesoprostol
MAT_UTER.1
ergometrin
MAT_UTER.1
Other uterotonics
MAT_SBR.LNumber of Live births
B&D_Ntfc
MAT_B&D_INumber of Institutional birth notifications given
MAT_B&D_INumber of Institutional death notifications given

MAT_EPNC.Number of postnatal visits within 7 days of delivery
MAT_EPNC.1
24Hrs (1day)
MAT_EPNC.1
25 - 48 hrs (1 - 2 days)
MAT_EPNC.1
49 - 72 hrs (2 - 3 days)
MAT_EPNC.1
73 hrs - 7 days (4 - 7 days)
RMH_L&D_Caesarean section
MAT_CAC Number of women receiving comprehensive abortion care services dis aggregated by maternal age
MAT_CAC_Number of safe abortions performed
MAT_CAC_S
10 - 14 years
MAT_CAC_S
15 - 19 years
MAT_CAC_S
20 - 24 years
MAT_CAC_S
25 - 29 years
MAT_CAC_S
>= 30 years
MAT_CAC_Number of post abortion/emergency care
MAT_CAC_P
10 - 14 years
MAT_CAC_P
15 - 19 years
MAT_CAC_P
20 - 24 years
MAT_CAC_P
25 - 29 years
MAT_CAC_P
>= 30 years
MAT_CAC.TNumber of women receiving comprehensive abortion care disaggregated by trimester
MAT_CAC.Tr
MAT_CAC.Tr
MAT_CAC.M
Number of women receiving post abortion care family planning methods disaggregated by Methods
MAT_CAC.MA
Oral contraceptives
MAT_CAC.MA
Injectables
MAT_CAC.MA
Implants
MAT_CAC.MA
IUCD
MAT_CAC.MA
Vasectomy
MAT_CAC.MA
Tubal ligation
MAT_CAC.MA
Others
MAT_OFC_Id
10 - 14 years
MAT_OFC_Id
15 - 19 years
MAT_OFC_Id
20 - 24 years
MAT_OFC_Id
25 - 29 years
MAT_OFC_Id
>= 30 years
MAT_OFC_T
Number of obstetric fistula cases treated by Age
MAT_OFC_Tr
10 - 14 years
MAT_OFC_Tr
15 - 19 years
MAT_OFC_Tr
20 - 24 years
MAT_OFC_Tr
25 - 29 years
MAT_OFC_Tr
>= 30 years
MAT_TngP Total number of teenage girls tested positive for pregnancy
MAT_TngP_10 - 14 years
MAT_TngtstTotal number of women tested positive for pregnancy
02 - PMTCT | Hospital, Health center, Clinic | Monthly (Nehase 2014)
S.No Activity
RMCH__PMT
MTCT PMTCT
MTCT_TST Pregnant and lactating women who were tested for HIV and know their results
MTCT_TST.Number of Pregnant women tested and know their HIV result during pregnancy
03 - EPI | Hospital, Health center, Health post, Clinic | Monthly (Nehase 2014)
S.No Activity
EPI_HepBDNumber of Live births who receive a HepB-Birth dose(BD)
EPI_HepBD.Within 24 to 14 days after birth
EPI_BCG1. Number of children under one year of age who have received BCG vaccine
EPI_DPT1.1Number of children under one year of age who have received first dose of pentavalent vaccine
EPI_DPT3.1Number of children under one year of age who have received third dose of pentavalent vaccine
EPI_OPV1.1Number of children under one year of age who have received first dose of polio vaccine
EPI_OPV3.1Number of children under one year of age who have received third dose of Polio vaccine
EPI_PCV1.1Number of children under one year of age who have received first dose of pneumococcal vaccine
EPI_PCV3.1Number of children under one year of age who have received third dose of pneumococcal vaccine
EPI_IPV.1. Number of children under one year of age who have received one dose of inactivated polio vaccine
EPI_Rota1.1Number of children under one year of age who have received first dose of Rotavirus vaccine
EPI_Rota2.1Number of children under one year of age who have received 2nd dose of Rotavirus vaccine
EPI_MCV1.1Number of children under one year of age who have received first dose of measles vaccine
EPI_FI.1. Number of children received all vaccine doses before 1st birthday
EPI_MCV2.1Number of children (15-23 ) months of age who have received second dose of measles vaccine
EPI_PAB Proportion of under one children protected against Neonatal Tetanus(PAB)
EPI_PAB.1. Number of infants whose mothers had protective doses of TD against NNT (PAB)
EPI_HPV1 HPV 1 (Human Papilloma Virus vaccine (1st dose) Immunization coverage (14 years old girls)
EPI_HPV2 HPV 2 (Human Papilloma Virus vaccine (2nd dose) Immunization coverage (14 years old girls)
EPI_HPV2.1Number of girls 14 years of age who have received second dose of human papillomavirus vaccine in 6 month interval from the fi
EPI_VWR_He
EPI_VWR_He
EPI_VWR_He
EPI_VWR_He
EPI_VWR_BBCG doses given (all ages)
EPI_VWR_BBCG doses opened
EPI_VWR_BBCG doses expired
EPI_VWR_Pe
EPI_VWR_Pe
EPI_VWR_PPentavalent (DPT-HepB-Hib) doses damaged
EPI_VWR_Pe
EPI_VWR_PPneumococcal conjugated vaccine doses given
EPI_VWR_PPneumococcal conjugated vaccine doses opened
EPI_VWR_PC
EPI_VWR_RT
EPI_VWR_RRota doses opened
EPI_VWR_RT
Rota doses expired
EPI_VWR_PV
EPI_VWR_PPolio doses opened
EPI_VWR_PV
Polio doses expired
EPI_VWR_M
EPI_VWR_M
Measles doses opened
EPI_VWR_M
Measles doses damaged
EPI_VWR_M
EPI_VWR_TD
EPI_VWR_TTD doses opened
EPI_VWR_TD
TD doses expired
EPI_VWR_IP
IPV doses given
EPI_VWR_IP
IPV doses opened
EPI_VWR_IIPV doses damaged
EPI_VWR_IP
IPV doses expired
HPV Vaccine wastage rate
EPI_VWR_HHPV doses given
EPI_VWR_HHPV doses opened
EPI_VWR_HHPV doses damaged
EPI_VWR_HHPV doses expired
04.2 - Neonatal and Child Health | Health center, Hospital and clinic | Monthly (Nehase 2014)
S.No Activity
CH Child Health
CH_TX_PN Under-five children with pneumonia received antibiotic treatment
CH_TX_PNE
Number of under 5 children treated for pneumonia
CH_TX_SYI.Number of sick young infants 0-2 months treated for Critical illness
CH_TX_SYI.Treated for Very Severe Diseases
CH_TX_SYI.Treated for Local bacterial infection ( LBI)
CH_TX_SYI.Treated for Pneumonia
CH_TX_DIAChildren treated with Zinc and ORS for diarrhea
CH_TX_DIAR
CH_TX_DIAR
Treated by ORS only
CH_KMC.1.Total number of newborns weighing <2000gm and/or premature newborns for which KMC initiated
CH_KMC.2.Total number of newborns weighing <2000gm and/or premature
CH_ASPH.1Number of neonates resuscitated and survived
CH_ASPH.2Total number of neonates resuscitated
CH_TX_NICU
Recovered
CH_TX_NICU
Dead
CH_TX_NICU
Transferred
CH_TX_NICU
CH_CHX Newborns that received at least one dose of CHX to the cord on the first day after birth
CH_CHX.1. Number of Newborns that received at least one dose of CHX to the cord on the first day after birth
CH_CHDM Children aged 0 to 59 months Assessed for developmental milestone
CH_CHDMSChildren aged 0 to 59 months Assessed for developmental milestone and there status
CH_CHDMS.
Suspected Developmental Delay
CH_CHDMS.
Developmental Delay
CH_CHDMS.
No Developmental Delay
05.2 - Nutrition | Hospital, Health center | Monthly (Nehase 2014)
S.No Activity
NUT Nutrition
NUT_LBW.2Total number of live births weighed
NUT_GMP Proportion of < 2 year children who have participated in growth monitoring and promotion (GMP)
NTR_GMP.1Number of children less than 2 yr weighted during GMP session
NTR_GMP.1.
0 - 5 months
NTR_GMP.1.
6 - 23 months
NUT_GMP.M
Number of weights recorded with moderate malnutrition, by age (Z-score between -2 and -3)
NUT_GMP.M
0 - 5 months
NUT_GMP.M
6 - 23 months
NUT_GMP_Number of weights recorded with severe malnutrition, by age (Z-score below (-3)
NUT_GMP_S
0 - 5 months
NUT_GMP_S
6 - 23 months
NCH_NTR_Children aged 6-59 months who received vitamin A supplementation
NUT_VITA Total number of children aged 6-59 months who received Vitamin A supplementation dis aggregated by
NUT_VITA.2Total number of children aged 6-59 months who received Vitamin A supplementation dis aggregated by
NUT_VITA.2First dose
NUT_VITA.2Second dose
NUT_DeW.1Total number of children aged 24 - 59 months dewormed
NUT_DeW.1.
First dose
NUT_DeW.1.
Second dose
NUT_DeW.2Number of pregnant women De-wormed
NUT_IFA Proportion of pregnant women received iron and folic acid (IFA) supplements at least 90 plus
NUT_IFA.1 Total number of Pregnant women received IFA at least 90 plus
NUT_IFA.1. >= 20 years
NUT_PreSMProportion of Pregnant and lactating women (PLW) screened for malnutrition
NUT_PreSMTotal number of PLW screened for acute malnutrition by MUAC status
NUT_PreSMN
MUAC < 23 cm
NUT_PreSMN
MUAC >= 23 cm
NUT_PreSMTotal number of PLW screened for acute malnutrition By maternal status:
NUT_PreSMN
Pregnant
NUT_PreSMN
lactating
NUT_U5SMChildren aged <5 yrs screened for acute malnutrition
NUT_U5SMTotal Number of children < 5 yr screened for acute malnutrition
NUT_U5SMN
0 - 5 months
NUT_U5SMN
6 - 23 months
NUT_U5SMN
24 - 59 Months
NUT_U5SMN
NUT_U5SMN
0 - 5 months
NUT_U5SMN
6 - 23 months
NUT_U5SMN
24 - 59 Months
NUT_U5SMN
NUT_U5SMN
0 - 5 months
NUT_U5SMN
6 - 23 months
NUT_U5SMN
24 - 59 Months
NUT_TX-U Admission and treatment outcome for management of severe acute malnutrition in children under 5 yrs
NUT_TX-U Total SAM at the beginning of the month
NUT_TX-U5Total number of children with SAM admitted to SC during the reporting period(new and re-admision)
NUT_TX-U5Number of children stablized
NUT_TX-U5Number of children cured
NUT_TX-U Number of children -non-respondent
NUT_TX-U5Number of children Medical transfer
NUT_TX-U5Number of children who exit from severe acute malnutrition treatment during the reporting period by ag
NUT_TX-U5Admission and treatment outcome for management of severe acute malnutrition in children under 6-59
NUT_TX-U5Total SAM at the beginning of the month for OTP
NUT_TX-U5OTP_Number of children stabilized
NUT_TX-U5OTP_Number of children cured
NUT_TX-U5OTP_Number of children Medical transfer
NUT_TX-U5OTP_Number of children unknown status
NUT_TX-U5Total number of children with SAM admitted to OTP during the reporting period
NUT_TX-U5Number of children who exit from severe acute malnutrition treatment during the reporting period(OTP)
NUT_TX-U Admission and treatment outcome for management of MAM for childern 6-59 months
NUT_TX-U5MAM_Number of children stabilized
NUT_TX-U5MAM_Number of children cured
NUT_TX-U5MAM_Number of children -non-respondent
NUT_Adl&YTotal number of Adolescent girls Aged 14-19 years screened for malnutrition
NUT_Adl&Yo
10 - 14 years, Male
NUT_Adl&Yo
NUT_Adl&Yo
15 - 19 years, Male
NUT_Adl&Yo
06 - HIV | Hospital, Health center, Clinic | Monthly (Nehase 2014)
S.No Activity
HIV_HTS_TClients receiving HIV test results (at VCT)
HIV_HTS_T< 1 year, Male
HIV_HTS_T< 1 year, Female
HIV_HTS_T1 - 4 years, Male
HIV_HTS_T1 - 4 years, Female
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TClients testing positive for HIV (at VCT)
HIV_HTS_T>= 50 years, Male
HIV_HTS_T>= 50 years, Female
HIV_HTS_TClients receiving HIV test results (at PITC)
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TClients testing positive for HIV (at PITC)
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_THIV testing service - HTS who received result by population group
HIV_HTS_THIV testing service - HTS who tested positive by population group
HIV_TST_PFemale comercial Sex workers : Received result
HIV_HTS_TFemale comercial Sex workers :Positive
HIV_HTS_TLong distance drivers: Received result
HIV_HTS_TLong distance drivers :Positive
HIV_HTS_TMobile/Daily Laborers: Received result
HIV_HTS_TMobile/Daily Laborers: Positive
HIV_HTS_TOVC of PLHIV :Received result
HIV_HTS_TOVC of PLHIV: Positive
HIV_HTS_TChildren of PLHIV: Received result
HIV_HTS_TChildren of PLHIV: Positive
HIV_HTS_TPrisoners :Received result
HIV_HTS_TPrisoners : Positive
HIV_HTS_TPartners of PLHIV: Received result
HIV_HTS_TPartners of PLHIV: Positive
HIV_HTS_TOther MARPs:Received result
HIV_HTS_TOther MARPs: Positive
HIV_HTS_TGeneral population: Received result
HIV_HTS_TGeneral population: Positive
HIV_HTS_TNumber of individuals who were identified and tested using Index testing services and received their res
HIV_HTS_TNumber of index cases offered
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TNumber of contacts elicited
HIV_HTS_TS
< 15 years, Male
HIV_HTS_TS
< 15 years, Female
HIV_HTS_TS
>= 15 years, Male
HIV_HTS_TS
>= 15 years, Female
HIV_HTS_TNumber of contacts tested
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TNumber of contacts by test result (Positive)
HIV_HTS_TNew positive
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TKnown positive
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TNumber of Individual HIV self test KIT distribued
HIV_HTS_TDirectly assisted
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TUnassisted
HIV_HTS_TMale
HIV_HTS_TFemale
HIV_HIV_TrDoes health facility provide Monthly PMTCT / ART Treatment Service?
HIV_TX_CUChildren聽currently on ART aged <1 yr
HIV_TX_CUChildren currently on ART aged <1 yr on First line聽 regimen by sex
HIV_TX_CUMale
HIV_TX_CUFemale
HIV_TX_CUChildren currently on ART aged <1 yr on Second line聽 regimen by sex
HIV_TX_CUMale
HIV_TX_CUFemale
HIV_TX_CUMale
HIV_TX_CUFemale
HIV_TX_CUChildren聽currently on ART aged 1-4 yr
HIV_TX_CUChildren currently on ART aged 1-4 yr on First line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren currently on ART aged 1-4 yr on Second-line聽 regimen by sex

HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren聽currently on ART aged 5-9 yr on First line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren聽currently on ART aged 5-9 yr on Second line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren聽currently on ART aged 5-9 yr on Third line regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren聽 currently on ART aged 10-14 year
HIV_TX_CUChildren聽 currently on ART aged 10-14 year on First line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren currently on ART aged 10-14 year on Second line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUAdult currently on ART aged 15-19 on First line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUAdult currently on ART aged 15-19 on Second-line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUAdult currently on ART aged 25-29 on Second line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female

HIV_TX_CUAdult currently on ART aged 50+ on First line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUAdult currently on ART aged 50+ on Second line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUAdult currently on ART aged 50+ on Third line regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_C Currently on ART by pregnancy status
HIV_TX_CUPregnant
HIV_TX_CUChildren currently on ART aged <1 yr on First line聽 regimen by regimen type
HIV_TX_CU5e=ABC + 3TC + LPV/r
HIV_TX_CU5m = ABC + 3TC + DTG
HIV_TX_CU5n= AZT + 3TC + DTG
HIV_TX_CU5j=other secondline
HIV_TX_CU6c=DRV/r+DTG+AZT+3TC
HIV_TX_CU6f= DRV/r + DTG + ABC + 3TC
HIV_TX_CU6e=Other thirdline regimen
HIV_TX_CU聽Children currently on ART aged 1-4 yr on First line regimen by regimen type
HIV_TX_CU4d = AZT+3TC+EFV
HIV_TX_CU4L= ABC + 3TC + EFV
HIV_TX_CU5h=ABC + 3TC + EFV
HIV_TX_CU6g= DRV/r +ABC+3TC+ EFV
HIV_TX_CU6h= DRV/r +AZT+3TC+EFV
HIV_TX_CU4e= TDF+3TC+EFV
HIV_TX_CU4i= TDF + 3TC + DTG
HIV_TX_CU5g= TDF + 3TC + EFV
HIV_TX_CU5i=TDF + 3TC+ LPV/r
HIV_TX_CU5o= TDF + 3TC + DTG
HIV_TX_CU6d=DRV/r+DTG+TDF+3TC
HIV_TX_CUChildren currently on ART aged 10-14 year on 聽First line regimen by regimen type
HIV_TX_CUAdult currently on ART aged 15-19 on聽First line regimen by regimen type
HIV_TX_CU1d = AZT-3TC-EFV
HIV_TX_CU1e = TDF-3TC-EFV
HIV_TX_CU1g= ABC + 3TC + EFV
HIV_TX_CU1j=TDF + 3TC + DTG
HIV_TX_CU1k= AZT +3TC +DTG
HIV_TX_CU1i = Other specify
HIV_TX_CU2e= AZT+3TC+LPV/r
HIV_TX_CU2f=AZT+3TC+ATV/r
HIV_TX_CU2g= TDF-3TC-LPV/r
HIV_TX_CU2h =TDF-3TC-ATV/r
HIV_TX_CU2i = ABC + 3TC + LPV/r
HIV_TX_CU2j = TDF + 3TC + DTG
HIV_TX_CU2k = AZT + 3TC + DTG
HIV_TX_CU2l=other secondline
HIV_TX_CU3a=DRV/r+DTG+AZT/3TC
HIV_TX_CU3b=DRV/r+DTG+TDF/3TC
HIV_TX_CU3c=DRV/r+ABC+3TC+DTG
HIV_TX_CU3e= DRV/r+TDF+3TC+EFV
HIV_TX_CU3f= DRV/r+AZT+3TC +EFV

HIV_TX_CU3d=Other thirdline
HIV_TX_CUAdults >=20 years currently on First line聽 regimen by regimen type
HIV_TX_CU1d = AZT-3TC-EFV, Male
HIV_TX_CU1d = AZT-3TC-EFV, Female - pregnant
HIV_TX_CU1d = AZT-3TC-EFV, Female - non-pregnant
HIV_TX_CU1e = TDF-3TC-EFV, Male
HIV_TX_CU1e = TDF-3TC-EFV, Female - pregnant
HIV_TX_CU1e = TDF-3TC-EFV, Female - non-pregnant
HIV_TX_CU1g= ABC + 3TC + EFV, Male
HIV_TX_CU1g= ABC + 3TC + EFV, Female - pregnant
HIV_TX_CU1g= ABC + 3TC + EFV, Female - non-pregnant
HIV_TX_CU1j=TDF + 3TC + DTG, Male
HIV_TX_CU1j=TDF + 3TC + DTG, Female - pregnant
HIV_TX_CU1j=TDF + 3TC + DTG, Female - non-pregnant
HIV_TX_CU1k= AZT +3TC +DTG, Male
HIV_TX_CU1k= AZT +3TC +DTG, Female - pregnant
HIV_TX_CU1k= AZT +3TC +DTG, Female - non-pregnant
HIV_TX_CU1i = Other specify, Male
HIV_TX_CU1i = Other specify, Female - pregnant
HIV_TX_CU1i = Other specify, Female - non-pregnant
HIV_TX_CU聽Adults >=20 years currently on Second line regimen by regimen type
HIV_TX_CU2e= AZT+3TC+LPV/r, Male
HIV_TX_CU2e= AZT+3TC+LPV/r, Female - pregnant
HIV_TX_CU2e= AZT+3TC+LPV/r, Female - non-pregnant
HIV_TX_CU2f=AZT+3TC+ATV/r, Male
HIV_TX_CU2f=AZT+3TC+ATV/r, Female - pregnant
HIV_TX_CU2f=AZT+3TC+ATV/r, Female - non-pregnant
HIV_TX_CU2g= TDF-3TC-LPV/r, Male
HIV_TX_CU2g= TDF-3TC-LPV/r, Female - pregnant
HIV_TX_CU2g= TDF-3TC-LPV/r, Female - non-pregnant
HIV_TX_CU2h =TDF-3TC-ATV/r, Male
HIV_TX_CU2h =TDF-3TC-ATV/r, Female - pregnant
HIV_TX_CU2h =TDF-3TC-ATV/r, Female - non-pregnant
HIV_TX_CU2i = ABC + 3TC + LPV/r, Male
HIV_TX_CU2i = ABC + 3TC + LPV/r, Female - pregnant
HIV_TX_CU2i = ABC + 3TC + LPV/r, Female - non-pregnant
HIV_TX_CU2j = TDF + 3TC + DTG, Male
HIV_TX_CU2j = TDF + 3TC + DTG, Female - pregnant
HIV_TX_CU2j = TDF + 3TC + DTG, Female - non-pregnant
HIV_TX_CU2k = AZT + 3TC + DTG, Male
HIV_TX_CU2k = AZT + 3TC + DTG, Female - pregnant
HIV_TX_CU2k = AZT + 3TC + DTG, Female - non-pregnant
HIV_TX_CU2l=other secondline, Male
HIV_TX_CU2l=other secondline, Female - pregnant
HIV_TX_CU2l=other secondline, Female - non-pregnant
HIV_TX_CU3a=DRV/r+DTG+AZT/3TC, Male
HIV_TX_CU3a=DRV/r+DTG+AZT/3TC, Female - pregnant
HIV_TX_CU3a=DRV/r+DTG+AZT/3TC, Female - non-pregnant
HIV_TX_CU3b=DRV/r+DTG+TDF/3TC, Male
HIV_TX_CU3b=DRV/r+DTG+TDF/3TC, Female - pregnant
HIV_TX_CU3b=DRV/r+DTG+TDF/3TC, Female - non-pregnant
HIV_TX_CU3c=DRV/r+ABC+3TC+DTG, Male
HIV_TX_CU3c=DRV/r+ABC+3TC+DTG, Female - pregnant
HIV_TX_CU3c=DRV/r+ABC+3TC+DTG, Female - non-pregnant
HIV_TX_CU3e= DRV/r+TDF+3TC+EFV, Male
HIV_TX_CU3e= DRV/r+TDF+3TC+EFV, Female - pregnant
HIV_TX_CU3e= DRV/r+TDF+3TC+EFV, Female - non-pregnant
HIV_TX_CU3f= DRV/r+AZT+3TC +EFV, Male
HIV_TX_CU3f= DRV/r+AZT+3TC +EFV, Female - pregnant
HIV_TX_CU3f= DRV/r+AZT+3TC +EFV, Female - non-pregnant
HIV_TX_CU3d=Other thirdline, Male
HIV_TX_CU3d=Other thirdline, Female - pregnant
HIV_TX_CU3d=Other thirdline, Female - non-pregnant
HIV_TX_NENumber of adults and children with HIV infection newly started on ART
HIV_TX_NE< 1 year, Male
HIV_TX_NE< 1 year, Female - non-pregnant
HIV_TX_NE1 - 4 years, Male
HIV_TX_NE1 - 4 years, Female - non-pregnant
HIV_TX_NE15 - 19 years, Female - pregnant
HIV_TX_NE>= 50 years, Male
HIV_TX_NE>= 50 years, Female - non-pregnant
HIV_ART_RART retention rate (Percentage of adult and children on ART treatment after 12 month of initation of AR
HIV_ART_RE
< 1 year, Male
HIV_ART_RE
HIV_ART_RE
1 - 4 years, Male
HIV_ART_RE
HIV_ART_RE
5 - 9 years, Male
HIV_ART_RE
HIV_ART_RE
10 - 14 years, Male
HIV_ART_RE
HIV_ART_RE
15 - 19 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
20 - 24 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
25 - 29 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
30 - 34 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
35 - 39 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
40 - 44 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
45 - 49 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
>= 50 years, Male
HIV_ART_RE
HIV_ART_R< 1 year, Male
HIV_ART_R< 1 year, Female - non-pregnant
HIV_ART_R1 - 4 years, Male
HIV_ART_R1 - 4 years, Female - non-pregnant
HIV_ART_R15 - 19 years, Female - pregnant
HIV_ART_R>= 50 years, Male
HIV_ART_R>= 50 years, Female - non-pregnant
HIV_ART_ Linkage outcome of of newly identified Hiv positive individuals in the reporting period
HIV_ART_NDied
HIV_ART_NOthers
HIV_TX_PVViral load Suppression (Percentage of ART clients with a suppressed viral load among those with a viral
HIV_TX_PVNumber of adult and pediatric ART patients for whom viral load test result received in the reporting period
HIV_TX_PVL
< 1 year, Male
HIV_TX_PVL
HIV_TX_PVL
1 - 4 years, Male
HIV_TX_PVL
HIV_TX_PVL
5 - 9 years, Male
HIV_TX_PVL
HIV_TX_PVL
10 - 14 years, Male
HIV_TX_PVL
HIV_TX_PVL
15 - 19 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
20 - 24 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
25 - 29 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
30 - 34 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
35 - 39 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
40 - 44 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
45 - 49 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
>= 50 years, Male
HIV_TX_PVL
HIV_TX_PVTotal number of adult and paediatric ART patients with an undetectable viral load(<50 copies/ml) in the reporting period
HIV_TX_PVL
< 1 year, Male
HIV_TX_PVL
HIV_TX_PVL
1 - 4 years, Male
HIV_TX_PVL
HIV_TX_PVL
5 - 9 years, Male
HIV_TX_PVL
HIV_TX_PVL
10 - 14 years, Male
HIV_TX_PVL
HIV_TX_PVL
15 - 19 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
20 - 24 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
25 - 29 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
30 - 34 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
35 - 39 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
40 - 44 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
45 - 49 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
>= 50 years, Male
HIV_TX_PVL
HIV_TX_DSTotal number of adult and paediatric ART patients with low level viremia (50 -1000 copies/ml) in the reporting period
HIV_TX_DSD
< 1 year, Male
HIV_TX_DSD
HIV_TX_DSD
1 - 4 years, Male
HIV_TX_DSD
HIV_TX_DSD
5 - 9 years, Male
HIV_TX_DSD
HIV_TX_DSD
10 - 14 years, Male
HIV_TX_DSD
HIV_TX_DSD
15 - 19 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
20 - 24 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
25 - 29 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
30 - 34 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
35 - 39 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
40 - 44 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
45 - 49 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
>= 50 years, Male
HIV_TX_DSD
HIV_TX_DSProportion of PLHIV currently on differentiated service Delivery model (DSD)
HIV_TX_3MTotal number of clients on 3MMD
HIV_TX_3M< 1 year, Male
HIV_TX_3M< 1 year, Female
HIV_TX_3M1 - 4 years, Male
HIV_TX_3M1 - 4 years, Female
HIV_TX_3M>= 50 years, Male
HIV_TX_3M>= 50 years, Female
HIV_TX_ASTotal number of clients on ASM(6MMD)
HIV_TX_ASM
15 - 19 years, Male
HIV_TX_ASM
HIV_TX_ASM
20 - 24 years, Male
HIV_TX_ASM
HIV_TX_ASM
25 - 49 years, Male
HIV_TX_ASM
HIV_TX_ASM
>= 50 years, Male
HIV_TX_ASM
>= 50 years, Female
HIV_TX_FTA
15 - 19 years, Male
HIV_TX_FTA
HIV_TX_FTA
20 - 24 years, Male
HIV_TX_FTA
HIV_TX_FTA
25 - 49 years, Male
HIV_TX_FTA
HIV_TX_FTA
>= 50 years, Male
HIV_TX_FTA
>= 50 years, Female
HIV_TX_CAG
15 - 19 years, Male
HIV_TX_CAG
HIV_TX_CAG
20 - 24 years, Male
HIV_TX_CAG
HIV_TX_CAG
25 - 49 years, Male
HIV_TX_CAG
HIV_TX_CAG
>= 50 years, Male
HIV_TX_CAG
>= 50 years, Female
HIV_TX_PCTotal number of clients on PCAD
HIV_TX_PCA
15 - 19 years, Male
HIV_TX_PCA
HIV_TX_PCA
20 - 24 years, Male
HIV_TX_PCA
HIV_TX_PCA
25 - 49 years, Male
HIV_TX_PCA
HIV_TX_PCA
>= 50 years, Male
HIV_TX_PCA
>= 50 years, Female
.
HIV_TX_AdoTotal number of clients on Adolescent DSD
HIV_TX_KPTotal number of clients on KP DSD
HIV_TX_ othTotal number of clients on other types of DSD
HIV_TX_A Total number of clients on "Advanced HIV Disease Care Model"
HIV_TX_AH< 1 year, Male
HIV_TX_AH< 1 year, Female
HIV_TX_AH1 - 4 years, Male
HIV_TX_AH1 - 4 years, Female
HIV_TX_AH>= 50 years, Male
HIV_TX_AH>= 50 years, Female
HIV_ART_I Transferred out
HIV_ART_I Refused (stopped) treatement
HIV_ART_I Died
HIV_ART_R< 15 years, Male
HIV_ART_R< 15 years, Female
HIV_ART_R>= 15 years, Female
HIV_PrEP.1PrEP (New Number of individuals who were newly enrolled on PrEP)
HIV_PrEP.1By age and Sex
HIV_PrEP.1By Client Category
HIV_PrEP.1PrEP Curr (Number of individuals that received oral PrEP during the reporting period)
HIV_PEP. 1Occupational
HIV_PEP. 2Sexual violence
HIV_PEP. 3Other Non occupational
HIV_PLHIV Proportion of clinically undernourished People Living with HIV (PLHIV) who received therapeutic or supplementary food
HIV_PLHIV Number of PLHIV that were nutritionally assessed and found to be clinically undernourished (disaggregated by Age, Se
HIV_PLHIV Total MAM
HIV_PLHIV < 15 years, Male
HIV_PLHIV < 15 years, Female
HIV_PLHIV >= 15 years, Male
HIV_PLHIV >= 15 years, Female
HIV_PLHIV Total SAM
HIV_PLHIV Clinically undernourished PLHIV who received therapeutic or supplementary food (disaggregated by age, sex and preg
HIV_PLHIV Total MAM who received therapeutic or supplementary food
HIV_PLHIV Total SAM who received therapeutic or supplementary food
HIV_STI_SCMale
HIV_STI_SCFemale
HIV_STI_SCMale
HIV_STI_SCFemale
HIV_ART_FNumber of non-pregnant women living with HIV on ART aged 15-49 reporting the use of any method of modern family p
HIV_ART_FP
10 - 14 years
HIV_ART_FP
15 - 19 years
HIV_ART_FP
20 - 24 years
HIV_ART_FP
25 - 29 years
HIV_ART_FP
30 - 49 years
HIV_ART_FOral contraceptives
HIV_ART_FInjectables
HIV_ART_FImplants
HIV_ART_FIUCD
HIV_ART_FOthers
HIV_TB.1. 1< 15 years, Male
HIV_TB.1. 2< 15 years, Female
HIV_TB.1. 3>= 15 years, Male
HIV_TB.1. 4>= 15 years, Female
HIV_TB_SC< 15 years, Male
HIV_TB_SC< 15 years, Female
HIV_TB_SC>= 15 years, Male
HIV_TB_SC>= 15 years, Female
HIV_ART_TNumber of ART patients who started on a standard course of TB Preventive Treatment (TPT) in the reporting period
HIV_TB_TPPatients on 6H
HIV_TB_TPT
< 15 years, Male
HIV_TB_TPT
< 15 years, Female
HIV_TB_TPT
>= 15 years, Male
HIV_TB_TPT
>= 15 years, Female
HIV_ART_TPatients on 3HP
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_TPatients on 3HR
HIV_ART_T< 15 years, Male
HIV_ART_T< 15 years, Female
HIV_ART_T>= 15 years, Male
HIV_ART_T>= 15 years, Female
HIV_ART_TNumber of ART patients who were initiated on any course of TPT 12 months before the reporting period
HIV_ART_TPatients on 3HP 12 months prior to the reporting period
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_TPatients on 3HR 12 months prior to the reporting period
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_TNumber of ART patients who started TPT 12 months prior to the reproting period that completed a full course of therapy
HIV_ART_TPatients who completed 6H
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_TPatients who completed 3HP
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_TPatients who completed 3HR
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_CXCA Cervical Cancer screening by type of test
HIV_CXCA_S
15 - 19 years
HIV_CXCA_S
20 - 24 years
HIV_CXCA_S
25 - 29 years
HIV_CXCA_S
30 - 49 years
07 - TB/Leprosy | Hospital, Health center, clinic | Monthly (Nehase 2014)
S.No Activity
TB_TX_PTBNumber of all forms of TB (New and Relapse) cases that were notified and treated during the reporting period
TB Number of bacteriologically confirmed New Pulmonary TB cases detected and enrolled in the reporting period by a
TB_TX_PTBNumber of clinically diagnosed New pulmonary TB cases detected and enrolled in the reporting period by age and
TB_TX_PTB.
0 - 4 years, Male
TB_TX_PTB.
0 - 4 years, Female
TB_TX_PTB.
5 - 9 years, Male
TB_TX_PTB.
5 - 9 years, Female
TB_TX_PTB.
10 - 14 years, Male
TB_TX_PTB.
TB_TX_PTB.
15 - 19 years, Male
TB_TX_PTB.
TB_TX_PTB.
20 - 24 years, Male
TB_TX_PTB.
TB_TX_PTB.
25 - 34 years, Male
TB_TX_PTB.
TB_TX_PTB.
35 - 44 years, Male
TB_TX_PTB.
TB_TX_PTB.
45 - 54 years, Male
TB_TX_PTB.
TB_TX_PTB.
55 - 64 years, Male
TB_TX_PTB.
TB_TX_PTB.
>=65 yr, Male
TB_TX_PTB.
>=65 yr, Female
TB_TX_EPTNumber of clinically diagnosed and bacteriological confirmed new EPTB cases detected and enrolled in the reporti
TB_TX_EPTB
0 - 4 years, Male
TB_TX_EPTB
0 - 4 years, Female
TB_TX_EPTB
5 - 9 years, Male
TB_TX_EPTB
5 - 9 years, Female
TB_TX_EPTB
10 - 14 years, Male
TB_TX_EPTB
TB_TX_EPTB
15 - 19 years, Male
TB_TX_EPTB
TB_TX_EPTB
20 - 24 years, Male
TB_TX_EPTB
TB_TX_EPTB
25 - 34 years, Male
TB_TX_EPTB
TB_TX_EPTB
35 - 44 years, Male
TB_TX_EPTB
TB_TX_EPTB
45 - 54 years, Male
TB_TX_EPTB
TB_TX_EPTB
55 - 64 years, Male
TB_TX_EPTB
TB_TX_EPTB
>=65 yr, Male
TB_TX_EPTB
>=65 yr, Female
TB_TX_RTB.
0 - 4 years, Male
TB_TX_RTB.
0 - 4 years, Female
TB_TX_RTB.
5 - 9 years, Male
TB_TX_RTB.
5 - 9 years, Female
TB_TX_RTB.
10 - 14 years, Male
TB_TX_RTB.
TB_TX_RTB.
15 - 19 years, Male
TB_TX_RTB.
TB_TX_RTB.
20 - 24 years, Male
TB_TX_RTB.
TB_TX_RTB.
25 - 34 years, Male
TB_TX_RTB.
TB_TX_RTB.
35 - 44 years, Male
TB_TX_RTB.
TB_TX_RTB.
45 - 54 years, Male
TB_TX_RTB.
TB_TX_RTB.
55 - 64 years, Male
TB_TX_RTB.
TB_TX_RTB.
>=65 yr, Male
TB_TX_RTB.
>=65 yr, Female
TB_KEY_P Number of notified TB cases from key affected population group during the reporting period
TB_KEY_POHealth care workers including HEWs
TB_KEY_PODiabetes
TB_KEY_POHomeless
TB_KEY_PORefugee
TB_KEY_POPrisoners
TB_KEY_POMiners
TB_KEY_POCongregated Settings
TB_KEY_POTB Contacts
TB_KEY_POOther key affected population
CDC_TB_RTB Treatment-outcome
TB_TX_OUTTotal number of bacteriologically confirmed new Pulmonary TB cases enrolled in cohort (PTB+) in the same mo
TB_CR_PTB
TB_CR_PTB.
Completed
TB_CR_PTB.
Cured
TB_CR_PTB.
Lost to follow-up
TB_CR_PTB.
Dead
TB_CR_PTB.
Failed
TB_CR_PTB.
Not evaluated
TB_CR_PTB.
TB_CR_PNTTotal number of new clinically diagnosed pulmonary TB cases enrolled in the cohort (P/Neg) in the same month of the prev
TB_CR_PNT
TB_CR_PNTB
Completed
TB_CR_PNTB
Lost to follow-up
TB_CR_PNTB
Deaths
TB_CR_PNTB
Failed
TB_CR_PNTB
TB_CR_PNTB
Not evaluated
TB_CR_EPTTotal number of new EPTB cases enrolled in the cohort (EPTB) in the same month of previous EFY
TB_CR_EPTTreatment outcome of cohort of new extra pulmonary TB (EPTB)cases
TB_CR_EPTB
Completed
TB_CR_EPTB
Lost to follow-up
TB_CR_EPTB
Deaths
TB_CR_EPTB
Failed
TB_CR_EPTB
TB_CR_EPTB
Not evaluated
TB_CR_RTBTotal number of all Relapse cases enrolled in the cohort in the same month of previous EFY
TB_CR_RTB
TB_CR_RTB.
Completed
TB_CR_RTB.
Cured
TB_CR_RTB.
Lost to follow-up
TB_CR_RTB.
Dead
TB_CR_RTB.
Failed
TB_CR_RTB.
Not evaluated
TB_CR_RTB.
TB_COMM. Number of all forms TB cases detected and registered on TB unit register who are initially referred by the community
TB_CBTSR.Number of cohort TB patients (all forms) who were successfully treated (cured plus completed treatment) who received su
TB_CBTSR.Total number of patients who started TB treatment in same reporting month of pervious year and who received any form of
TB_DX_PRINumber of TB cases (all forms) notified in public health facilities with initial referral by PPM sites for TB diagnosis or initiation of T
TB_CI.1.1 Total number of contacts with index bacteriologically confirmed drug susceptible TB cases during the reporting M
TB_CI.1.1. 10 - 4 years
TB_CI.1.1. 25 - 14 years
TB_CI.1.1. 3>= 15 years
TB_CI.1.2. 10 - 4 years
TB_CI.1.2. 25 - 14 years
TB_CI.1.2. 3>= 15 years
TB_CI_SCRContacts of drug susceptible TB cases screened for TB
TB_CI_SCR.0 - 4 years
TB_CI_SCR.>= 15 years
TB_CI_SCRContacts of drug Resistant TB cases screened for TB
TB_CI_SCRNumber of contacts with index bacteriologically confirmed TB (drug susceptible) cases screened negative for TB in
TB_CI_SCR_
0 - 4 years
TB_CI_SCR_
5 - 14 years
TB_CI_SCR_
>= 15 years
TB_TPT Number of contacts screened negative for TB and others eligible and put on TB Preventive Therapy (TPT) in the re
TB_TPT.1.4By Regimen Type
TB_TPT.1.4.3HP
TB_TPT.1.4.3RH
TB_TPT.1.4.6H
TB_TPT.2.1Number of cohort of individuals started TPT 12 months prior to the reporting period by Age Group
TB_TPT.2.5.3HP
TB_TPT.2.5.3RH
TB_TPT.2.5.6H
TB_IPT.3. 10 - 4 years
TB_IPT.3. 3>= 15 years
TB_IPT.3.4.3HP
TB_IPT.3.4.3RH
TB_IPT.3.4.6H
TB_TST-W Number of new and relapse bacteriologically confirmed pulmonary TB patients initially tested using a WHO recommend
TB_TST-WH0 - 4 years, Male
TB_TST-WH0 - 4 years, Female
TB_TST-WH>= 15 years, Male
TB_TST-WH>= 15 years, Female
TB_DST.1 Number of notified bacteriologically confirmed TB cases evaluated for drug susceptibility testing according to nati
TB_DST.1. New
TB_DST.1. Previously treated including relapse
TB_DST.1. Unknown treatment History
TB_DST.2. New
TB_DR_DRNumber of Hr-TB TB cases
TB_DR_DR.7
< 15 years, Male
TB_DR_DR.7
< 15 years, Female
TB_DR_DR.7
>= 15 years, Male
TB_DR_DR.7
>= 15 years, Female
TB_DR_DR.1
< 15 years, Male
TB_DR_DR.1
< 15 years, Female
TB_DR_DR.1
>= 15 years, Male
TB_DR_DR.1
>= 15 years, Female
TB_DR_DR.1
< 15 years, Male
TB_DR_DR.1
< 15 years, Female
TB_DR_DR.1
>= 15 years, Male
TB_DR_DR.1
>= 15 years, Female
TB_DR_DR.2
< 15 years, Male
TB_DR_DR.2
< 15 years, Female
TB_DR_DR.2
>= 15 years, Male
TB_DR_DR.2
>= 15 years, Female
TB_DR_TX.Positive
TB_DR_TX.Negative
TB_DR_TX.Unknown
TB_DR_TX.By Registration Group
TB_DR_TX.5
New
TB_DR_TX.5
TB_DR_TX.5
TB_DR_TX.5
Unknown
TB_DR_DST
DR TB cases put on second line treatment by regimen type
TB_DR_DST.
Shorter regimen
TB_DR_DST.
Longer regimen
TB_DR_DST.
TB_DR_DST
DR TB cases put on second line treatment by HIV status
TB_DR_DST.
Positive
TB_DR_DST.
Negative
TB_DR_DST.
Unknown
TB_DR_DST
DR TB cases put on second line treatment by registration group
TB_DR_DST.
New
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
Unknown
TB_DR_DST
DR TB cases put on second line treatment by diagnosis type
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DS RR/MDR-TB cases with DST result at least for fluoroquinolone during the reporting month
TB_DR_DSTwith susceptibility result
TB_DR_DSTwith resistant strain
TB_DR_DSTwhom Susceptibility result unknown
TB_DR_CT Total Number of聽 cohort聽 DR-TB cases initiated on second-line anti-TB the same month of the previous year (12 mon
TB_DR_CTXShort term regimen
TB_DR_CTXLong term
TB_DR_CTX
Number of cohort DR-TB cases started short term second-line anti-TB treatment regimen the same month of the previou
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
Number of聽 cohort DR-TB cases started聽 long term second-line anti-TB treatment regimen the same month of the pre
TB_DR_CTX
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_TxO.
Cured
TB_DR_TxO.
Completed
TB_DR_TxO.
Died
TB_DR_TxO.
Failed
TB_DR_TxO.
Lost to follow-up
TB_DR_TxO.
Not evaluated
TB_DR_CTX
TB_DR_CTX.
Cured
TB_DR_CTX.
Completed
TB_DR_CTX.
Died
TB_DR_CTX.
Failed
TB_DR_CTX.
Lost to follow-up
TB_DR_CTX.
Not evaluated
TB_DR_CTX
TB_DR_CTX.
Cured
TB_DR_CTX.
Completed
TB_DR_CTX.
Died
TB_DR_CTX.
Failed
TB_DR_CTX.
Lost to follow-up
TB_DR_CTX.
Not evaluated
TB_DR_NUT
Number of drug susceptible TB cases screened for Malnutrition during the reporting period
TB_DR_NUT.
Normal
TB_DR_NUT.
MAM
TB_DR_NUT.
SAM
TB_MN. 1 Normal
TB_MN. 2 MAM
TB_MN. 3 SAM
TB_HIV_N Total number of new and relapse TB patients registered during the reporting period having a documented HIV negative
TB_ART.1. >= 15 years, Male
TB_ART.1. >= 15 years, Female
TB_NEW_AR
TB_NEW_AR
0 - 4 years, Male
TB_NEW_AR
0 - 4 years, Female
TB_NEW_AR
5 - 14 years, Male
TB_NEW_AR
TB_NEW_AR
>= 15 years, Male
TB_NEW_AR
>= 15 years, Female
LEP_NOT_.1
New Leprosy cases detected(PB)
LEP_NOT_.1
< 15 years, Male
LEP_NOT_.1
< 15 years, Female
LEP_NOT_.1
>= 15 years, Male
LEP_NOT_.1
>= 15 years, Female
LEP_NOT_.1
New Leprosy cases detected(MB)
LEP_NOT_.1.
< 15 years, Male
LEP_NOT_.1.
< 15 years, Female
LEP_NOT_.1.
>= 15 years, Male
LEP_NOT_.1.
>= 15 years, Female
LEP_NOT_.1
LEP_NOT_.1
LEP_CSCR.Total number of household contacts of leprosy patients that are screened for Leprosy in the reporting period
LEP_CSCR.Total number of household contacts diagnosed with Leprosy cases in the reporting month
08.2 - Malaria, NTD, NCD | Hospital, Health center, Clinic | Monthly (Nehase 2014)
S.No Activity
MAL Total number of slides or RDT performed for malaria diagnosis
MAL. 1 < 5 years, Male
MAL. 2 < 5 years, Female
MAL. 3 5 - 14 years, Male
MAL. 4 5 - 14 years, Female
MAL. 5 >= 15 years, Male
MAL. 6 >= 15 years, Female
MAL_POS.1Total number of slides or RDT Positive
MAL_POS.1.>= 15 years, Male
MAL_FULL.1
Number of index cases investigated and classified (Elimination Ditricts)
MAL_FULL.2
Number of secondary cases during investigation (Elimination Ditricts)
NTD. Does the facility provide leishmaniasis treatment?
NTD_VL.1. < 5 years, Male
NTD_VL.1. < 5 years, Female
NTD_VL.1. >= 15 years, Male
NTD_VL.1. >= 15 years, Female
NTD_VL.2. Primary visceral leishmaniasis
NTD_VL.2. Relapse visceral leishmaniasis
NTD_VL.2. Post Kala-azar dermal leishmaniasis (PKDL)
NTD_VL.3. Cured
NTD_VL.3. Defaulted
NTD_VL.3. Failed
NTD_VL.3. Dead
NTD_VL.3. Referred
NTD_VL.4. Positive
NTD_VL.4. Negative
NTD_CL.1. < 5 years, Male
NTD_CL.1. < 5 years, Female
NTD_CL.1. >= 15 years, Male
NTD_CL.1. >= 15 years, Female
NTD_CL.2. Primary cutaneous leishmaniasis
NTD_CL.2. Relapse cutaneous leishmaniasis
NTD_CL.3. Cured
NTD_CL.3. Defaulted
NTD_CL.3. Failed
NTD_CL.3. Dead
NTD_CL.3. Referred
NTD_TT.1. < 15 years, Male
NTD_TT.1. < 15 years, Female
NTD_TT.1. >= 15 years, Male
NTD_TT.1. >= 15 years, Female
NTD_HYD. < 15 years, Male
NTD_HYD. >= 15 years, Male
NTD_POD. < 15 years, Male
NTD_POD. < 15 years, Female
NTD_POD. >= 15 years, Male
NTD_POD. >= 15 years, Female
NCT_HTN Number of Individuals screened for hypertension
NCT_HTN. >=70 years, Male
NCT_HTN. >=70 years, Female
NCD_HTNDX
NCD_HTNDX.
Raised BP
NCD_HTNDX.
Normal BP
NCD_HTNDX
NCD_HTNDX
NCD_HTNDX
NCD_HTNDX
NCD_HTNDX.
18 - 29 years, Male
NCD_HTNDX.
NCD_HTNDX.
30 - 39 years, Male
NCD_HTNDX.
NCD_HTNDX.
40 - 69 years, Male
NCD_HTNDX.
NCD_HTNDX.
>=70 years, Male
NCD_HTNDX.
>=70 years, Female
NCD_HTNDX
NCD_HTNDX.
NCD_HTNDX.
Previously in care
NCD_HTNTX
NCD_HTNTTreatment outcome for cohort of patient registered for hypertension treatment six months prior to the r
NCD_HTNTX
Controlled
NCD_HTNTX
Uncontrolled
NCD_HTNTX
Lost to follow-up
NCD_HTNTX
Died
NCD_HTNTX
Transferred out
NCD_HTNTX
Not evaluated
NCD_CVD.2.
40 - 59 Years, Male
NCD_CVD.2.
40 - 59 Years, Female
NCD_CVD.2.
60 - 74 Years, Male
NCD_CVD.2.
NCD_CVD.3.
With Statin
NCD_CVD.3.
Without Statin
NCD_CVD.4.
40 - 59 Years, Male
NCD_CVD.4.
NCD_CVD.4.
60 - 74 Years, Male
NCD_CVD.4.
NCD_DMDX.
Individuals screened for Diabetes Mellitus by age and sex
NCD_DMDX.1
< 40 years, Male
NCD_DMDX.1
< 40 years, Female
NCD_DMDX.1
>= 40 years, Male
NCD_DMDX.1
>= 40 years, Female
NCD_DMDX.
Number of Individuals screened for Diabetes Mellitus by result of screening
NCD_DMDX.1
Raised blood sugar
NCD_DMDX.1
Normal blood sugar
NCD_DMDXDiabetic patients enrolled to care by types of Diabete
NCD_DMDX.
Type I
NCD_DMDX.
Type II
NCD_DMDX.
Gestational DM
NCD_DMDX.
Diabetic patients enrolled to care by type of treatment
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.
Diabetic patients enrolled to care by age and sex
NCD_DMDX.2
< 15 years, Male
NCD_DMDX.2
< 15 years, Female
NCD_DMDX.2
15 - 29 years, Male
NCD_DMDX.2
NCD_DMDX.2
30 - 39 years, Male
NCD_DMDX.2
NCD_DMDX.2
>= 40 years, Male
NCD_DMDX.2
>= 40 years, Female
NCD_DMDX.
Diabetic patients by Timing of enrollment
NCD_DMDX.2
NCD_DMDX.2
Previously in care
NCD_DMTX.Total number of cohort of hypertensive pateints registered for diabetes treatment six months prior to the reporti
NCD_DMTXTreatment outcome for cohort of patient registered for diabetes treatment six months prior to the report
NCD_DMTX.Controlled
NCD_DMTX.Died
NCD_DMTX.Treatment outcome for cohort of patient registered for diabetes treatment six months prior to the reporting period by ag
NCD_DMTX.< 15 years, Male
NCD_DMTX.< 15 years, Female
NCD_DMTX.15 - 29 years, Male
NCD_DMTX.15 - 29 years, Female
NCD_DMTX.>= 40 years, Male
NCD_DMTX.>= 40 years, Female
NCD_CV_SC
NCD_CV_SC
Screened by VIA
NCD_CV_SC
Screened by HPV DNA
NCD_CV_SC
NCD_CV_SCR
Negative
NCD_CV_SCR
Positive: Eligible for Cryotherapy/ thermocoagulation
NCD_CV_SCR
Positive: not iligible for Cryotherapy/ thermocoagulation
NCD_CV_SCR
Suspicious cancerous lesion
NCD_CV_SC
Women age 30 - 49 years who have been screened for cervical Ca HPV/DNA screening result
NCD_CV_SCR
Positive
NCD_CV_SCR
Negative
NCD_CV_TX
Eligible women who received treatment for cervical lesion
NCD_CV_TX.
Crayotherapy
NCD_CV_TX.
LEEP
NCD_CV_TX.
Thermal Abrasion/Thermocoagulation
NCD_CV_TX
Women screened for cervical lesion 1 year after treatment follow up by Screening type
NCD_CV_TX.
Screened by VIA
NCD_CV_TX.
Screened by HPV DNA
NCD_CV_TX
Women screened for cervical lesion 1 year after treatment follow up VIA screening result
NCD_CV_TX.
Negative
09.2 - Medical services | Health center | Monthly (Nehase 2014)
S.No Activity
MS Number of outpatient visits
MS. 1 < 5 years, Male
MS. 2 < 5 years, Female
MS. 14 >= 66 years, Female
MS_OPD_Nu
MS_IPD_BOTotal length of stay (in days) in the reporting period
MS_IPD_BOTotal Number of beds in the reporting period
MS_ALS.1. Total length of stay (in days) during discharge
MS_ALS.2. Number of inpatient discharges
MS_LaBT.1.Monthly score of essential laboratorial tests of the facility
MS_RoR.1 Number of people referred to other health facility
MS_RoR.1. Emergency referral
MS_RoR.1. Non-emergency referral
MS_NumRI.Emergency referral
MS_NumRI.Non-emergency referral
MS_AMBU.Number of clients that came to health facility using ambulance
MS_AMBU.1Pre-facility
MS_AMBU.1Between facility
MS_AMBUR1
MS_AMBUR1
MS_AMBURe
MS_AMBUR2
MS_AMBUR2
MS_AMBUR2
Trauma
MS_AMBUR2
Burn & Poisoning
MS_AMBUR2
Others
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_IPD_AR.
Number of inpatient admissions
HSQI_IPD_ Inpatient mortality rate
MS_IPIMR.1< 24 hours
MS_IPIMR.1>= 24 hours
MS_UBDT.1.
direct family replacement
MS_UBDT.1.
from blood bank
MS_RTI.1. 4Others
PMS. Medroxyprogesterone Injection
PMS_AVAIL.Pentavalent vaccine
PMS_AVAIL.Magnesium Sulphate injection
PMS_AVAIL.Oxytocine inj
PMS_AVAIL.Gentamycin injection
PMS_AVAIL.ORS+/- Zinc sulphate
PMS_AVAIL.Amoxcillin dispersable/suspension/capsule
PMS_AVAIL.Iron + folic acid
PMS_AVAIL.Albendazole/Mebendazole tablet/suspension
PMS_AVAIL.TTC eye ointment
PMS_AVAIL.RHZE/RH
PMS_AVAIL.TDF/3TC/DTG
PMS_AVAIL.Co-trimoxazole 240mg/5ml suspension
PMS_AVAIL.Arthmeter + Lumfanthrine tablet
PMS_AVAIL.Amlodipine tablet
PMS_AVAIL.Frusamide tablets
PMS_AVAIL.Metformin tablet
PMS_AVAIL.Normal Saline 0.9%
PMS_AVAIL.40% glucose
PMS_AVAIL.Adrenaline injection
PMS_AVAIL.Tetanus Anti Toxin (TAT) injection
PMS_AVAIL.Omeprazole capsule
PMS_AVAIL.Metronidazole capsule
PMS_AVAIL.Ciprofloxcaxillin tablet
PMS_AVAIL.Hydralizine injection
PMS_ABIOTI
Number of encounter with one or more antibiotics
PMS_ABIOTI
Total number of encounters
PMS_FILL10MS_Number of clients who received 100% of prescribed drugs
PMS_FILL10Total number of clients who received prescriptions
PMS_FSMLPercentage of medicines prescribed from the facility’s medicines list
PMS_MPFMTotal number of medicines prescribed from Health facility medicine list
PMS_MP_NTotal number of medicine prescribed
EIDM_LQA Proportion of health facilities that conduct reporting consistency check using LQAS
EBDM. Did the HF conduct LQAS for service report?
DQ_DA.1.1.LQAS first score for service report
DQ_DA.1.2.LQAS last score for service report
DQ_DA2. Did the HF conduct LQAS for OPD report?
DQ_DA.2.1.LQAS first score for OPD report
DQ_DA.2.2.LQAS last score for OPD report
DQ_DA3. Did the HF conduct LQAS for IPD report?
DQ_DA.3.1.LQAS first score for IPD report
DQ_DA.3.1.LQAS last score for IPD report
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
365 408 312 436 419 344 2284

133 147 150 171 105 94 800
21 5 6 13 10 2 57
34 33 44 27 16 17 171
46 62 63 59 31 41 302
32 47 37 72 48 34 270
232 261 162 265 314 250 1484
5 8 4 11 28
37 44 39 53 36 39 248
86 99 55 99 74 103 516
109 118 63 105 200 97 692
365 408 312 436 419 344 2284
133 147 150 171 105 94 800
30 36 37 13 7 23 146
51 85 103 130 66 63 498
50 22 10 27 31 8 148
2 4 1 1 8
232 261 162 265 314 250 1484

53 24 34 19 35 12 177
114 237 115 188 232 185 1071
64 12 47 45 48 216
1 1 11 2 5 20
8 10 3 27 48
5 5
2 4 1 14 21
1 5 2 4 12
5 1 4 10
4 3 14 21
60 81 71 76 82 96 466
22 44 49 33 73 50 271
6 2 43 6 57
32 37 20 9 40 138
60 81 71 76 82 96 466
4 3 33 19 9 68
56 81 68 43 63 87 398
35 55 56 54 79 45 324
39 39
6 3 15 15 4 43
29 55 53 64 41 242
35 55 56 54 79 45 324
22 30 20 72
13 25 56 34 79 45 252
71 71
42 81 71 76 82 96 448
42 81 71 76 82 96 448
42 81 71 76 82 96 448
42 81 71 76 82 96 448
53 68 65 90 80 80 436
53 68 65 90 80 356
53 68 65 90 80 356
12.5 12.5
1 1
53 106 65 90 80 79 473
53 68 65 90 80 79 435
53 68 65 90 80 80 436
53 68 65 90 80 80 436
2 2
4 6 12 4 26
6 8 1 15
3 1 4
2 4 6
1 3 4
1 1
4 4 3 11
3 2 1 6
1 1 1 3
1 1 2
4 6 12 4 26
4 6 12 4 26
4 6 9 2 21
3 3
4 9 2 15
3 3
3 24 15 17 59
1 1
3 24 14 17 58
60 81 295 66 43 545
Natri PHC Gebjiro P Baso PHC Deneba P Kumbi PH Sokoru P Total

0 0 0 0 0 1 1
68 81 71 90 82 96 488
68 81 71 90 82 96 488
68 90 158
68 90 158
73 79 109 143 90 90 584

74 78 111 133 89 89 574
68 78 110 131 89 89 565
74 78 111 133 89 89 574
68 78 110 131 89 89 565
74 78 111 133 89 89 574
68 78 110 131 89 89 565
68 78 110 131 89 89 565
70 78 111 133 89 89 570
68 78 110 131 85 90 562
68 78 110 131 89 90 566
68 78 110 131 89 90 566
68 78 110 131 73 86 546
68 78 111 131 89 89 566
e in 6 month interval from the first dose
63 93 91 104 85 113 549

36 94 34 140 70 56 430
10 45 25 144 3 27 254
1 5 4 10
9 9
34.8 0 34.8
68 180 248
70 180 250
14.1 12.2 16.2 10.6 32.9 30.8 116.8

73 79 109 143 104 90 598
85 90 130 160 155 130 750
0 0 0 0 0 0 0
210 234 331 395 267 268 1705
210 234 331 395 267 268 1705
3.7 3.3 2.6 3.7 6.3 0.74 20.34

210 234 331 395 267 268 1705
214 242 340 410 285 270 1761
2 2
2 2
0 0 0 0 0 0 0
144 156 221 264 174 179 1138
144 156 221 264 174 179 1138
6.4 4.5 2.6 2.2 16.6 10.7 43

206 234 331 362 267 268 1668
220 245 340 370 320 300 1795
4 5.5 3.9 9.3 13.8 7.4 43.9

144 156 221 263 168 176 1128
150 165 230 290 195 190 1220
8.3 3.3 3.2 1.5 4.1 1.4 21.8

110 232 150 384 163 434 1473
120 240 155 390 170 440 1515
8 8.2 8.3 9.7 21.9 15.2 71.3
69 78 110 131 89 89 566
75 85 120 145 114 105 644
100 100
1 1
107 92 79 302 148 44 772

7 15 13 4 39
3 3
7 15 3 2 27
7 2 9
138 75 123 229 180 93 838
138 75 123 229 180 93 838
5 48 35 53 80 221
4 4
4 4
4 4
0 0 0 0 0 0 0
53 80 133
53 80 133
340 340
240 240
100 100
240 281 1 522
240 281 1 522
53 68 72 90 80 79 442
2075 1960 1853 2440 2016 1528 11872

351 61 394 168 262 227 1463
1724 1899 1459 2272 1754 1301 10409
19 28 6 16 9 6 84
5 5
19 23 6 16 9 6 79
5 3 4 12 6 4 34
1 2 3
5 2 2 12 6 4 31
166 490 726 476 198 611 2667

21 140 259 129 94 141 784
145 350 467 347 104 470 1883
166 490 726 476 198 611 2667
166 490 726 476 107 233 2198
91 378 469
123 402 196 270 411 1402

123 402 171 270 130 1096
25 281 306
111 17 270 28 426
60 81 107 240 102 88 678
28 44 56 19 9 156
32 81 63 184 83 79 522
961 212 114 501 582 1052 3422

1 6 15 22
960 212 108 501 582 1037 3400
793 190 111 501 515 1052 3162
478 140 111 501 362 216 1808
315 50 153 836 1354
3828 966 3271 3844 4475 4530 20914

58 105 111 66 340
708 415 1349 1120 1661 1480 6733
3062 551 1817 2613 2814 2984 13841
26 51 18 20 12 20 147
4 4
7 18 12 14 4 7 62
19 33 6 6 4 13 81
8 3 3 12 7 8 41
2 2 1 6 1 12
6 1 2 12 1 7 29
2 3 2 6 40 53
2 1 22 25
2 1 1 6 18 28
5 2 7
3 1 4
2 1 3
7 2 2 11
4 1 1 6
3 1 1 5
3 2 5
2 1 3
1 1 2
5 6 40 51
3 5 6 14
3 6 7 16
3 12 7 22
12 12
9 7 16
12 7 19
12 7 19
79 50 129
79 50 129
35 35
19 19
12 2 14
13 48 61

245 157 101 248 67 291 1109
7 7
10 10
1 14 15
20 20
12 12
4 6 22 32
45 1 8 7 61
200 5 25 20 250
1 39 21 61
35 23 10 16 84
8 20 28
1 10 25 36
4 11 15
81 80 25 186
4 98 65 10 177
1 18 2 20 41
2 20 8 30
7 6 13
2 12 7 21
10 10
2 2
1 1
1 1
245 157 101 248 67 291 1109

2 2
0 0 1 0 0 1 2
2 2
1 1
1 1
10 10
6 6
4 4
4 4
2 2
2 2
3 3
1 1
2 2
19 19
7 7
12 12
46 46
16 16
30 30
2 2
2 2
47 47
12 12
35 35
2 2
2 2
36 36
12 12
24 24
12 12
5 5
7 7
14 14
4 4
10 10
9 9
8 8
1 1
2 2
2 2
10 10
9 9
1 1
4 4
4 4
174 174
72 72
94 94
8 8
4 4
2 2
2 2
2 2
1 1
1 1
se transferred out (net current cohort) 194 194
1 1
2 2
8 8
2 2
2 2
1 1
2 2
7 7
12 12
16 16
29 29
1 1
14 14
35 35
12 12
24 24
5 5
7 7
4 4
10 10
2 2
2 2
reporting period
es/ml) in the reporting period
ml) in the reporting period

82 82
1 1
3 3
2 2
6 6
1 1
2 2
2 2
3 3
21 21
29 29
5 5
7 7
112 112
7 7
9 9
29 29
56 56
4 4
7 7
n by exposure type
peutic or supplementary food
39 39
3 3
7 7
8 8
21 21
ed (disaggregated by Age, Sex and Pregnancy)
regated by age, sex and pregnancy status)
7 7
7 7
7 7
2 2
5 5
y method of modern family planning by age 56 56
3 3
11 11
42 42
y method of modern family planning by method 56 56
54 54
2 2
2 2
2 2
39 39
3 3
7 7
8 8
21 21
T) in the reporting period

2 2
2 2
porting period
pleted a full course of therapy

5 5
5 5
5 5
2 2
3 3
he reporting period 85.2 12.2 36.5 133.9

the reporting period by a 2 3 5
1 1
1 1
1 1
1 1
1 1
orting period by age and 3 1 4
2 2
1 1
1 1
nd enrolled in the reporti 2 2
1 1
1 1
4 2 1 1 8
4 2 1 1 8
2 2
2 2 1 1 6
e same month of the prev 2 1 1 1 5

2 1 1 1 5
2 1 1 1 5
1 2 4 1 8
1 2 4 1 8
1 2 4 1 8
d by the community 1 2 3
atment) who received su 2 2
who received any form of 2 2 4
or TB diagnosis or initiation of TB treatment. in the reporting month
s during the reporting M 2 19 21

3 3
8 8
2 8 10
eporting Month
2 19 21
3 3
8 8
2 8 10
2 2
2 2
reened negative for TB in 9 9
9 9
e Therapy (TPT) in the re 9 19 28
3 3
8 8
9 8 17
9 11 20
9 11 20
9 9
9 9
9 9
9 9
2 months prior to the reporting period by Age Group
ted using a WHO recommended rapid tests (GeneXpert and others) at the time of TB diagnosis by age and sex
testing according to nati 2 3 5

2 3 5
e reporting period 2 3 5
2 3 5
0 0 0 0 0 0
ear (12 month earlier)
of the previous year (12 month earlier)
he same month of the previous year (12 month earlier)
en the same month of the previous year (12 month earlier)
egimen 24 months earlier.
gimen 24 months earlier.
d) second-line anti-TB treatment regimen 36 months earlier.

e reporting period
g a documented HIV positive test result
g a documented HIV negative test result

2 2 2 6
1 1 1 3
1 1 1 3
2 2 2 6
1 1 1 3
1 1 1 3

22 55 10 615 161 176 1039
69 18 23 110
86 4 24 114
101 12 22 135
7 126 5 14 152
14 43 10 126 62 47 302
1 12 107 60 46 226
59 18 7 84
2 2 1 5
7 7
10 1 1 12
8 1 2 11
18 10 2 30
14 4 1 19
1 1
1 6 2 8 2 6 25
0 0 0 0 0 0
3 3
1 1
2 2
50 300 53 41 150 70 664

25 3 28
30 2 32
35 20 16 71
40 15 11 66
60 20 10 40 16 146
50 70 33 15 70 15 253
20 7 2 4 33
20 9 3 3 35
50 300 53 41 150 594
8 6 1 15
42 294 53 41 149 579
8 6 1 63 78
8 6 1 63 78
8 6 1 63 78
3 3
2 2
9 9
11 11
4 1 16 21
2 15 17
8 4 12
3 3
8 6 1 63 78
8 6 1 3 18
60 60
2 10 3 5 209 229
2 10 3 5 209 229
2 10 3 5 209 229
40 10 50
5 5
4 2 6
18 5 23
13 3 16
10 10
10 10
10 10
10 10
10 10
8 8
2 2
10 10
2 2
5 5
3 3
135 135
125 125
10 10
7 2 1 10 20
7 2 1 10 20
7 2 1 10 20
r to the reporting period by age and sex 2 1 10 13
1 1
1 1
1 10 11
145 31 176
145 31 176
145 31 176
145 31 176
84 84
84 84
84 84
84 84
3753 5177 3719 8207 7208 3788 31852
619 746 917 754 1736 372 5144
850 1271 683 767 2266 249 6086
125 293 376 328 129 195 1446
136 175 166 375 104 314 1270
276 202 209 384 201 261 1533
201 212 203 526 149 311 1602
233 190 140 648 355 306 1872
380 361 136 736 558 242 2413
218 101 249 706 465 327 2066

263 1251 127 439 202 167 2449
196 214 145 559 231 247 1592
9 86 126 217 92 304 834

1482 1308 1325 4998 2330 2900 14343
29 18 32 79
3 3 3 9
18 18 36
18 9 18 45
0 0 0 0 100 95 195
26 20 6 48 15 38 153
21 20 1 31 5 13 91
5 5 17 10 25 62
26 20 6 48 38 138
21 20 1 31 13 86
5 5 17 25 52
26 20 6 48 38 138
21 20 6 48 38 133
5 5
26 20 6 48 38 138
21 20 6 31 25 103
5 17 13 35
30 38 7 50 40 165
26 20 6 48 38 138
21 20 5 31 25 102
5 3 8
3 3
1 1
1 17 6 24
18 18
57 18 75
9 18 27
31 3 34
11 11
15 1 16
5 2 7
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
100 100 100 100 55.6 100 555.6
1482 2347 1455 5353 1500 2900 15037
1482 2347 1455 5353 2700 2900 16237
1482 1300 1455 5353 2328 2900 14818
1482 1300 1455 5353 2328 2900 14818
100 100 100 100 100 100 600
1482 1300 1455 5353 6984 2900 19474
1482 1300 1455 5353 6984 2900 19474
6 6 6 7 12 5 42
94.2 92.5 95 94.3 94.2 95 565.2
95 94.2 95 93.6 95 95 567.8
1 4 2 5 5 5 22
95 95 95 94 92 95 566
95 95 95 94 93 95 567
0 1 1 1 1 1 5
95 95 95 95 95 475
95 95 95 95 95 475
01.2 - Reproductive and Maternal Health | Hospital, Health center, Clinic | Monthly (Meskerem 2015)
S.No
RMH
MAT_CAR
MAT_CAR_A
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_A
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_
MAT_CAR_M
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_M
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
RMH_FP_IP
MAT_IPPCA
MAT_IPPCA
MAT_IPPCA
MAT_IPPCA
MAT_IPPCA
MAT_IPPCA
RMH_FP_L
MAT_LAFPP
MAT_LAFPPR
MAT_LAFPPR
MAT_LAFPPR
MAT_TLAFP
MAT_ANC1
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC4
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC8
MAT_ANC8+
RMH_ANC_
MAT_SYPH.
MAT_SYPH.1
MAT_SYPH.1
MAT_SYPH.
MAT_Hepa
MAT_Hepa.
MAT_Hepa.
MAT_Prp.1.
RMH_L&D_
L&D_SBA.1.
MAT_PPH.1
MAT_PPH.1.
MAT_PPH.1.
MAT_UTER
MAT_UTER.
MAT_UTER.1
MAT_UTER.1
MAT_UTER.1
MAT_UTER.1
MAT_SBR
MAT_SBR.S
MAT_SBR.L
B&D_Ntfc
MAT_B&D_I
MAT_B&D_I
MAT_EPNC.
MAT_EPNC.
MAT_EPNC.1
MAT_EPNC.1
MAT_EPNC.1
MAT_EPNC.1
RMH_L&D_
MAT_CS.1.
MAT_CAC
MAT_CAC_
MAT_CAC_S
MAT_CAC_S
MAT_CAC_S
MAT_CAC_S
MAT_CAC_S
MAT_CAC_
MAT_CAC_P
MAT_CAC_P
MAT_CAC_P
MAT_CAC_P
MAT_CAC_P
MAT_CAC.T
MAT_CAC.Tr
MAT_CAC.Tr
MAT_CAC.M
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_OFC_I
MAT_OFC_Id
MAT_OFC_Id
MAT_OFC_Id
MAT_OFC_Id
MAT_OFC_Id
MAT_OFC_T
MAT_OFC_Tr
MAT_OFC_Tr
MAT_OFC_Tr
MAT_OFC_Tr
MAT_OFC_Tr
MAT_IMD
MAT_IMD.1.
MAT_TngP
MAT_TngP_
MAT_TngP_
MAT_Tngtst
02 - PMTCT | Hospital, Health center, Clinic | Monthly (Meskerem 2015)
S.No
RMCH__PMT
MTCT
MTCT_TST
MTCT_TST.
MTCT_TST.
03 - EPI | Hospital, Health center, Health post, Clinic | Monthly (Meskerem 2015)
S.No
EPI
EPI_HepBD
EPI_HepBD.
EPI_HepBD.
EPI_BCG1.
EPI_DPT1.1
EPI_DPT3.1
EPI_OPV1.1
EPI_OPV3.1
EPI_PCV1.1
EPI_PCV3.1
EPI_IPV.1.
EPI_Rota1.1
EPI_Rota2.1
EPI_MCV1.1
EPI_FI.1.
EPI_MCV2
EPI_MCV2.1
EPI_PAB
EPI_PAB.1.
EPI_HPV1
EPI_HPV1.1
EPI_HPV2
EPI_HPV2.1
EPI_TD
EPI_TD1.1.
EPI_TD2.1.
EPI_TD3.1.
EPI_TD4.1.
EPI_TD5.1.
EPI_VWR
EPI_VWR_He
EPI_VWR_He
EPI_VWR_He
EPI_VWR_He
EPI_VWR_B
EPI_VWR_B
EPI_VWR_B
EPI_VWR_B
EPI_VWR_Pe
EPI_VWR_Pe
EPI_VWR_P
EPI_VWR_Pe
EPI_VWR_P
EPI_VWR_P
EPI_VWR_P
EPI_VWR_PC
EPI_VWR_RT
EPI_VWR_R
EPI_VWR_R
EPI_VWR_RT
EPI_VWR_PV
EPI_VWR_P
EPI_VWR_P
EPI_VWR_PV
EPI_VWR_M
EPI_VWR_M
EPI_VWR_M
EPI_VWR_M
EPI_VWR_TD
EPI_VWR_T
EPI_VWR_T
EPI_VWR_TD
EPI_VWR_IP
EPI_VWR_IP
04.2 - Neonatal and Child Health | Health center, Hospital and clinic | Monthly (Meskerem 2015)
S.No
CH
CH_IND
CH_IND. 1
CH_IND. 2
CH_IND. 3
CH_TX_PN
CH_TX_PNE
CH_TX_SYI.
CH_TX_SYI.
CH_TX_SYI.
CH_TX_SYI.
CH_TX_DIA
CH_TX_DIAR
CH_TX_DIAR
CH_KMC
CH_KMC.1.
CH_KMC.2.
CH_ASPH
CH_ASPH.1
CH_ASPH.2
CH_TX_NIC
CH_TX_NIC
CH_TX_NIC
CH_TX_NICU
CH_TX_NICU
CH_TX_NICU
CH_TX_NICU
CH_CHX
CH_CHX.1.
CH_CHDM
CH_CHDM.
CH_CHDM.
CH_CHDMS
CH_CHDMS.
CH_CHDMS.
CH_CHDMS.
05.2 - Nutrition | Hospital, Health center | Monthly (Meskerem 2015)
S.No
NUT
NUT_LBW
NUT_GMP.
NUT_LBW.2
NUT_GMP
NTR_GMP.1
NTR_GMP.1.
NTR_GMP.1.
NUT_GMP.M
NUT_GMP.M
NUT_GMP.M
NUT_GMP_
NUT_GMP_S
NUT_GMP_S
NCH_NTR_
NUT_VITA
NUT_VITA.
NUT_VITA.
NUT_VITA.2
NUT_VITA.2
NUT_VITA.2
NUT_DeW
NUT_DeW.1
NUT_DeW.1.
NUT_DeW.1.
NUT_DeW.2
NUT_IFA
NUT_IFA.1
NUT_IFA.1.
NUT_IFA.1.
NUT_IFA.1.
NUT_PreSM
NUT_PreSM
NUT_PreSMN
NUT_PreSMN
NUT_PreSM
NUT_PreSMN
NUT_PreSMN
NUT_U5SM
NUT_U5SM
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_TX-U
NUT_TX-U
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&Yo
NUT_Adl&Yo
NUT_Adl&Yo
NUT_Adl&Yo
NUT_Adl&
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&Y
06 - HIV | Hospital, Health center, Clinic | Monthly (Meskerem 2015)
S.No
HIV
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HCT_P
HIV_HTS_T
HIV_HTS_T
HIV_TST_P
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HIV_Tr
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_C
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_ART_R
HIV_ART_R
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_
HIV_ART_N
HIV_ART_N
HIV_ART_N
HIV_ART_N
HIV_ART_N
HIV_ART_N
HIV_TX_PV
HIV_TX_PV
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PV
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_DS
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DS
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_AS
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_FT
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_CA
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_PC
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
.
HIV_TX_Ado
HIV_TX_KP
HIV_TX_MC
HIV_TX_ oth
HIV_TX_A
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_ART_I
HIV_ART_I
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_I
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_PrEP
HIV_PrEP.1
HIV_PrEP.1
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1
HIV_PrEP_
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_
HIV_PrEP_C
HIV_PrEP_C
HIV_PEP
HIV_PEP. 1
HIV_PEP. 2
HIV_PEP. 3
HIV_PLHIV
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_STI_S
HIV_STI_SC
HIV_STI_SC
HIV_STI_SC
HIV_STI_S
HIV_STI_SC
HIV_STI_SC
HIV_STI_S
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_ART_F
HIV_ART_FP
HIV_ART_FP
HIV_ART_FP
HIV_ART_FP
HIV_ART_FP
HIV_ART_F
HIV_ART_F
HIV_ART_F
HIV_ART_F
HIV_ART_F
HIV_ART_F
HIV_TB_SC
HIV_TB.1
HIV_TB.1. 1
HIV_TB.1. 2
HIV_TB.1. 3
HIV_TB.1. 4
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_ART_T
HIV_TB_TP
HIV_TB_TPT
HIV_TB_TPT
HIV_TB_TPT
HIV_TB_TPT
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_T
HIV_ART_T
HIV_ART_T
HIV_ART_T
HIV_ART_T
HIV_TPT
HIV_TPT. 1
HIV_TPT. 2
HIV_TPT. 3
HIV_TPT. 4
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_CXCA
HIV_CXCA_
HIV_CXCA_
HIV_CXCA_
HIV_CXCA_
HIV_CXCA_S
HIV_CXCA_S
HIV_CXCA_S
07 - TB/Leprosy | Hospital, Health center, clinic | Monthly (Meskerem 2015)
S.No
TB_COMM
TB_TX_PTB
TB
TB. 1
TB. 2
TB. 3
TB. 4
TB. 5
TB. 6
TB. 7
TB. 8
TB. 9
TB. 10
TB. 11
TB. 12
TB. 13
TB. 14
TB. 15
TB. 16
TB. 17
TB. 18
TB. 19
TB. 20
TB_TX_PTB
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_EPT
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_RTB
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_RET
TB_RET. 1
TB_RET. 2
TB_RET. 3
TB_RET. 4
TB_RET. 5
TB_RET. 6
TB_RET. 7
TB_RET. 8
TB_KEY_P
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
CDC_TB_R
TB_TX_OUT
TB_CR_PTB
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PNT
TB_CR_PNT
TB_CR_PNTB
TB_CR_PNTB
TB_CR_PNTB
TB_CR_PNTB
TB_CR_PNTB
TB_CR_PNTB
TB_CR_EPT
TB_CR_EPT
TB_CR_EPTB
TB_CR_EPTB
TB_CR_EPTB
TB_CR_EPTB
TB_CR_EPTB
TB_CR_EPTB
TB_CR_RTB
TB_CR_RTB
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_COMM.
TB_CBTSR.
TB_CBTSR.
TB_DX_PRI
TB_CI
TB_CI.1.1
TB_CI.1.1. 1
TB_CI.1.1. 2
TB_CI.1.1. 3
TB_CI.1.2
TB_CI.1.2. 1
TB_CI.1.2. 2
TB_CI.1.2. 3
TB_CI_SCR
TB_CI_SCR.
TB_CI_SCR.
TB_CI_SCR.
TB_CI_SCR
TB_CI_SCR.
TB_CI_SCR.
TB_CI_SCR.
TB_CI_SCR
TB_CI_SCR_
TB_CI_SCR_
TB_CI_SCR_
TB_TPT
TB_TPT
TB_TPT. 1
TB_TPT. 2
TB_TPT. 3
TB_TPT.1.4
TB_TPT.1.4.
TB_TPT.1.4.
TB_TPT.1.4.
TB_TPT.2.1
TB_TPT.2.1.
TB_TPT.2.1.
TB_TPT.2.1.
TB_TPT.2.5
TB_TPT.2.5.
TB_TPT.2.5.
TB_TPT.2.5.
TB_TPT.3
TB_IPT.3
TB_IPT.3. 1
TB_IPT.3. 2
TB_IPT.3. 3
TB_IPT.3.4
TB_IPT.3.4.
TB_IPT.3.4.
TB_IPT.3.4.
TB_TST-W
TB_TST-WH
TB_TST-WH
TB_TST-WH
TB_TST-WH
TB_TST-WH
TB_TST-WH
TB_DST.1
TB_DST.1.
TB_DST.1.
TB_DST.1.
TB_DST.2
TB_DST.2.
TB_DST.2.
TB_DST.2.
TB_DR_DR.
TB_DR_DR
TB_DR_DR.
TB_DR_DR.
TB_DR_DR.
TB_DR_DR.
TB_DR_DR.
TB_DR_DR.7
TB_DR_DR.7
TB_DR_DR.7
TB_DR_DR.7
TB_DR_DR.
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.
TB_DR_DR.2
TB_DR_DR.2
TB_DR_DR.2
TB_DR_DR.2
TB_DR_TX
TB_DR_TX
TB_DR_TX.
TB_DR_TX.
TB_DR_TX.
TB_DR_TX.
TB_DR_TX.5
TB_DR_TX.5
TB_DR_TX.5
TB_DR_TX.5
TB_DR_DST
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DST
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DST
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DST
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DS
TB_DR_DST
TB_DR_DST
TB_DR_DST
TB_DR_CTX
TB_DR_CT
TB_DR_CTX
TB_DR_CTX
TB_DR_CTX
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_TxO
TB_DR_TxO.
TB_DR_TxO.
TB_DR_TxO.
TB_DR_TxO.
TB_DR_TxO.
TB_DR_TxO.
TB_DR_CTX
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_NUT
TB_DR_NUT.
TB_DR_NUT.
TB_DR_NUT.
TB_MN
TB_MN. 1
TB_MN. 2
TB_MN. 3
TBHIV
TBHIV. 1
TBHIV. 2
TBHIV. 3
TBHIV. 4
TB_HIV_N
TB_HIV_N.
TB_HIV_N.
TB_HIV_N.
TB_HIV_N.
TB_ART.1
TB_ART.1.
TB_ART.1.
TB_ART.1.
TB_ART.1.
TB_ART.1.
TB_ART.1.
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
LEP_NOT_1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1.
LEP_NOT_.1.
LEP_NOT_.1.
LEP_NOT_.1.
LEP_NOT_.1
LEP_NOT_.1
LCS
LEP_CSCR.
LEP_CSCR.
LEP_CSCR.
LEP_DIS.1
LEP_DIS.1.
LEP_DIS.1.
LEP_DIS.1.
LEP_DIS.1.
LEP_TX.r
LEP_TX.r.
LEP_TX.2.
LEP_TX.3.
LEP_TX.4.
LEP_TX.5.
TB_LB
TB_LB. 1
TB_LB. 2
TB_LB_AFB
TB_LB_AFB.
TB_LB_AFB.
08.2 - Malaria, NTD, NCD | Hospital, Health center, Clinic | Monthly (Meskerem 2015)
S.No
MAL
MAL. 1
MAL. 2
MAL. 3
MAL. 4
MAL. 5
MAL. 6
MAL_POS.1
MAL_POS.1.
MAL_POS.1.
MAL_POS.1.
MAL_POS.1.
MAL_POS.1.
MAL_POS.1.
Mal_Travel.
Mal_Noti.
MAL_FULL.1
MAL_FULL.2
MAL_FOCI.1
NTD.
NTD_VL.1
NTD_VL.1.
NTD_VL.1.
NTD_VL.1.
NTD_VL.1.
NTD_VL.1.
NTD_VL.1.
NTD_VL.2
NTD_VL.2.
NTD_VL.2.
NTD_VL.2.
NTD_VL.3
NTD_VL.3.
NTD_VL.3.
NTD_VL.3.
NTD_VL.3.
NTD_VL.3.
NTD_VL.4
NTD_VL.4.
NTD_VL.4.
NTD_CL.1
NTD_CL.1.
NTD_CL.1.
NTD_CL.1.
NTD_CL.1.
NTD_CL.1.
NTD_CL.1.
NTD_CL.2
NTD_CL.2.
NTD_CL.2.
NTD_CL.3
NTD_CL.3.
NTD_CL.3.
NTD_CL.3.
NTD_CL.3.
NTD_CL.3.
NTD_TT.1
NTD_TT.1.
NTD_TT.1.
NTD_TT.1.
NTD_TT.1.
NTD_HYD
NTD_HYD.
NTD_HYD.
NTD_POD
NTD_POD.
NTD_POD.
NTD_POD.
NTD_POD.
NCT_HTN
NCT_HTN
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCD_HTNDX
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX
NCD_HTNDX
NCD_HTNDX
NCD_HTNDX
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNTX
NCD_HTNT
NCD_HTNTX
NCD_HTNTX
NCD_HTNTX
NCD_HTNTX
NCD_HTNTX
NCD_HTNTX
CVD
CVD
CVD. 1
CVD. 2
NCD_CVD.2
NCD_CVD.2.
NCD_CVD.2.
NCD_CVD.2.
NCD_CVD.2.
NCD_CVD.3
NCD_CVD.3.
NCD_CVD.3.
NCD_CVD.4
NCD_CVD.4.
NCD_CVD.4.
NCD_CVD.4.
NCD_CVD.4.
DM
NCD_DMDX.
NCD_DMDX.1
NCD_DMDX.1
NCD_DMDX.1
NCD_DMDX.1
NCD_DMDX.
NCD_DMDX.1
NCD_DMDX.1
NCD_DMDX
NCD_DMDX.
NCD_DMDX.
NCD_DMDX.
NCD_DMDX.
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.
NCD_DMDX.2
NCD_DMDX.2
NCD_DMTX
NCD_DMTX.
NCD_DMTX
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_CV_SC
NCD_CV_SC
NCD_CV_SC
NCD_CV_SC
NCD_CV_SCR
NCD_CV_SCR
NCD_CV_SCR
09.2 - Medical services | Health center | Monthly (Meskerem 2015)
S.No
MS
MS. 1
MS. 2
MS. 3
MS. 4
MS. 5
MS. 6
MS. 7
MS. 8
MS. 9
MS. 10
MS. 11
MS. 12
MS. 13
MS. 14
MS_OPD_Nu
MS_BOR
MS_IPD_BO
MS_IPD_BO
MS_ALOS
MS_ALS.1.
MS_ALS.2.
MS_LaBT
MS_LaBT.1.
MS_RoR
MS_RoR.1
MS_RoR.1.
MS_RoR.1.
MS_AMBU
MS_NumRI
MS_NumRI.
MS_NumRI.
MS_AMBU.
MS_AMBU.1
MS_AMBU.1
MS_AMBUR
MS_AMBUR
MS_AMBUR1
MS_AMBUR1
MS_AMBURe
MS_AMBUR
MS_AMBUR2
MS_AMBUR2
MS_AMBUR2
MS_AMBUR2
MS_AMBUR2
MS_EMERG
MS_EMERG
MS_EMERG
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG
MS_NumEM
MS_EMERG
MS_EMERG_
MS_IPD_AR.
HSQI_IPD_
MS_IPIMR.1
MS_IPIMR.1
MS_IPIMR.1
MS_UBDR.1
MS_UBDT.1
MS_UBDT.1.
MS_UBDT.1.
MS_SATIR.1
MS_RTI.1
MS_RTI.1. 1
MS_RTI.1. 2
MS_RTI.1. 3
MS_RTI.1. 4
PMS
PMS.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_ABIOT
PMS_ABIOTI
PMS_ABIOTI
PMS_FILL10
PMS_FILL10
PMS_FSML
PMS_MPFM
PMS_MP_N
EIDM_LQA
EIDM_LQA
EBDM.
DQ_DA.1.1.
DQ_DA.1.2.
DQ_DA2.
DQ_DA.2.1.
DQ_DA.2.2.
DQ_DA3.
DQ_DA.3.1.
DQ_DA.3.1.
01.2 - Reproductive and Maternal Health | Hospital, Health center, Clinic | Monthly (Meskerem 2015)
Activity
Reproductive and Maternal Health

Total number of new and repeat acceptors by age
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
30 - 49 years
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
30 - 49 years
Oral contraceptives
Injectables
Implants
IUCD
Vasectomy
Tubal ligation
Others
Oral contraceptives
Injectables
Implants
IUCD
Vasectomy
Tubal ligation
Others
Immediate Postpartum Contraceptive Acceptance (IPPFP)

Total PPFP 聽acceptors,聽disaggregated by age
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
30 - 49 years
Premature Removal of Long term family planning methods (PRLAFP)

Implants
IUCD
Others
Total LAFP removal in the reporting period
Antenatal Care (ANC) coverage 鈥

<= 12 weeks
> 12 and <=16 weeks
> 16 weeks
10 - 14 years
15 - 19 years
>= 20 years
Antenatal care (ANC) coverage 鈥

10 - 14 years
15 - 19 years
>= 20 years
Total number of pregnant women that received four or more antenatal care contacts by gestational week
<= 30 weeks
> 30 weeks

Pregnant women attending antenatal care tested for syphilis
Total Number of pregnant women tested for syphilis
Reactive
Non-Reactive
Total Number of Pregnant women attending antenatal care tested for hepatitis B
Reactive
Non-Reactive
Total Number of pregnant women who were received prophylaxis for HBV
Births attended by skilled health personnel

Total number of births attended by skilled health personnel
Total number of women who developed postpartum hemorrhage (PPH)
Home delivery
Facility delivery
Percentage women who received uterotonics in the first one minute after delivery
Total number of women who received uterotonics in the first one minute after delivery
oxytocin
mesoprostol
ergometrin
Other uterotonics
Still birth rate
Number of still births

Early postnatal care coverage

Number of postnatal visits within 7 days of delivery
24Hrs (1day)
25 - 48 hrs (1 - 2 days)
49 - 72 hrs (2 - 3 days)
73 hrs - 7 days (4 - 7 days)
Caesarean section
Number of women having given birth by caesarean section
Number of women receiving comprehensive abortion care services dis aggregated by maternal age
Number of safe abortions performed
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
>= 30 years
Number of post abortion/emergency care
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
>= 30 years
Oral contraceptives
Injectables
Implants
IUCD
Vasectomy
Tubal ligation
Others
Number of obstetric fistula cases identified by Age
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
>= 30 years
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
>= 30 years
Proportion of maternal death(institutional)
Number of maternal deaths in health facility
Total number of teenage girls tested positive for pregnancy
10 - 14 years
15 - 19 years
Total number of women tested positive for pregnancy
02 - PMTCT | Hospital, Health center, Clinic | Monthly (Meskerem 2015)
Activity
PMTCT
Pregnant and lactating women who were tested for HIV and know their results
Number of pregnant women tested and know their HIV result during labour & delivery
03 - EPI | Hospital, Health center, Health post, Clinic | Monthly (Meskerem 2015)
Activity
Expanded Program on Immunization (EPI)
Number of Live births who receive a HepB-Birth dose(BD)
Within 24 hours after birth
Within 24 to 14 days after birth
Number of children under one year of age who have received BCG vaccine
Number of children under one year of age who have received first dose of pentavalent vaccine
Number of children under one year of age who have received third dose of pentavalent vaccine
Number of children under one year of age who have received first dose of polio vaccine
Number of children under one year of age who have received third dose of Polio vaccine
Number of children under one year of age who have received first dose of pneumococcal vaccine
Number of children under one year of age who have received third dose of pneumococcal vaccine
Number of children under one year of age who have received one dose of inactivated polio vaccine
Number of children under one year of age who have received first dose of Rotavirus vaccine
Number of children under one year of age who have received 2nd dose of Rotavirus vaccine
Number of children under one year of age who have received first dose of measles vaccine
Number of children received all vaccine doses before 1st birthday
Measles dose coverage
Number of children (15-23 ) months of age who have received second dose of measles vaccine
Proportion of under one children protected against Neonatal Tetanus(PAB)
Number of infants whose mothers had protective doses of TD against NNT (PAB)
HPV 1 (Human Papilloma Virus vaccine (1st dose) Immunization coverage (14 years old girls)
Number of girls 14 year of age who have received first dose of human papilloma virus vaccine
HPV 2 (Human Papilloma Virus vaccine (2nd dose) Immunization coverage (14 years old girls)
Number of girls 14 years of age who have received second dose of human papillomavirus vaccine in 6 month interval from the first dose
TD Vaccination
women who have received TD1 vaccination
Vaccine wastage rate
BCG doses opened
BCG doses damaged
BCG doses expired
Pneumococcal conjugated vaccine doses opened
Pneumococcal conjugated vaccine doses damaged
Rota doses opened
Rota doses damaged
Rota doses expired
Polio doses opened
Polio doses damaged
Polio doses expired
TD doses opened
TD doses damaged
TD doses expired
IPV doses given
IPV doses opened
04.2 - Neonatal and Child Health | Health center, Hospital and clinic | Monthly (Meskerem 2015)
Activity
Child Health
Institutional neonatal death
Number of neonatal deaths in the first 24 hrs of life
Number of neonatal deaths between 1 -7 days of life
Under-five children with pneumonia received antibiotic treatment
Number of sick young infants 0-2 months treated for Critical illness
Children treated with Zinc and ORS for diarrhea
Treated by ORS only
Low birth weight or premature newborns for whom KMC was initiated after delivery
Total number of newborns weighing <2000gm and/or premature newborns for which KMC initiated
Total number of newborns weighing <2000gm and/or premature
Asphyxiated neonates who were resuscitated (with bag & mask) and survived
Number of neonates resuscitated and survived
Total number of neonates resuscitated
Treatment outcome of neonates admitted to NICU
Total neonates admitted to NICU
Total neonates discharged from NICU
Recovered
Dead
Transferred
Newborns that received at least one dose of CHX to the cord on the first day after birth
Number of Newborns that received at least one dose of CHX to the cord on the first day after birth
Children aged 0 to 59 months Assessed for developmental milestone
0 to 24 months
24 to 59 months
Children aged 0 to 59 months Assessed for developmental milestone and there status
Developmental Delay
05.2 - Nutrition | Hospital, Health center | Monthly (Meskerem 2015)
Activity
Nutrition
Percentage of live births that weigh less than 2,500gm out of the total live births weighed
Number of live-born babies with birth weight less than 2,500 gm
Total number of live births weighed
Proportion of < 2 year children who have participated in growth monitoring and promotion (GMP)
Number of children less than 2 yr weighted during GMP session
0 - 5 months
6 - 23 months
0 - 5 months
6 - 23 months
Number of weights recorded with severe malnutrition, by age (Z-score below (-3)
0 - 5 months
6 - 23 months
Children aged 6-59 months who received vitamin A supplementation
Total number of children aged 6-59 months who received Vitamin A supplementation dis aggregated by age
6 - 11 months
12 - 59 months
Total number of children aged 6-59 months who received Vitamin A supplementation dis aggregated by dose
First dose
Second dose
Proportion of children 24-59 months de-wormed
Total number of children aged 24 - 59 months dewormed
First dose
Second dose
Number of pregnant women De-wormed
Proportion of pregnant women received iron and folic acid (IFA) supplements at least 90 plus
Total number of Pregnant women received IFA at least 90 plus
10 - 14 years
15 - 19 years
>= 20 years
Proportion of Pregnant and lactating women (PLW) screened for malnutrition
Total number of PLW screened for acute malnutrition by MUAC status
MUAC < 23 cm
MUAC >= 23 cm
Total number of PLW screened for acute malnutrition By maternal status:
Pregnant
lactating
Children aged <5 yrs screened for acute malnutrition
Total Number of children < 5 yr screened for acute malnutrition
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
Admission and treatment outcome for management of severe acute malnutrition in children under 5 yrs for SC
Total SAM at the beginning of the month
0 - 5 months
6 - 23 months
24 - 59 Months
Total number of children with SAM admitted to SC during the reporting period(new and re-admision)
0 - 5 months
6 - 23 months
24 - 59 Months
Number of children stablized
0 - 5 months
6 - 23 months
24 - 59 Months
Number of children cured
0 - 5 months
6 - 23 months
24 - 59 Months
Number of children died
0 - 5 months
6 - 23 months
24 - 59 Months
Number of children transferred out
0 - 5 months
6 - 23 months
24 - 59 Months
Number of children defaulted
0 - 5 months
6 - 23 months
24 - 59 Months
Number of children -non-respondent
0 - 5 months
6 - 23 months
24 - 59 Months
Number of children Medical transfer
0 - 5 months
6 - 23 months
24 - 59 Months
Number of children unknown status
0 - 5 months
6 - 23 months
24 - 59 Months
Number of children who exit from severe acute malnutrition treatment during the reporting period by age(SC)
0 - 5 months
6 - 23 months
24 - 59 Months
Admission and treatment outcome for management of severe acute malnutrition in children under 6-59 Months f
Total SAM at the beginning of the month for OTP
OTP_Number of children stabilized
OTP_Number of children cured
OTP_Number of children died
OTP_Number of children transferred out
OTP_Number of children defaulted
OTP_Number of children -non-respondent
OTP_Number of children Medical transfer
OTP_Number of children unknown status
Total number of children with SAM admitted to OTP during the reporting period
Number of children who exit from severe acute malnutrition treatment during the reporting period(OTP)
Admission and treatment outcome for management of MAM for childern 6-59 months
Total MAM at the beginning of the month
Total number of children with MAM admitted to OTP during the reporting period
MAM_Number of children stabilized
MAM_Number of children cured
MAM_Number of children died
MAM_Number of children transferred out
MAM_Number of children defaulted
MAM_Number of children Medical transfer
MAM_Number of children unknown status
Number of children who exit from MAM treatment during the reporting period
Adolescent and Youth Nutrition Service
Adolescent and Youth Aged 10-19 screened for nutrition-Normal
10 - 14 years, Male
15 - 19 years, Male
Adolescent and Youth Aged 10-19 screened for nutrition-underweight
10 - 14 years, Male
15 - 19 years, Male
Adolescent and Youth Aged 10-19 screened for nutrition-overweight
10 - 14 years, Male
15 - 19 years, Male
06 - HIV | Hospital, Health center, Clinic | Monthly (Meskerem 2015)
Activity
HIV Prevention and Control
Clients receiving HIV test results (at VCT)
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Clients testing positive for HIV (at VCT)
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Clients receiving HIV test results (at PITC)
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
HCT by population group
HIV testing service - HTS who received result by population group
HIV testing service - HTS who tested positive by population group
Number of individuals who were identified and tested using Index testing services and received their result
Number of index cases offered
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Number of contacts by test result (Positive)
New positive
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Known positive
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Number of Individual HIV self test KIT distribued
Directly assisted
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Unassisted
Male
Female
Does health facility provide Monthly PMTCT / ART Treatment Service?
Number of adults and children who are currently on ART by age, sex and regimen category
Number of children (<15) who are currently on ART
Children聽currently on ART aged <1 yr
Children currently on ART aged <1 yr on First line聽 regimen by sex
Male
Female
Children currently on ART aged <1 yr on Second line聽 regimen by sex
Male
Female
Children currently on ART aged <1 yr on Third line regimen by sex
Male
Female
Children聽currently on ART aged 1-4 yr

Children currently on ART aged 1-4 yr on First line聽 regimen by sex
Male
Female
Children currently on ART aged 1-4 yr on Second-line聽 regimen by sex
Male
Female
Children currently on ART aged 1-4 yr on Third line regimen by sex
Male
Female
Children聽currently on ART aged 5-9 yr on First line聽 regimen by sex
Male
Female
Children聽currently on ART aged 5-9 yr on Second line聽 regimen by sex
Male
Female
Children聽currently on ART aged 5-9 yr on Third line regimen by sex
Male
Female
Children聽 currently on ART aged 10-14 year
Children聽 currently on ART aged 10-14 year on First line聽 regimen by sex
Male
Female
Children currently on ART aged 10-14 year on Second line聽 regimen by sex
Male
Female
Children currently on ART aged 10-14 years on Third line regimen by sex
Male
Female
Number of adults who are currently on ART (>=15)
Adult currently on ART aged 15-19
Adult currently on ART aged 15-19 on First line聽 regimen by sex
Male
Female
Adult currently on ART aged 15-19 on Second-line聽 regimen by sex
Male
Female
Adult currently on ART aged 15-19 on Third line regimen by sex
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Adult currently on ART aged 25-29 on Second line聽 regimen by sex
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Adult currently on ART aged 50+
Male
Female
Male
Female
Male
Female
Currently on ART by pregnancy status
Pregnant
Non pregnant
Number of children (<19) who are currently on ART by regimen type
Children currently on ART aged <1 yr by regimen type
Children currently on ART aged <1 yr on First line聽 regimen by regimen type
4j= ABC +3TC + DTG
4k= AZT + 3TC + DTG
4h=other first line
Children currently on ART aged <1 yr on second line regimen by regimen type
5n= AZT + 3TC + DTG
5j=other secondline
Children currently on ART aged <1 yr on Third line regimen by regimen type
Children currently on ART aged 1-4 yr by regimen type
聽Children currently on ART aged 1-4 yr on First line regimen by regimen type
4d = AZT+3TC+EFV
4j= ABC +3TC + DTG
4k= AZT + 3TC + DTG
4L= ABC + 3TC + EFV
4h=other first line
Children currently on ART aged 1-4 yr on Second-line regimen by regimen type
5h=ABC + 3TC + EFV
5n= AZT + 3TC + DTG
5j=other secondline
Children currently on ART aged 1-4 yr on Third Line regimen by regimen type

Children currently on ART aged 5-9 yr on by regimen type
Children currently on ART aged 5-9 yr on First line regimen by regimen type
4d = AZT+3TC+EFV
4e= TDF+3TC+EFV
4i= TDF + 3TC + DTG
4j= ABC +3TC + DTG
4k= AZT + 3TC + DTG
4L= ABC + 3TC + EFV
4h=other first line
Children currently on ART aged 5-9 yr on Second line regimen by regimen type
5g= TDF + 3TC + EFV
5h=ABC + 3TC + EFV
5i=TDF + 3TC+ LPV/r
5n= AZT + 3TC + DTG
5o= TDF + 3TC + DTG
5j=other secondline
Children currently on ART aged 10-14 year by regimen type
Children currently on ART aged 10-14 year on 聽First line regimen by regimen type
4d = AZT+3TC+EFV
4e= TDF+3TC+EFV
4i= TDF + 3TC + DTG
4j= ABC +3TC + DTG
4k= AZT + 3TC + DTG
4L= ABC + 3TC + EFV
4h=other first line
Children currently on ART aged 10-14 year on Second line regimen by regimen type
5g= TDF + 3TC + EFV
5h=ABC + 3TC + EFV
5i=TDF + 3TC+ LPV/r
5n= AZT + 3TC + DTG
5o= TDF + 3TC + DTG
5j=other secondline
Children currently on ART aged 10-14 year on Third Line regimen by regimen type
Adult currently on ART aged 15-19 by regimen type
Adult currently on ART aged 15-19 on聽First line regimen by regimen type
1d = AZT-3TC-EFV
1e = TDF-3TC-EFV
1g= ABC + 3TC + EFV
1j=TDF + 3TC + DTG
1k= AZT +3TC +DTG
1i = Other specify
Adult currently on ART aged 15-19 on Second line regimen by regimen type
2e= AZT+3TC+LPV/r
2f=AZT+3TC+ATV/r
2g= TDF-3TC-LPV/r
2h =TDF-3TC-ATV/r
2l=other secondline
Adult currently on ART aged 15-19 on Third Line regimen by regimen type
3d=Other thirdline
Adults >=20 years currently on ART by regimen type
Adults >=20 years currently on First line聽 regimen by regimen type
聽Adults >=20 years currently on Second line regimen by regimen type
Adults >=20 years currently on Third Line regimen by regimen type
Number of adults and children with HIV infection newly started on ART
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
ART retention rate (Percentage of adult and children on ART treatment after 12 month of initation of ARV therapy
Number of adults and children who are still on treatment at 12 months after initiating ART
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
Number of persons on ART in the original cohort including those transferred in, minus those transferred out (net current cohort)
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
Linkage outcome of of newly identified Hiv positive individuals in the reporting period
Linked to care and treatment
Known on ART
Lost to follow up art
Referred to other facility
Died
Others
Viral load Suppression (Percentage of ART clients with a suppressed viral load among those with a viral load test
Number of adult and pediatric ART patients for whom viral load test result received in the reporting period
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
Total number of adult and paediatric ART patients with an undetectable viral load(<50 copies/ml) in the reporting period
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
Total number of adult and paediatric ART patients with low level viremia (50 -1000 copies/ml) in the reporting period
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
Proportion of PLHIV currently on differentiated service Delivery model (DSD)
Total number of clients on 3MMD
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Total number of clients on ASM(6MMD)
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Total number of clients on FTAR
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Total number of clients on CAG
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Total number of clients on PCAD
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female

Total number of clients on KP DSD
Total number of clients on MCH DSD
Total number of clients on "Advanced HIV Disease Care Model"
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Number of ART Clients that interrupted Treatment
Number of ART Clients Interrupted treatment by outcome
Lost after treatemnt < 3month
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Lost after treatemnt > 3month
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Transferred out
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Refused (stopped) treatement
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Died
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Number of ART clients restarted ARV treatment in the reporting period
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Number of individuals receiving Pre-Exposure Prophylaxis
PrEP (New Number of individuals who were newly enrolled on PrEP)
By age and Sex
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
By Client Category
Discordant Couple
Female sex worker[FSW]
PrEP Curr (Number of individuals that received oral PrEP during the reporting period)
By age and Sex
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
By Client Category
Discordant Couple
Number of persons provided with post-exposure prophylaxis (PEP) for risk of HIV infection by exposure type
Occupational
Sexual violence
Other Non occupational
Proportion of clinically undernourished People Living with HIV (PLHIV) who received therapeutic or supplementary food
Number of PLHIV who were assessed/screened for malnutrition
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Number of PLHIV that were nutritionally assessed and found to be clinically undernourished (disaggregated by Age, Sex and Pregn
Total MAM
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Total SAM
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Clinically undernourished PLHIV who received therapeutic or supplementary food (disaggregated by age, sex and pregnancy statu
Total MAM who received therapeutic or supplementary food
< 15 years, Male
< 15 years, Female - pregnant
< 15 years, Female - non-pregnant
>= 15 years, Male
>= 15 years, Female - pregnant
Total SAM who received therapeutic or supplementary food
< 15 years, Male
>= 15 years, Male
Proportion of STI cases tested for HIV
Number of STI cases tested for HIV
Male
Female
Number of STI cases tested positive for HIV
Male
Female
Total number of STI cases, by syndrome
Urethral discharge
Persistent urethral discharge
Scrotal swelling
Vaginal discharge
PID (pelvic inflammatory disease)
Non vesicular genital ulcer disease (NVGUD)
Vesicular genital ulcer disease (VGUD)
Inguinal bubo
Neonatal conjunctivitis
Neonatal herpes
Number of non-pregnant women living with HIV on ART aged 15-49 reporting the use of any method of modern family planning by
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
30 - 49 years
Oral contraceptives
Injectables
Implants
IUCD
Others
Proportion of patients enrolled in HIV care who were screened for TB (FD)
Number of NEWLY Enrolled ART clients who were screened for TB during the reporting period
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Screened Positive for TB
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Number of PLHIVs PREVIOUSLY on ART and screened for TB
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Patients on 6H
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Patients on 3HP
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Patients on 3HR
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Number of ART patients who were initiated on any course of TPT 12 months before the reporting period
Patients on 6H 12 months prior to the reporting period
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Number of ART patients who started TPT 12 months prior to the reproting period that completed a full course of therapy
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Cervical Cancer screening by type of test
Screened by VIA
Screened by HPV DNA
VIA Screening Result
Normal cervix:
15 - 19 years
20 - 24 years
25 - 29 years
07 - TB/Leprosy | Hospital, Health center, clinic | Monthly (Meskerem 2015)
Activity
Proportion of all forms of TB cases notified and treated from community referral
Number of all forms of TB (New and Relapse) cases that were notified and treated during the reporting period
Number of bacteriologically confirmed New Pulmonary TB cases detected and enrolled in the reporting period b
0 - 4 years, Male
0 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 34 years, Male
35 - 44 years, Male
45 - 54 years, Male
55 - 64 years, Male
>=65 yr, Male
>=65 yr, Female
Number of clinically diagnosed New pulmonary TB cases detected and enrolled in the reporting period by age and sex
0 - 4 years, Male
0 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 34 years, Male
35 - 44 years, Male
45 - 54 years, Male
55 - 64 years, Male
>=65 yr, Male
>=65 yr, Female
Number of clinically diagnosed and bacteriological confirmed new EPTB cases detected and enrolled in the reporting period by ag
0 - 4 years, Male
0 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 34 years, Male
35 - 44 years, Male
45 - 54 years, Male
55 - 64 years, Male
>=65 yr, Male
>=65 yr, Female
Number of all RELAPSE TB cases detected and enrolled in the reporting period
0 - 4 years, Male
0 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 34 years, Male
35 - 44 years, Male
45 - 54 years, Male
55 - 64 years, Male
>=65 yr, Male
>=65 yr, Female
Tuberculosis Re-treatment
Treatment after Relapse (R), Male
Treatment after Relapse (R), Female
Failed, Male
Failed, Female
Lost to follow-up, Male
Lost to follow-up, Female
Other previously treated (unknown & undocumented treatment outcome) (O), Male
Other previously treated (unknown & undocumented treatment outcome) (O), Female
Number of notified TB cases from key affected population group during the reporting period
Diabetes
Homeless
Refugee
Prisoners
Miners
TB Contacts
TB Treatment-outcome
Total number of bacteriologically confirmed new Pulmonary TB cases enrolled in cohort (PTB+) in the same month of the previous EFY
Completed
Cured
Lost to follow-up
Dead
Failed
Not evaluated
Total number of new clinically diagnosed pulmonary TB cases enrolled in the cohort (P/Neg) in the same month of the previous EFY
Completed
Lost to follow-up
Deaths
Failed
Not evaluated
Completed
Lost to follow-up
Deaths
Failed
Not evaluated
Completed
Cured
Lost to follow-up
Dead
Failed
Not evaluated
Number of all forms TB cases detected and registered on TB unit register who are initially referred by the community
Number of cohort TB patients (all forms) who were successfully treated (cured plus completed treatment) who received support for treatment
Total number of patients who started TB treatment in same reporting month of pervious year and who received any form of treatment adhere
Number of TB cases (all forms) notified in public health facilities with initial referral by PPM sites for TB diagnosis or initiation of TB treatment
Contact investigation coverage
Total number of contacts with index bacteriologically confirmed drug susceptible TB cases during the reporting
0 - 4 years
5 - 14 years
>= 15 years
Total number of contacts with index bacteriologically confirmed DR-TB cases during the reporting Month
0 - 4 years
5 - 14 years
>= 15 years
Contacts of drug susceptible TB cases screened for TB
0 - 4 years
5 - 14 years
>= 15 years
Contacts of drug Resistant TB cases screened for TB
0 - 4 years
5 - 14 years
>= 15 years
Number of contacts with index bacteriologically confirmed TB (drug susceptible) cases screened negative for TB in the reporting p
0 - 4 years
5 - 14 years
>= 15 years
TB Preventive Therapy (TPT) Coverage
Number of contacts screened negative for TB and others eligible and put on TB Preventive Therapy (TPT) in the
0 - 4 years
5 - 14 years
>= 15 years
By Regimen Type
3HP
3RH
6H
Number of cohort of individuals started TPT 12 months prior to the reporting period by Age Group
0 - 4 years
5 - 14 years
>= 15 years
By Regimen Type
3HP
3RH
6H
TPT completion rate
Number of cohort of individuals that completed TPT treatment among those who started 12 months prior to the
0 - 4 years
5 - 14 years
>= 15 years
By Regimen Type
3HP
3RH
6H
Number of new and relapse bacteriologically confirmed pulmonary TB patients initially tested using a WHO recommended rapid te
0 - 4 years, Male
0 - 4 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
Number of notified bacteriologically confirmed TB cases evaluated for drug susceptibility testing according to national policy durin
New
Previously treated including relapse
Unknown treatment History
Number of TB cases with drug susceptibility testing result for at least rifampicin during the reporting period
New
Number of DR TB cases detected (Hr, RR Only, MDR- TB , Pre XDR and XDR TB cases)
Number of Hr-TB TB cases
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Total Number of confirmed RR only TB cases
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Total number of confirmed MDR TB cases
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Total number of confirmed Pre-XDR TB cases
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Total number of confirmed XDR- TB cases
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
DR TB treatment coverage
Number of Hr-TB put on Hr-TB regimen by HIV status
Positive
Negative
Unknown
By Registration Group
New
Unknown
Shorter regimen
Longer regimen
Positive
Negative
Unknown
New
Unknown
RR/MDR-TB cases with DST result at least for fluoroquinolone during the reporting month
DR TB Treatment Interim result for cohort of patient registered the same month of the previous year (12 month earlier)
Total Number of聽 cohort聽 DR-TB cases initiated on second-line anti-TB the same month of the previous year (12 month earlier)
Short term regimen
Long term
Number of cohort DR-TB cases started short term second-line anti-TB treatment regimen the same month of the previous year (12
Number of聽 cohort DR-TB cases started聽 long term second-line anti-TB treatment regimen the same month of the previous year
Total number of cohort DR-TB cases started on short term second-line anti-TB treatment regimen 24 months earlier.
Cured
Completed
Died
Failed
Lost to follow-up
Not evaluated
Cured
Completed
Died
Failed
Lost to follow-up
Not evaluated
Total number of cohort DR-TB cases started on long term( standardized and individualized) second-line anti-TB treatment regimen
Cured
Completed
Died
Failed
Lost to follow-up
Not evaluated
Normal
MAM
SAM
Number of DR TB cases enrolled to second line drugs screened for Malnutrition during the reporting period
Normal
MAM
SAM
Total number of new and relapse TB patients registered during the reporting period having a documented HIV positive test result
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Total number of new and relapse TB patients registered during the reporting period having a documented HIV neg
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Total number of HIV-positive new and relapse TB patients who are already on ART
0 - 4 years, Male
0 - 4 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
0 - 4 years, Male
0 - 4 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
All new leprosy cases detected (MB+PB)
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Leprosy contact screening
Total number of household contacts of leprosy cases registered in the reporting period
New leprosy cases with Grade II disability (MB+PB)
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Leprosy Treatment Completion Rate
Result of new leprosy cohort cases registered during 16-18 months prior to this reporting period
Registered cohort of MB cases
Treatment completed MB cases
Registered cohort of PB cases
Treatment completed PB cases
TB_Total Number of AFB tests performed by Method
Ziehl-Neelsen based AFB Microscopy
Fluorescent based AFB Microscopy
TB_Total Number of AFB tested positive by Method
08.2 - Malaria, NTD, NCD | Hospital, Health center, Clinic | Monthly (Meskerem 2015)
Activity
Total number of slides or RDT performed for malaria diagnosis
< 5 years, Male
< 5 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
Total number of slides or RDT Positive
< 5 years, Male
< 5 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
Malaria with Travel History
Case notified to PHCU for further investigation (Elimination Districts)
Number of foci investigated and classified (Elimination Ditricts)
Does the facility provide leishmaniasis treatment?
Number of visceral leishmaniasis patients treated by age and sex
< 5 years, Male
< 5 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
Number of visceral leishmaniasis patients treated by treatment type
Primary visceral leishmaniasis
Relapse visceral leishmaniasis
Post Kala-azar dermal leishmaniasis (PKDL)
Number of visceral leishmaniasis patients treated by treatment outcome
Cured
Defaulted
Failed
Dead
Referred
Number of visceral leishmaniasis patients treated by HIV test result status
Positive
Negative
Number of cutaneous leishmaniasis treated by age and sex
< 5 years, Male
< 5 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
Number of cutaneous leishmaniasis patients treated by type
Primary cutaneous leishmaniasis
Relapse cutaneous leishmaniasis
Number of cutaneous leishmaniasis patients treated by treatment outcome
Cured
Defaulted
Failed
Dead
Referred
Number of people with TT who received corrective TT surgery
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Number of hydrocele cases operated (due to lymphatic filariasis)
< 15 years, Male
>= 15 years, Male
Number of lymph edema cases managed (podoconosis and lymphatic filariasis)
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Hypertension
Number of Individuals screened for hypertension
18 - 29 years, Male
30 - 39 years, Male
40 - 69 years, Male
>=70 years, Male
>=70 years, Female
Raised BP
Normal BP
18 - 29 years, Male
30 - 39 years, Male
40 - 69 years, Male
>=70 years, Male
>=70 years, Female
Previously in care
Treatment outcome for cohort of patient registered for hypertension treatment six months prior to the reporting
Controlled
Uncontrolled
Lost to follow-up
Died
Transferred out
Not evaluated
Cardio vascular diseases
Number of individuals in high CVD risk by type of risk category :
Lab based risk category ( >=20%)
Non-Lab based category (>=10%)
Number of individuals in high CVD risk by Age Catagory:
40 - 59 Years, Male
60 - 74 Years, Male
Number of patients with high CVD risk who received treatment by type of treatment:
With Statin
Without Statin
patients with high CVD risk who received treatment by Age Catagory:
40 - 59 Years, Male
60 - 74 Years, Male
Diabetes mellitus
< 40 years, Male
< 40 years, Female
>= 40 years, Male
>= 40 years, Female
Raised blood sugar
Normal blood sugar
Diabetic patients enrolled to care by types of Diabete
Type I
Type II
Gestational DM
< 15 years, Male
< 15 years, Female
15 - 29 years, Male
30 - 39 years, Male
>= 40 years, Male
>= 40 years, Female
Previously in care
Six-monthly control of diabetes among individuals treated for diabetes
Total number of cohort of hypertensive pateints registered for diabetes treatment six months prior to the reporting period
Treatment outcome for cohort of patient registered for diabetes treatment six months prior to the reporting period
Controlled
Uncontrolled
Lost to follow-up
Died
Transferred out
Not evaluated
Treatment outcome for cohort of patient registered for diabetes treatment six months prior to the reporting period by age and sex
< 15 years, Male
< 15 years, Female
15 - 29 years, Male
30 - 39 years, Male
>= 40 years, Male
>= 40 years, Female
Screened by VIA
Screened by HPV DNA
Negative
09.2 - Medical services | Health center | Monthly (Meskerem 2015)
Activity
Number of outpatient visits
< 5 years, Male
< 5 years, Female
5 - 10 years, Male
11 - 19 years, Male
20 - 29 years, Male
30 - 45 years, Male
46 - 65 years, Male
>= 66 years, Male
>= 66 years, Female
Bed occupancy rate
Average length of stay
Total length of stay (in days) during discharge
Number of inpatient discharges
Essential laboratorial tests available
Monthly score of essential laboratorial tests of the facility
Referral-out rate
Number of people referred to other health facility
Emergency referral
Non-emergency referral
Ambulance service utilization for referral service
Total number of referral-ins
Emergency referral
Number of clients that came to health facility using ambulance
Pre-facility
Between facility
Ambulance service response rate
Total number of Ambulance dispatched - by technician
Total number of Ambulance dispatched in the reporting period - by Case
Trauma
Burn & Poisoning
Others
Emergency unit mortality
Facility emergency department mortality rate
Total death in the emergency unit
Total number of emergency unit attendance during the reporting period
Inpatient mortality rate
Total number of inpatient death in the reporting period
< 24 hours
>= 24 hours
Total units of blood received from NBTS & regional blood banks
Total number of units of blood transfused
from blood bank
Number of serious adverse transfusion incidents and reactions occurred
Number of road traffic injury cases dis aggregated by accident type
Vehicle occupant
Motor cyclist
Pedestrian
Others
Improve access to pharmaceuticals & medical devices & their rational & proper use
Medroxyprogesterone Injection
Pentavalent vaccine
Magnesium Sulphate injection
Oxytocine inj
Gentamycin injection
ORS+/- Zinc sulphate
Amoxcillin dispersable/suspension/capsule
Iron + folic acid
Albendazole/Mebendazole tablet/suspension
TTC eye ointment
RHZE/RH
TDF/3TC/DTG
Co-trimoxazole 240mg/5ml suspension
Arthmeter + Lumfanthrine tablet
Amlodipine tablet
Frusamide tablets
Metformin tablet
Normal Saline 0.9%
40% glucose
Adrenaline injection
Tetanus Anti Toxin (TAT) injection
Omeprazole capsule
Metronidazole capsule
Ciprofloxcaxillin tablet
Hydralizine injection
Percentage of encounters with an antibiotic prescribed
MS_Number of clients who received 100% of prescribed drugs
Total number of clients who received prescriptions
Percentage of medicines prescribed from the facility’s medicines list
Proportion of health facilities that conduct reporting consistency check using LQAS
Did the HF conduct LQAS for service report?
LQAS first score for service report
LQAS last score for service report
Did the HF conduct LQAS for OPD report?
LQAS first score for OPD report
LQAS last score for OPD report
Did the HF conduct LQAS for IPD report?
LQAS first score for IPD report
LQAS last score for IPD report
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
372 387 334 275 442 473 2283

163 151 180 74 112 144 824
11 20 14 12 6 63
56 18 63 20 39 44 240
58 81 44 17 42 51 293
38 52 53 23 19 43 228
209 236 154 201 330 329 1459
22 3 5 11 5 46
39 26 31 53 74 51 274
74 126 55 69 120 117 561
74 84 65 74 125 156 578
383 387 334 275 442 473 2294
161 151 180 74 112 144 822
27 16 21 1 13 14 92
67 88 125 41 68 110 499
67 39 34 32 31 19 222
8 1 9
222 236 154 201 330 329 1472

37 28 23 3 20 10 121
126 208 122 147 236 255 1094
54 9 41 74 55 233
5 10 9 24
10 26 11 4 28 79
1 8 9
2 5 7 2 9 25
1 12 3 1 9 26
7 9 1 2 19
4 4
4 4
16 8 2 22 48
64 97 135 167 106 115 684

24 57 98 89 83 64 415
11 10 13 15 51 100
29 40 27 65 8 169
64 97 135 167 106 115 684
8 12 27 21 21 89
56 97 123 140 85 94 595
51 60 68 42 68 40 329
5 3 8 6 10 32
46 60 65 34 62 30 297
51 60 68 42 68 50 339
42 10 52
51 18 68 42 68 40 287
58 58
51 97 135 167 106 115 671
51 97 135 167 106 115 671
51 97 135 167 106 115 671
51 97 135 167 106 115 671
58 75 72 92 99 86 482
58 75 72 92 99 86 482
58 75 72 92 99 86 482
10.9 23.3 34.2

1 2 3
58 75 105 91 99 84 512
58 75 72 91 99 395
58 75 72 114 99 86 504
58 75 72 93 99 86 483
3 3
5 5
13 13
7 17 7 3 15 6 55
1 15 7 6 1 30
1 1
4 1 5
3 4 7
7 3 1 11
1 5 6
6 2 3 9 5 25
1 6 7
1 2 1 4
3 1 1 1 2 8
3 1 2 6
7 17 7 3 15 6 55
7 17 7 3 15 6 55
7 17 3 9 5 41
3 2 5
6 3 9
1 4 9 3 17
7 3 10
20 139 16 7 182
20 139 16 7 182
135 479 57 35 706
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
0 0 0 1 0 1 2
64 70 116 167 106 115 638

64 70 82 167 106 115 604
34 34
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
48 78 108 147 68 102 551

48 78 102 142 87 102 559
45 78 101 138 87 102 551
47 78 102 142 87 102 558
60 78 101 138 87 102 566
62 78 102 142 87 102 573
58 78 101 138 87 102 564
48 59 99 140 87 102 535
58 78 100 142 87 102 567
47 78 97 134 82 101 539
45 78 99 135 85 101 543
45 78 99 135 85 101 543
31 78 57 90 67 94 417
49 58 20 142 87 102 458
nth interval from the first dose
64 75 1 95 107 128 470

45 84 17 86 62 123 417
2 14 23 43 7 24 113
5 9 2 13 29
1 8 9
56.6 8.2 0 26.5 57.5 36.3 185.1

59 78 108 147 68 102 562
136 85 108 200 160 160 849
1.7 0 0 0 0 0 1.7
172 234 124 414 266 305 1515
175 234 124 414 266 305 1518
2 3.3 0 1.9 7.6 0.33 15.13

198 234 124 414 266 305 1541
202 242 124 422 288 306 1584
0 0 0 0.72 0 0 0.72
116 156 197 276 179 203 1127
116 156 197 278 179 203 1129
5.1 4.5 0 3.7 14.2 10.3 37.8

204 234 139 414 266 305 1562
215 245 139 430 310 340 1679
19.2 5.5 0 9.6 20 9.3 63.6

97 156 167 226 152 195 993
120 165 167 250 190 215 1107
0 3.5 0 6.7 6.3 4.2 20.7

180 275 51 224 178 297 1205
180 285 51 240 190 310 1256
9.5 8.2 0 15.2 17.1 18.4 68.4
95 78 102 140 87 102 604
105 85 102 165 105 125 687
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
183 32 70 203 234 12 734

8 61 41 22 132
4 5 14 1 24
4 56 27 21 108
41 132 77 197 241 11 699
41 132 77 197 241 11 699
1 44 23 15 7 90
2 2
2 2
2 2
0 0 0 1 0 1
99 99
99 99
468 468
217 217
251 251
468 468
1 1
467 467
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
58 75 72 99 84 388
1453 1908 1423 2151 1636 2365 10936

178 539 68 118 315 201 1419
1275 1369 1355 2033 1321 2164 9517
28 11 245 8 8 10 310
2 5 3 10
26 6 245 5 8 10 300
8 3 255 2 2 5 275
1 2 2 5
8 2 253 2 5 270
293 467 376 1361 228 758 3483

119 187 70 381 90 162 1009
174 280 306 980 138 596 2474
293 467 376 1361 228 758 3483
229 467 339 1361 90 758 3244
64 37 138 239
145 355 234 807 540 2081

100 355 187 797 540 1979
45 47 10 102
101 140 22 77 340
64 179 218 175 106 141 883
2 28 21 29 80
64 179 216 147 85 112 803
884 340 577 920 538 1337 4596

65 1 2 3 4 17 92
819 339 575 917 534 1320 4504
844 340 585 920 538 1337 4564
117 155 264 260 246 473 1515
727 185 321 660 292 864 3049
2691 4656 3600 3997 3955 5335 24234

231 606 63 80 71 1051
1077 1191 1251 1196 1332 1485 7532
1383 2859 2286 2721 2623 3779 15651
1065 16 129 10 9 23 1252
4 3 7
337 9 49 8 8 411
724 4 80 2 1 23 834
6 4 38 2 8 9 67
3 2 8 2 2 5 22
3 2 30 6 4 45
2 2 46 50
2 1 15 18
1 31 32
11 2 2 15
4 2 1 7
7 1 8
11 11
10 10
1 1
2 6 8
2 5 7
1 1
3 3
3 3
2 2
2 2
2 647 46 695
2 10 12
2 2
2 2
2 10 8 9 29
2 10 2 9 23
7 11 9 27
7 10 9 9 35
10 10
7 6 9 22
1 1
12 12
7 7
7 9 16
49 204 253
44 75 119
12 19 31
19 16 35
6 8 14
7 32 39
5 86 91
1 21 22
1 25 26
2 11 13
1 29 30
43 43
12 12
13 13
10 10
8 8
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
319 70 480 301 329 328 1827
1 1
4 2 6
3 3
1 1 2
3 2 5
11 6 17
2 5 2 33 42
11 10 46 66 4 137
3 12 1 98 114
71 56 59 88 4 278
2 67 73 142
118 84 104 99 2 407
5 67 64 136
80 70 93 68 40 5 356
6 33 12 51
2 23 18 36 4 83
2 10 4 16
9 1 6 16
1 3 1 5
1 4 5
1 1 2 4
1 1
38 38
319 70 480 301 329 290 1789

0 0 0 0 0 1 1
2 2
1 1
1 1
10 10
6 6
4 4
4 4
2 2
2 2
3 3
1 1
2 2
19 19
7 7
12 12
46 46
16 16
30 30
2 2
2 2
47 47
12 12
35 35
36 36
12 12
24 24
12 12
5 5
7 7
15 15
4 4
11 11
3 3
2 2
1 1
2 2
2 2
10 10
9 9
1 1
4 4
4 4
175 175
72 72
8 8
95 95
4 4
2 2
2 2
erred out (net current cohort) 195 195
1 1
1 1
2 2
8 8
2 2
2 2
1 1
2 2
7 7
12 12
16 16
1 1
29 29
14 14
35 35
12 12
24 24
5 5
7 7
4 4
10 10
the reporting period
reporting period
81 81
1 1
3 3
2 2
6 6
1 1
2 2
1 1
3 3
21 21
29 29
5 5
7 7
113 113
7 7
9 9
29 29
56 56
4 4
8 8
supplementary food
39 39
3 3
7 7
8 8
21 21
gregated by Age, Sex and Pregnancy)
y age, sex and pregnancy status)
3 3
3 3
3 3
3 3
d of modern family planning by age 57 57
50 50
7 7
d of modern family planning by method 2 2
2 2
39 39
3 3
7 7
8 8
21 21
reporting period
ull course of therapy

4 4
4 4
4 4
2 2
2 2
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
24.3 24.3 24.3 12.2 24.3 109.4

2 2 1 1 6
1 1
1 1
1 1
2 1 3
iod by age and sex 1 1

1 1
ed in the reporting period by age and sex 2 2
1 1
1 1
2 2
2 2
e month of the previous EFY 2 2

2 1 1 2 6
1 1
1 1 1 2 5
month of the previous EFY

4 4
4 4
1 1
1 1
1 1
2 2 4
who received support for treatment adherence by 2 2
ved any form of treatment adherence support from 2 2
gnosis or initiation of TB treatment. in the reporting month
7 19 5 31
5 2 7
2 13 1 16
4 4 8
12 12
12 12
egative for TB in the reporting perio 12 12
12 12
5 12 1 18
5 5
12 1 13
12 1 13
1 1
12 12
7 7
7 7
5 5
5 5
5 5
5 5
g a WHO recommended rapid tests (GeneXpert and others) at the time of TB diagnosis by age and sex
ccording to national policy during the reporting month

0 0 0 1 0 1
evious year (12 month earlier)
month of the previous year (12 month earlier)
me month of the previous year (12 month earlier)
4 months earlier.
4 months earlier.
-line anti-TB treatment regimen 36 months earlier.
mented HIV positive test result
3 2 1 6
2 1 3
1 1 1 3
2 2
2 2
6 6
6 6
2 2
1 1
1 1
2 2
1 1
1 1
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
72 17 102 844 267 362 1664
2 49 18 34 103
5 81 26 45 157
15 3 10 225 37 30 320
16 1 17 127 21 37 219
17 8 46 139 117 104 431
24 5 22 223 48 112 434
11 15 107 68 29 230
12 3 2 17
1 6 4 4 15
1 2 27 12 6 48
15 5 7 27
7 8 34 35 8 92
3 4 13 9 2 31
1 1
7 6 6 2 4 8 33
36 36
36 36
1 0 0 1 1 0 3
10 10
5 5
5 5
57 57
21 21
36 36
47 74 6 189 1800 2116

3 1 20 76 100
2 1 25 52 80
7 2 30 326 365
3 5 1 35 409 453
10 13 1 28 396 448
13 16 33 361 423
7 26 1 8 91 133
2 12 1 10 89 114
45 74 6 189 63 377
1 4 63 68
44 70 6 189 309
1 4 63 68
3 3
1 1 63 65
1 4 69 74
1 1
2 2
1 1
29 29
25 25
1 2 3
3 3 6
1 6 7
45 4 63 112
45 4 6 55
57 57
3 2 2 3 8 18
3 2 2 3 8 18
3 2 2 3 8 18
1 30 121 152
7 7
38 38
1 10 20 31
20 56 76
1 1 1 3
1 1
1 1 2
1 1
1 1
1 1
1 1
1 1
1 1
121 121
121 121
1 2 18 21
eporting period 1 2 18 21
1 2 18 21
eporting period by age and sex 1 1
1 1
292 52 344
146 52 198
146 146
140 52 192
139 52 191
1 1
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
3255 20263 5527 10802 7082 3736 50665
385 395 670 1317 1971 277 5015
496 179 879 1712 1984 256 5506
311 197 378 400 111 108 1505
240 248 147 506 112 225 1478
101 414 134 447 200 195 1491
94 2076 225 655 188 136 3374
260 116 276 480 339 291 1762
372 774 404 928 661 565 3704
235 324 747 1190 686 685 3867

116 380 880 526 230 199 2331
99 2047 144 799 220 252 3561
9 10264 65 233 14 91 10676

1775 1856 1098 7616 2900 3652 18897
15 40 49 11 8 123
3 3 3 3 3 15
15 20 49 11 8 103
8 20 25 8 3 64
0 0 90 0 100 95 285
30 25 20 51 12 54 192
28 23 8 29 2 9 99
2 2 12 22 10 45 93
25 8 51 54 138
23 6 29 9 67
2 2 22 45 71
3 25 8 54 90
23 9 32
3 2 8 45 58
25 29 54 108
23 29 54 106
2 2
14 25 29 55 123
25 29 54 108
23 9 45 77
12 1 13
8 6 14
2 2 4
3 3
3 3
8 8 3 19
7 50 12 95 2 166
3 4 2 9
4 9 8 2 2 25
41 91 132
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 0 1 1 5
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 0 0 1 1 4
1 1 1 1 1 1 6
0 1 0 1 1 1 4
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 0 1 1 1 5
1 1 1 0 1 1 5
1 1 1 1 1 1 6
1 1 0 1 1 1 5
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 0 1 1 1 5
1 1 0 1 1 1 5
100 33.3 100 100 333.3
1856 802 2999 3713 9370
1856 2406 2999 3713 10974
1481 1856 1604 2999 3713 11653
1583 1856 2406 2999 3713 12557
105.7 100 66.1 100 100 471.8
280 1856 1590 8997 3700 16423
265 1856 2406 8997 3700 17224
6 6 6 6 11 7 42
93.3 94.2 89.2 95 83.2 94.3 549.2
95 93.3 92.5 95 90.5 95 561.3
6 6 6 2 12 7 39
95 92.5 89.2 95 81.4 94.3 547.4
95 92.5 90.8 95 90.5 95 558.8
1 1 1 1 1 5
95 95 90 90 90 460
95 95 90 95 95 470
01.2 - Reproductive and Maternal Health | Hospital, Health center, Clinic | Monthly (Tikemet 2015)
S.No
RMH
MAT_CAR
MAT_CAR_A
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_A
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_
MAT_CAR_M
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_M
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
RMH_FP_IP
MAT_IPPCA
MAT_IPPCA
MAT_IPPCA
MAT_IPPCA
MAT_IPPCA
MAT_IPPCA
RMH_FP_L
MAT_LAFPP
MAT_LAFPPR
MAT_LAFPPR
MAT_LAFPPR
MAT_TLAFP
MAT_ANC1
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC4
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC8
MAT_ANC8+
RMH_ANC_
MAT_SYPH.
MAT_SYPH.1
MAT_SYPH.1
MAT_SYPH.
MAT_Hepa
MAT_Hepa.
MAT_Hepa.
MAT_Prp.1.
RMH_L&D_
L&D_SBA.1.
MAT_PPH.1
MAT_PPH.1.
MAT_PPH.1.
MAT_UTER
MAT_UTER.
MAT_UTER.1
MAT_UTER.1
MAT_UTER.1
MAT_UTER.1
MAT_SBR
MAT_SBR.S
MAT_SBR.L
B&D_Ntfc
MAT_B&D_I
MAT_B&D_I
MAT_EPNC.
MAT_EPNC.
MAT_EPNC.1
MAT_EPNC.1
MAT_EPNC.1
MAT_EPNC.1
RMH_L&D_
MAT_CS.1.
MAT_CAC
MAT_CAC_
MAT_CAC_S
MAT_CAC_S
MAT_CAC_S
MAT_CAC_S
MAT_CAC_S
MAT_CAC_
MAT_CAC_P
MAT_CAC_P
MAT_CAC_P
MAT_CAC_P
MAT_CAC_P
MAT_CAC.T
MAT_CAC.Tr
MAT_CAC.Tr
MAT_CAC.M
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_OFC_I
MAT_OFC_Id
MAT_OFC_Id
MAT_OFC_Id
MAT_OFC_Id
MAT_OFC_Id
MAT_OFC_T
MAT_OFC_Tr
MAT_OFC_Tr
MAT_OFC_Tr
MAT_OFC_Tr
MAT_OFC_Tr
MAT_IMD
MAT_IMD.1.
MAT_TngP
MAT_TngP_
MAT_TngP_
MAT_Tngtst
02 - PMTCT | Hospital, Health center, Clinic | Monthly (Tikemet 2015)
S.No
RMCH__PMT
MTCT
MTCT_TST
MTCT_TST.
MTCT_TST.
MTCT_TST.
MTCT_Test.
MTCT_NWpo
03 - EPI | Hospital, Health center, Health post, Clinic | Monthly (Tikemet 2015)
S.No
EPI
EPI_HepBD
EPI_HepBD.
EPI_HepBD.
EPI_BCG1.
EPI_DPT1.1
EPI_DPT3.1
EPI_OPV1.1
EPI_OPV3.1
EPI_PCV1.1
EPI_PCV3.1
EPI_IPV.1.
EPI_Rota1.1
EPI_Rota2.1
EPI_MCV1.1
EPI_FI.1.
EPI_MCV2
EPI_MCV2.1
EPI_PAB
EPI_PAB.1.
EPI_HPV1
EPI_HPV1.1
EPI_HPV2
EPI_HPV2.1
EPI_TD
EPI_TD1.1.
EPI_TD2.1.
EPI_TD3.1.
EPI_TD4.1.
EPI_TD5.1.
EPI_VWR
EPI_VWR_He
EPI_VWR_He
EPI_VWR_He
EPI_VWR_He
EPI_VWR_B
EPI_VWR_B
EPI_VWR_B
EPI_VWR_B
EPI_VWR_Pe
EPI_VWR_Pe
EPI_VWR_P
EPI_VWR_Pe
EPI_VWR_P
EPI_VWR_P
EPI_VWR_P
EPI_VWR_PC
EPI_VWR_RT
EPI_VWR_R
EPI_VWR_R
EPI_VWR_RT
EPI_VWR_PV
EPI_VWR_P
EPI_VWR_P
EPI_VWR_PV
EPI_VWR_M
EPI_VWR_M
EPI_VWR_M
EPI_VWR_M
EPI_VWR_TD
EPI_VWR_T
EPI_VWR_T
EPI_VWR_TD
EPI_VWR_IP
EPI_VWR_IP
04.2 - Neonatal and Child Health | Health center, Hospital and clinic | Monthly (Tikemet 2015)
S.No
CH
CH_IND
CH_IND. 1
CH_IND. 2
CH_IND. 3
CH_TX_PN
CH_TX_PNE
CH_TX_SYI.
CH_TX_SYI.
CH_TX_SYI.
CH_TX_SYI.
CH_TX_DIA
CH_TX_DIAR
CH_TX_DIAR
CH_KMC
CH_KMC.1.
CH_KMC.2.
CH_ASPH
CH_ASPH.1
CH_ASPH.2
05.2 - Nutrition | Hospital, Health center | Monthly (Tikemet 2015)

S.No
NUT
NUT_LBW
NUT_GMP.
NUT_LBW.2
NUT_GMP
NTR_GMP.1
NTR_GMP.1.
NTR_GMP.1.
NUT_GMP.M
NUT_GMP.M
NUT_GMP.M
NUT_GMP_
NUT_GMP_S
NUT_GMP_S
NCH_NTR_
NUT_VITA
NUT_VITA.
NUT_VITA.
NUT_VITA.2
NUT_VITA.2
NUT_VITA.2
NUT_DeW
NUT_DeW.1
NUT_DeW.1.
NUT_DeW.1.
NUT_DeW.2
NUT_IFA
NUT_IFA.1
NUT_IFA.1.
NUT_IFA.1.
NUT_IFA.1.
NUT_PreSM
NUT_PreSM
NUT_PreSMN
NUT_PreSMN
NUT_PreSM
NUT_PreSMN
NUT_PreSMN
NUT_U5SM
NUT_U5SM
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_TX-U
NUT_TX-U
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&Yo
NUT_Adl&Yo
NUT_Adl&Yo
NUT_Adl&Yo
06 - HIV | Hospital, Health center, Clinic | Monthly (Tikemet 2015)
S.No
HIV
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HCT_P
HIV_HTS_T
HIV_HTS_T
HIV_TST_P
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HIV_Tr
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_C
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_ART_R
HIV_ART_R
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_
HIV_ART_N
HIV_ART_N
HIV_ART_N
HIV_ART_N
HIV_ART_N
HIV_ART_N
HIV_TX_PV
HIV_TX_PV
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PV
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_DS
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DS
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_AS
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_FT
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_CA
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_PC
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
.
HIV_TX_Ado
HIV_TX_KP
HIV_TX_MC
HIV_TX_ oth
HIV_TX_A
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_ART_I
HIV_ART_I
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_I
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_PrEP
HIV_PrEP.1
HIV_PrEP.1
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1
HIV_PrEP_
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_
HIV_PrEP_C
HIV_PrEP_C
HIV_PEP
HIV_PEP. 1
HIV_PEP. 2
HIV_PEP. 3
HIV_PLHIV
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_STI_S
HIV_STI_SC
HIV_STI_SC
HIV_STI_SC
HIV_STI_S
HIV_STI_SC
HIV_STI_SC
HIV_STI_S
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_ART_F
HIV_ART_FP
HIV_ART_FP
HIV_ART_FP
HIV_ART_FP
HIV_ART_FP
HIV_ART_F
HIV_ART_F
HIV_ART_F
HIV_ART_F
HIV_ART_F
HIV_ART_F
HIV_TB_SC
HIV_TB.1
HIV_TB.1. 1
HIV_TB.1. 2
HIV_TB.1. 3
HIV_TB.1. 4
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_ART_T
HIV_TB_TP
HIV_TB_TPT
HIV_TB_TPT
HIV_TB_TPT
HIV_TB_TPT
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_T
HIV_ART_T
HIV_ART_T
HIV_ART_T
HIV_ART_T
HIV_TPT
HIV_TPT. 1
HIV_TPT. 2
HIV_TPT. 3
HIV_TPT. 4
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_CXCA
HIV_CXCA_
HIV_CXCA_
HIV_CXCA_
HIV_CXCA_
HIV_CXCA_S
HIV_CXCA_S
07 - TB/Leprosy | Hospital, Health center, clinic | Monthly (Tikemet 2015)
S.No
TB_COMM
TB_TX_PTB
TB
TB. 1
TB. 2
TB. 3
TB. 4
TB. 5
TB. 6
TB. 7
TB. 8
TB. 9
TB. 10
TB. 11
TB. 12
TB. 13
TB. 14
TB. 15
TB. 16
TB. 17
TB. 18
TB. 19
TB. 20
TB_TX_PTB
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_EPT
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_RTB
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_RET
TB_RET. 1
TB_RET. 2
TB_RET. 3
TB_RET. 4
TB_RET. 5
TB_RET. 6
TB_RET. 7
TB_RET. 8
TB_KEY_P
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
CDC_TB_R
TB_TX_OUT
TB_CR_PTB
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PNT
TB_CR_PNT
TB_CR_PNTB
TB_CR_PNTB
TB_CR_PNTB
TB_CR_PNTB
TB_CR_PNTB
TB_CR_PNTB
TB_CR_EPT
TB_CR_EPT
TB_CR_EPTB
TB_CR_EPTB
TB_CR_EPTB
TB_CR_EPTB
TB_CR_EPTB
TB_CR_EPTB
TB_CR_RTB
TB_CR_RTB
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_COMM.
TB_CBTSR.
TB_CBTSR.
TB_DX_PRI
TB_CI
TB_CI.1.1
TB_CI.1.1. 1
TB_CI.1.1. 2
TB_CI.1.1. 3
TB_CI.1.2
TB_CI.1.2. 1
TB_CI.1.2. 2
TB_CI.1.2. 3
TB_CI_SCR
TB_CI_SCR.
TB_CI_SCR.
TB_CI_SCR.
TB_CI_SCR
TB_CI_SCR.
TB_CI_SCR.
TB_CI_SCR.
TB_CI_SCR
TB_CI_SCR_
TB_CI_SCR_
TB_CI_SCR_
TB_TPT
TB_TPT
TB_TPT. 1
TB_TPT. 2
TB_TPT. 3
TB_TPT.1.4
TB_TPT.1.4.
TB_TPT.1.4.
TB_TPT.1.4.
TB_TPT.2.1
TB_TPT.2.1.
TB_TPT.2.1.
TB_TPT.2.1.
TB_TPT.2.5
TB_TPT.2.5.
TB_TPT.2.5.
TB_TPT.2.5.
TB_TPT.3
TB_IPT.3
TB_IPT.3. 1
TB_IPT.3. 2
TB_IPT.3. 3
TB_IPT.3.4
TB_IPT.3.4.
TB_IPT.3.4.
TB_IPT.3.4.
TB_TST-W
TB_TST-WH
TB_TST-WH
TB_TST-WH
TB_TST-WH
TB_TST-WH
TB_TST-WH
TB_DST.1
TB_DST.1.
TB_DST.1.
TB_DST.1.
TB_DST.2
TB_DST.2.
TB_DST.2.
TB_DST.2.
TB_DR_DR.
TB_DR_DR
TB_DR_DR.
TB_DR_DR.
TB_DR_DR.
TB_DR_DR.
TB_DR_DR.
TB_DR_DR.7
TB_DR_DR.7
TB_DR_DR.7
TB_DR_DR.7
TB_DR_DR.
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.
TB_DR_DR.2
TB_DR_DR.2
TB_DR_DR.2
TB_DR_DR.2
TB_DR_TX
TB_DR_TX
TB_DR_TX.
TB_DR_TX.
TB_DR_TX.
TB_DR_TX.
TB_DR_TX.5
TB_DR_TX.5
TB_DR_TX.5
TB_DR_TX.5
TB_DR_DST
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DST
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DST
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DST
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DS
TB_DR_DST
TB_DR_DST
TB_DR_DST
TB_DR_CTX
TB_DR_CT
TB_DR_CTX
TB_DR_CTX
TB_DR_CTX
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_TxO
TB_DR_TxO.
TB_DR_TxO.
TB_DR_TxO.
TB_DR_TxO.
TB_DR_TxO.
TB_DR_TxO.
TB_DR_CTX
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_NUT
TB_DR_NUT.
TB_DR_NUT.
TB_DR_NUT.
TB_MN
TB_MN. 1
TB_MN. 2
TB_MN. 3
TBHIV
TBHIV. 1
TBHIV. 2
TBHIV. 3
TBHIV. 4
TB_HIV_N
TB_HIV_N.
TB_HIV_N.
TB_HIV_N.
TB_HIV_N.
TB_ART.1
TB_ART.1.
TB_ART.1.
TB_ART.1.
TB_ART.1.
TB_ART.1.
TB_ART.1.
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
LEP_NOT_1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1.
LEP_NOT_.1.
LEP_NOT_.1.
LEP_NOT_.1.
LEP_NOT_.1
LEP_NOT_.1
LCS
LEP_CSCR.
LEP_CSCR.
LEP_CSCR.
LEP_DIS.1
LEP_DIS.1.
LEP_DIS.1.
LEP_DIS.1.
LEP_DIS.1.
LEP_TX.r
LEP_TX.r.
LEP_TX.2.
LEP_TX.3.
LEP_TX.4.
LEP_TX.5.
TB_LB
TB_LB. 1
TB_LB. 2
TB_LB_AFB
TB_LB_AFB.
TB_LB_AFB.
08.2 - Malaria, NTD, NCD | Hospital, Health center, Clinic | Monthly (Tikemet 2015)
S.No
MAL
MAL. 1
MAL. 2
MAL. 3
MAL. 4
MAL. 5
MAL. 6
MAL_POS.1
MAL_POS.1.
MAL_POS.1.
MAL_POS.1.
MAL_POS.1.
MAL_POS.1.
MAL_POS.1.
Mal_Travel.
Mal_Noti.
MAL_FULL.1
MAL_FULL.2
MAL_FOCI.1
NTD.
NTD_VL.1
NTD_VL.1.
NTD_VL.1.
NTD_VL.1.
NTD_VL.1.
NTD_VL.1.
NTD_VL.1.
NTD_VL.2
NTD_VL.2.
NTD_VL.2.
NTD_VL.2.
NTD_VL.3
NTD_VL.3.
NTD_VL.3.
NTD_VL.3.
NTD_VL.3.
NTD_VL.3.
NTD_VL.4
NTD_VL.4.
NTD_VL.4.
NTD_CL.1
NTD_CL.1.
NTD_CL.1.
NTD_CL.1.
NTD_CL.1.
NTD_CL.1.
NTD_CL.1.
NTD_CL.2
NTD_CL.2.
NTD_CL.2.
NTD_CL.3
NTD_CL.3.
NTD_CL.3.
NTD_CL.3.
NTD_CL.3.
NTD_CL.3.
NTD_TT.1
NTD_TT.1.
NTD_TT.1.
NTD_TT.1.
NTD_TT.1.
NTD_HYD
NTD_HYD.
NTD_HYD.
NTD_POD
NTD_POD.
NTD_POD.
NTD_POD.
NTD_POD.
NCT_HTN
NCT_HTN
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCD_HTNDX
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX
NCD_HTNDX
NCD_HTNDX
NCD_HTNDX
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNTX
NCD_HTNT
NCD_HTNTX
NCD_HTNTX
NCD_HTNTX
NCD_HTNTX
NCD_HTNTX
NCD_HTNTX
CVD
CVD
CVD. 1
CVD. 2
NCD_CVD.2
NCD_CVD.2.
NCD_CVD.2.
NCD_CVD.2.
NCD_CVD.2.
NCD_CVD.3
NCD_CVD.3.
NCD_CVD.3.
NCD_CVD.4
NCD_CVD.4.
NCD_CVD.4.
NCD_CVD.4.
NCD_CVD.4.
DM
NCD_DMDX.
NCD_DMDX.1
NCD_DMDX.1
NCD_DMDX.1
NCD_DMDX.1
NCD_DMDX.
NCD_DMDX.1
NCD_DMDX.1
NCD_DMDX
NCD_DMDX.
NCD_DMDX.
NCD_DMDX.
NCD_DMDX.
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.
NCD_DMDX.2
NCD_DMDX.2
NCD_DMTX
NCD_DMTX.
NCD_DMTX
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_CV_SC
NCD_CV_SC
NCD_CV_SC
NCD_CV_SC
NCD_CV_SCR
NCD_CV_SCR
09.2 - Medical services | Health center | Monthly (Tikemet 2015)
S.No
MS
MS. 1
MS. 2
MS. 3
MS. 4
MS. 5
MS. 6
MS. 7
MS. 8
MS. 9
MS. 10
MS. 11
MS. 12
MS. 13
MS. 14
MS_OPD_Nu
MS_BOR
MS_IPD_BO
MS_IPD_BO
MS_ALOS
MS_ALS.1.
MS_ALS.2.
MS_LaBT
MS_LaBT.1.
MS_RoR
MS_RoR.1
MS_RoR.1.
MS_RoR.1.
MS_AMBU
MS_NumRI
MS_NumRI.
MS_NumRI.
MS_AMBU.
MS_AMBU.1
MS_AMBU.1
MS_AMBUR
MS_AMBUR
MS_AMBUR1
MS_AMBUR1
MS_AMBURe
MS_AMBUR
MS_AMBUR2
MS_AMBUR2
MS_AMBUR2
MS_AMBUR2
MS_AMBUR2
MS_EMERG
MS_EMERG
MS_EMERG
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG
MS_NumEM
MS_EMERG
MS_EMERG_
MS_IPD_AR.
HSQI_IPD_
MS_IPIMR.1
MS_IPIMR.1
MS_IPIMR.1
MS_UBDR.1
MS_UBDT.1
MS_UBDT.1.
MS_UBDT.1.
MS_SATIR.1
MS_RTI.1
MS_RTI.1. 1
MS_RTI.1. 2
MS_RTI.1. 3
MS_RTI.1. 4
PMS
PMS.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_ABIOT
PMS_ABIOTI
PMS_ABIOTI
PMS_FILL10
PMS_FILL10
PMS_FSML
PMS_MPFM
PMS_MP_N
EIDM_LQA
EIDM_LQA
EBDM.
DQ_DA.1.1.
DQ_DA.1.2.
DQ_DA2.
DQ_DA.2.1.
DQ_DA.2.2.
DQ_DA3.
DQ_DA.3.1.
DQ_DA.3.1.
01.2 - Reproductive and Maternal Health | Hospital, Health center, Clinic | Monthly (Tikemet 2015)
Activity

10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
30 - 49 years
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
30 - 49 years
Oral contraceptives
Injectables
Implants
IUCD
Vasectomy
Tubal ligation
Others
Oral contraceptives
Injectables
Implants
IUCD
Vasectomy
Tubal ligation
Others

10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
30 - 49 years

Implants
IUCD
Others

<= 12 weeks
> 12 and <=16 weeks
> 16 weeks
10 - 14 years
15 - 19 years
>= 20 years

10 - 14 years
15 - 19 years
>= 20 years
<= 30 weeks
> 30 weeks

Reactive
Non-Reactive
Reactive
Non-Reactive

Home delivery
Facility delivery
oxytocin
mesoprostol
ergometrin
Other uterotonics
Still birth rate


24Hrs (1day)
25 - 48 hrs (1 - 2 days)
49 - 72 hrs (2 - 3 days)
73 hrs - 7 days (4 - 7 days)
Caesarean section
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
>= 30 years
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
>= 30 years
Oral contraceptives
Injectables
Implants
IUCD
Vasectomy
Tubal ligation
Others
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
>= 30 years
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
>= 30 years
10 - 14 years
15 - 19 years
02 - PMTCT | Hospital, Health center, Clinic | Monthly (Tikemet 2015)
Activity
PMTCT
Number of women tested and know their HIV result during the postpartum period
Number of women with known HIV positive status attending ANC, delivery and postpartum for new pregnancy
Number of new HIV positive women during ANC, L&D and Postpartum
03 - EPI | Hospital, Health center, Health post, Clinic | Monthly (Tikemet 2015)
Activity
TD Vaccination
BCG doses opened
BCG doses damaged
BCG doses expired
Rota doses opened
Rota doses damaged
Rota doses expired
Polio doses opened
Polio doses damaged
Polio doses expired
TD doses opened
TD doses damaged
TD doses expired
IPV doses given
IPV doses opened
04.2 - Neonatal and Child Health | Health center, Hospital and clinic | Monthly (Tikemet 2015)
Activity
Child Health
Treated by ORS only
05.2 - Nutrition | Hospital, Health center | Monthly (Tikemet 2015)
Activity
Nutrition
0 - 5 months
6 - 23 months
0 - 5 months
6 - 23 months
0 - 5 months
6 - 23 months
6 - 11 months
12 - 59 months
First dose
Second dose
First dose
Second dose
10 - 14 years
15 - 19 years
>= 20 years
MUAC < 23 cm
MUAC >= 23 cm
Pregnant
lactating
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
Admission and treatment outcome for management of severe acute malnutrition in children under 6-59 Months f
10 - 14 years, Male
15 - 19 years, Male
06 - HIV | Hospital, Health center, Clinic | Monthly (Tikemet 2015)
Activity
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
New positive
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Known positive
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Directly assisted
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Unassisted
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Pregnant
Non pregnant
4j= ABC +3TC + DTG
4k= AZT + 3TC + DTG

4h=other first line
5n= AZT + 3TC + DTG
5j=other secondline
4d = AZT+3TC+EFV
4j= ABC +3TC + DTG
4k= AZT + 3TC + DTG
4L= ABC + 3TC + EFV
4h=other first line
5h=ABC + 3TC + EFV
5n= AZT + 3TC + DTG
5j=other secondline
4d = AZT+3TC+EFV
4e= TDF+3TC+EFV
4i= TDF + 3TC + DTG
4j= ABC +3TC + DTG
4k= AZT + 3TC + DTG
4L= ABC + 3TC + EFV
4h=other first line
5g= TDF + 3TC + EFV
5h=ABC + 3TC + EFV
5i=TDF + 3TC+ LPV/r
5n= AZT + 3TC + DTG
5o= TDF + 3TC + DTG
5j=other secondline
4d = AZT+3TC+EFV
4e= TDF+3TC+EFV
4i= TDF + 3TC + DTG
4j= ABC +3TC + DTG
4k= AZT + 3TC + DTG
4L= ABC + 3TC + EFV
4h=other first line
5g= TDF + 3TC + EFV
5h=ABC + 3TC + EFV
5i=TDF + 3TC+ LPV/r
5n= AZT + 3TC + DTG
5o= TDF + 3TC + DTG
5j=other secondline
1d = AZT-3TC-EFV
1e = TDF-3TC-EFV
1g= ABC + 3TC + EFV
1j=TDF + 3TC + DTG
1k= AZT +3TC +DTG
1i = Other specify
2e= AZT+3TC+LPV/r
2f=AZT+3TC+ATV/r
2g= TDF-3TC-LPV/r
2h =TDF-3TC-ATV/r
2l=other secondline
3d=Other thirdline

< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
ART retention rate (Percentage of adult and children on ART treatment after 12 month of initation of ARV therapy
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
Known on ART
Died
Others
Viral load Suppression (Percentage of ART clients with a suppressed viral load among those with a viral load test
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female

< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Transferred out
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Died
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
By age and Sex
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
By Client Category
Discordant Couple
By age and Sex
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
By Client Category
Discordant Couple
Occupational
Sexual violence
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Total MAM
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Total SAM
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
>= 15 years, Male
< 15 years, Male
>= 15 years, Male
Male
Female
Male
Female
Urethral discharge
Scrotal swelling
Vaginal discharge
Inguinal bubo
Neonatal herpes
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
30 - 49 years
Oral contraceptives
Injectables
Implants
IUCD
Others
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Patients on 6H
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Patients on 3HP
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Patients on 3HR
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Screened by VIA
Screened by HPV DNA
Normal cervix:
15 - 19 years
20 - 24 years
07 - TB/Leprosy | Hospital, Health center, clinic | Monthly (Tikemet 2015)
Activity
Number of bacteriologically confirmed New Pulmonary TB cases detected and enrolled in the reporting period by
0 - 4 years, Male
0 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 34 years, Male
35 - 44 years, Male
45 - 54 years, Male
55 - 64 years, Male
>=65 yr, Male
>=65 yr, Female
Number of clinically diagnosed New pulmonary TB cases detected and enrolled in the reporting period by age and sex
0 - 4 years, Male
0 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 34 years, Male
35 - 44 years, Male
45 - 54 years, Male
55 - 64 years, Male
>=65 yr, Male
>=65 yr, Female
Number of clinically diagnosed and bacteriological confirmed new EPTB cases detected and enrolled in the reporting period by ag
0 - 4 years, Male
0 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 34 years, Male
35 - 44 years, Male
45 - 54 years, Male
55 - 64 years, Male
>=65 yr, Male
>=65 yr, Female
0 - 4 years, Male
0 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 34 years, Male
35 - 44 years, Male
45 - 54 years, Male
55 - 64 years, Male
>=65 yr, Male
>=65 yr, Female
Failed, Male
Failed, Female
Diabetes
Homeless
Refugee
Prisoners
Miners
TB Contacts
Total number of bacteriologically confirmed new Pulmonary TB cases enrolled in cohort (PTB+) in the same month of the previous EFY
Completed
Cured
Lost to follow-up
Dead
Failed
Not evaluated
Completed
Lost to follow-up
Deaths
Failed
Not evaluated
Completed
Lost to follow-up
Deaths
Failed
Not evaluated
Completed
Cured
Lost to follow-up
Dead
Failed
Not evaluated
Number of cohort TB patients (all forms) who were successfully treated (cured plus completed treatment) who received support for treatment
Total number of patients who started TB treatment in same reporting month of pervious year and who received any form of treatment adhere
Total number of contacts with index bacteriologically confirmed drug susceptible TB cases during the reporting
0 - 4 years
5 - 14 years
>= 15 years
0 - 4 years
5 - 14 years
>= 15 years
0 - 4 years
5 - 14 years
>= 15 years
0 - 4 years
5 - 14 years
>= 15 years
Number of contacts with index bacteriologically confirmed TB (drug susceptible) cases screened negative for TB
0 - 4 years
5 - 14 years
>= 15 years
Number of contacts screened negative for TB and others eligible and put on TB Preventive Therapy (TPT) in the
0 - 4 years
5 - 14 years
>= 15 years
By Regimen Type
3HP
3RH
6H
0 - 4 years
5 - 14 years
>= 15 years
By Regimen Type
3HP
3RH
6H
TPT completion rate
Number of cohort of individuals that completed TPT treatment among those who started 12 months prior to the reporting period by
0 - 4 years
5 - 14 years
>= 15 years
By Regimen Type
3HP
3RH
6H
0 - 4 years, Male
0 - 4 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
Number of notified bacteriologically confirmed TB cases evaluated for drug susceptibility testing according to na
New
New
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Positive
Negative
Unknown
New
Unknown
Shorter regimen
Longer regimen
Positive
Negative
Unknown
New
Unknown
Short term regimen
Long term
Cured
Completed
Died
Failed
Lost to follow-up
Not evaluated
Cured
Completed
Died
Failed
Lost to follow-up
Not evaluated
Cured
Completed
Died
Failed
Lost to follow-up
Not evaluated
Normal
MAM
SAM
Normal
MAM
SAM
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Total number of new and relapse TB patients registered during the reporting period having a documented HIV nega
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
0 - 4 years, Male
0 - 4 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
0 - 4 years, Male
0 - 4 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
08.2 - Malaria, NTD, NCD | Hospital, Health center, Clinic | Monthly (Tikemet 2015)
Activity
< 5 years, Male
< 5 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
< 5 years, Male
< 5 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
< 5 years, Male
< 5 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
Cured
Defaulted
Failed
Dead
Referred
Positive
Negative
< 5 years, Male
< 5 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
Cured
Defaulted
Failed
Dead
Referred
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
>= 15 years, Male
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Hypertension
18 - 29 years, Male
30 - 39 years, Male
40 - 69 years, Male
>=70 years, Male
>=70 years, Female
Raised BP
Normal BP
18 - 29 years, Male
30 - 39 years, Male
40 - 69 years, Male
>=70 years, Male
>=70 years, Female
Previously in care
Controlled
Uncontrolled
Lost to follow-up
Died
Transferred out
Not evaluated
40 - 59 Years, Male
60 - 74 Years, Male
With Statin
Without Statin
40 - 59 Years, Male
60 - 74 Years, Male
Diabetes mellitus
< 40 years, Male
< 40 years, Female
>= 40 years, Male
>= 40 years, Female
Raised blood sugar
Normal blood sugar
Type I
Type II
Gestational DM
< 15 years, Male
< 15 years, Female
15 - 29 years, Male
30 - 39 years, Male
>= 40 years, Male
>= 40 years, Female
Previously in care
Treatment outcome for cohort of patient registered for diabetes treatment six months prior to the reporting period
Controlled
Uncontrolled
Lost to follow-up
Died
Transferred out
Not evaluated
< 15 years, Male
< 15 years, Female
15 - 29 years, Male
30 - 39 years, Male
>= 40 years, Male
>= 40 years, Female
Screened by VIA
Screened by HPV DNA
Negative
09.2 - Medical services | Health center | Monthly (Tikemet 2015)
Activity
< 5 years, Male
< 5 years, Female
5 - 10 years, Male
11 - 19 years, Male
20 - 29 years, Male
30 - 45 years, Male
46 - 65 years, Male
>= 66 years, Male
>= 66 years, Female
Bed occupancy rate
Referral-out rate
Emergency referral
Emergency referral
Pre-facility
Between facility
Trauma
Burn & Poisoning
Others
< 24 hours
>= 24 hours
from blood bank
Vehicle occupant
Motor cyclist
Pedestrian
Others
Pentavalent vaccine
Oxytocine inj
Iron + folic acid
TTC eye ointment
RHZE/RH
TDF/3TC/DTG
Amlodipine tablet
Frusamide tablets
Metformin tablet
Normal Saline 0.9%
40% glucose
Omeprazole capsule
MS_Number of clients who received 100% of prescribed drugs
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
365 359 241 183 368 485 2001

169 161 131 49 79 140 729
20 13 22 7 12 74
33 23 40 15 20 36 167
51 100 45 7 37 62 302
65 38 33 5 15 30 186
196 198 110 134 289 345 1272
11 5 8 10 11 45
50 21 32 27 33 81 244
77 101 45 40 130 114 507
58 76 28 59 116 139 476
365 359 241 183 368 485 2001
174 161 131 49 79 140 734
30 12 29 10 27 108
58 93 85 19 41 87 383
86 43 17 29 28 26 229
13 1 14
191 198 110 134 289 345 1267

50 25 2 1 20 13 111
109 173 104 27 201 255 869
32 4 80 67 64 247
26 1 13 40
22 17 10 2 30 81
3 6 9
7 6 6 1 9 29
5 9 4 1 13 32
7 2 2 11
2 2
1 1
1 1
4 6 7 2 17 36
73 96 107 128 92 113 609

53 74 70 53 68 56 374
10 8 5 23
20 22 27 67 19 57 212
73 96 107 128 92 113 609
6 12 54 14 19 105
67 96 95 74 78 94 504
56 72 60 41 71 40 340
16 7 21 5 49
40 72 53 20 66 40 291
56 72 60 41 71 40 340
16 39 16 4 75
40 33 60 25 67 40 265
41 96 107 128 92 113 577
41 96 107 128 92 113 577
41 96 107 128 92 113 577
41 96 107 128 92 113 577
61 76 63 98 83 80 461
61 76 63 98 83 80 461
61 76 63 98 83 80 461
20.4 12.5 32.9

2 1 3
61 76 63 96 83 79 458
61 76 63 96 83 79 458
61 76 63 98 83 80 461
61 76 63 98 83 80 461
1 1
4 15 5 5 22 27 78
2 13 5 3 7 15 45
1 1
1 1 4 12 18
1 4 4 1 2 1 13
8 1 1 1 11
1 1 2
2 2 2 15 12 33
1 2 2 5
1 1 10 4 16
1 3 4 8
2 2 4
4 15 5 5 17 27 73
4 15 5 5 17 27 73
4 15 5 10 26 60
1 1
2 15 17
3 6 2 10 11 32
7 3 10
6 12 1 19
1 1
6 11 1 18
56 96 56 71 61 23 363

0 1 0 0 0 1 2
73 96 95 128 92 113 597

73 96 95 128 92 113 597
1 1
61 90 104 139 78 107 579

71 89 86 128 108 105 587
70 89 86 127 102 104 578
49 89 86 128 105 105 562
59 87 86 127 102 104 565
60 87 86 128 105 105 571
56 87 86 127 102 104 562
55 89 86 127 108 104 569
57 87 88 128 99 105 564
62 89 88 127 94 104 564
59 87 86 127 85 104 548
43 86 86 127 85 104 531
67 87 72 127 78 104 535
63 68 84 127 99 104 545

th interval from the first dose
79 101 90 97 93 134 594

67 50 23 84 74 150 448
9 10 32 72 3 27 153
2 2 11 2 16 33
3 7 15 25
56.4 10 1.3 10.3 56.7 28.7 163.4

61 90 158 139 78 107 633
140 100 160 155 180 150 885
0.54 0 0 0 -5.3 0 -4.76

184 267 144 382 298 313 1588
185 267 144 382 283 313 1574
1.6 0.74 0 3 2 5.6 12.94

185 267 120 382 298 219 1471
188 269 120 394 304 232 1507
0 0 0 0 -5.4 0 -5.4
121 178 188 255 196 209 1147
121 178 188 255 186 209 1137
6.5 11 10.6 6.8 14.9 5.2 55

159 267 118 382 298 313 1537
170 300 132 410 350 330 1692
12.2 8.4 1.8 6.7 23 9.6 61.7

137 174 162 224 154 208 1059
156 190 165 240 200 230 1181
10 2.3 0 2.7 4.4 3.7 23.1

144 259 170 253 172 342 1340
160 265 170 260 180 355 1390
20 22.6 4.4 5.9 15 13.3 81.2

68 89 86 127 102 104 576
85 115 90 135 120 120 665
200 132 164 305 217 140 1158

53 37 124 214
20 5 10 35
33 32 114 179
150 184 194 175 155 159 1017
150 184 194 175 155 159 1017
46 104 18 168
2 4 1 7
2 4 1 7
2 4 1 7
0 0 0 0 0 0 0
61 76 63 96 166 79 541
1748 2047 1878 2937 1755 1935 12300

51 1010 256 448 266 251 2282
1697 1037 1622 2489 1489 1684 10018
27 18 22 4 6 5 82
1 2 3
26 16 22 4 6 5 79
1 7 5 5 5 23
1 1
1 6 5 5 5 22
405 717 430 748 474 1617 4391

119 264 66 279 120 303 1151
286 453 364 469 354 1314 3240
405 717 430 748 474 1617 4391
129 717 430 748 474 1617 4115
276 276
348 392 265 272 576 1255 3108

105 392 265 272 576 1255 2865
243 243
106 74 78 258
73 150 62 128 92 169 674

2 2
2 54 14 29 99
73 148 60 74 78 140 573
584 189 218 611 92 574 2268

54 19 73
530 189 218 592 92 574 2195
690 189 249 611 92 574 2405
155 189 108 228 92 493 1265
535 141 383 81 1140
3258 5714 2504 7468 3610 4149 26703

710 66 776
1174 1987 945 2723 1425 1256 9510
2084 3017 1493 4745 2185 2893 16417
145 436 11 8 600
57 210 6 2 275
88 226 5 6 325
19 3 6 7 35
8 1 5 5 19
11 2 1 2 16
7 3 47 57
2 39 41
5 3 8 16
9 9
4 4
5 5
2 2
2 2
3 5 47 17 72
10 5 15
13 10 2 25
10 5 3 7 25
13 10 2 25
59 96 155
59 96 155
13 13
7 46 53
21 21
18 50 68

262 204 310 237 286 352 1651
1 1
2 2
1 1
2 2
10 2 12
2 5 8 1 6 22
29 5 10 59 49 33 185
5 1 12 2 4 24
58 50 32 82 92 98 412
3 25 1 4 33
88 96 36 42 107 73 442
1 2 15 5 23
38 31 69 42 30 64 274
3 2 10 14 29
33 56 4 7 12 112
3 5 13 21
1 11 4 4 20
2 1 6 9
2 7 4 13
2 3 1 4 10
1 1 2 4
1 1
1 1
2 2
31 31
204 310 236 286 319 1355

1 1
0 0 0 0 0 1 1
2 2
1 1
1 1
10 10
6 6
4 4
4 4
2 2
2 2
3 3
1 1
2 2
19 19
7 7
12 12
46 46
16 16
30 30
2 2
2 2
47 47
12 12
35 35
2 2
2 2
36 36
12 12
24 24
12 12
5 5
7 7
15 15
4 4
11 11
9 9
8 8
1 1
2 2
2 2
10 10
9 9
1 1
4 4
4 4
175 175
72 72
8 8
95 95
4 4
2 2
2 2
erred out (net current cohort) 195 195
1 1
1 1
2 2
8 8
2 2
2 2
1 1
2 2
7 7
12 12
16 16
1 1
29 29
14 14
35 35
12 12
24 24
5 5
10 10
7 7
4 4
25 25
4 4
4 4
7 7
5 5
3 3
2 2
the reporting period 25 25
4 4
4 4
7 7
5 5
3 3
2 2
reporting period
82 82
1 1
3 3
2 2
6 6
1 1
2 2
1 1
3 3
21 21
29 29
5 5
8 8
113 113
7 7
9 9
29 29
56 56
4 4
8 8
supplementary food
21 21
21 21
gregated by Age, Sex and Pregnancy)
y age, sex and pregnancy status)
1 1
1 1
1 1
1 1
of modern family planning by age 58 58
5 5
11 11
42 42
of modern family planning by method 58 58
56 56
2 2
eporting period
ull course of therapy
5 5
5 5
5 5
5 5
12.2 24.3 24.3 36.5 97.3

1 2 2 5
1 1
1 1
1 1
1 1
1 1
iod by age and sex
ed in the reporting period by age and sex 2 1 3
1 1
1 1
1 1
e month of the previous EFY 1 1
2 1 3
2 1 3
onth of the previous EFY 1 1

1 1 2
1 1 2
2 2
ho received support for treatment adherence by HEWs during in the same month of previous EFY
ved any form of treatment adherence support from Health extension workers
gnosis or initiation of TB treatment. in the reporting month
4 3 7
1 3 4
3 3
4 3 7
1 3 4
3 3
3 3
3 3
4 3 7
1 3 4
3 3
1 3 4
1 3 4
1 3 4
1 3 4
1 1
1 1
prior to the reporting period by Age Group

1 1
1 1
a WHO recommended rapid tests (GeneXpert and others) at the time of TB diagnosis by age and sex
1 1
1 1
1 2 3
1 2 3
0 0 0 0 0 0
evious year (12 month earlier)

me month of the previous year (12 month earlier)
4 months earlier.
months earlier.
-line anti-TB treatment regimen 36 months earlier.
mented HIV positive test result
1 2 2 3 8
2 1 3
1 1 3 5
1 1
1 1
1 2 3
1 1 2
1 1
1 2 2 5
1 1 2
1 1 1 3

58 42 160 856 356 438 1910
4 9 162 14 60 249
2 1 9 148 34 67 261
15 1 25 127 46 32 246
13 2 26 162 49 27 279
16 23 43 134 146 139 501
8 15 48 123 67 113 374
8 1 18 133 79 45 284
6 5 2 13
1 1 9 4 4 19
3 4 28 13 7 55
1 18 7 5 31
5 8 49 42 13 117
4 23 8 14 49
83 15 98
6 1 6 8 8 29
1 1 2 0 0 0 4
5 3 18 26
1 1 8 10
4 2 10 16
17 360 107 164 1789 2437

25 203 228
21 225 246
6 30 12 309 357
4 32 23 26 357 442
4 82 12 75 160 333
3 87 22 40 179 331
40 25 6 106 177
43 25 5 250 323
17 360 107 164 1789 2437
4 3 2 3 4 16
13 357 105 161 1785 2421
4 3 2 3 4 16
2 4 6
4 3 3 10
4 3 2 3 4 16
1 1
1 1
3 1 4 8
2 2 1 5
1 1
4 3 2 3 4 16
4 3 2 3 4 16
2 33 4 39
2 3 33 4 42
2 33 4 39
2 2
1 1
12 12 53 77
5 5
6 5 3 14
4 3 20 27
2 4 25 31
12 12 53 77
2 2 4
10 10 53 73
2 2 4
2 2 4
2 2 4
2 2
2 2
2 2 4
2 2 4
2 2 4
2 2 4
4 4
porting period 4 4
4 4
porting period by age and sex

90 25 115
90 25 115
90 25 115
89 25 114
1 1

2584 3549 4720 9779 6300 5800 32732
352 608 484 1125 1722 428 4719
306 562 489 1332 1960 581 5230
89 425 147 387 148 209 1405
92 157 111 708 156 413 1637
38 215 108 617 187 320 1485
47 293 311 490 199 155 1495
341 230 321 512 320 369 2093
390 204 268 1214 431 347 2854
258 191 801 863 353 316 2782

176 100 310 641 267 345 1839
125 110 287 641 242 920 2325
53 19 269 150 15 170 676

1089 2009 2130 5987 2591 3221 17027
24 30 53 20 23 150
3 3 3 3 3 15
24 20 3 20 23 90
24 20 53 10 23 130
0 85 0 89 100 95 369
17 23 13 53 6 50 162
2 17 4 37 10 70
15 6 9 16 6 40 92
17 23 13 53 6 50 162
2 17 4 37 10 70
15 6 9 16 6 40 92
17 23 13 53 6 50 162
13 53 50 116
17 23 6 46
17 23 13 53 6 50 162
15 17 13 37 6 40 128
2 6 16 10 34
20 25 13 56 10 52 176
17 23 13 53 6 50 162
15 17 9 37 6 40 124
1 1
2 6 4 1 10 23
14 14
53 10 58 121
53 10 58 121
53 10 58 121
16 76 5 97
1 6 1 8
15 1 4 20
69 69
1 0 1 1 1 1 5
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
0 1 1 1 1 1 5
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 0 1 1 1 1 5
0 1 1 1 1 1 5
1 1 1 1 1 1 6
1 1 1 1 1 0 5
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
1 1 1 1 1 1 6
100 100 100 100 400
1856 6331 2797 3346 14330
1856 6331 2797 3346 14330
100 6331 2797 3346 12574
1856 6331 2797 3346 14330
100 100 100 100 400
1856 6331 11188 3346 22721
1856 6331 11188 3346 22721
6 6 6 6 11 7 42
95 92.5 87.5 95 77.7 92.9 540.6
95 93.3 89.2 95 90.5 93.6 556.6
6 6 6 6 11 7 42
95 93.3 86.7 95 79.1 93.6 542.7
95 93.3 90.8 95 90.5 94.3 558.9
1 1 1 1 1 1 6
95 95 95 95 90 95 565
95 95 95 95 95 90 565
01.2 - Reproductive and Maternal Health | Hospital, Health center, Clinic | Monthly (Hidar 2015)
S.No Activity Natri PHCU
Gebjiro PHCU

MAT_CAR Total number of new and repeat acceptors by age 279 325
MAT_CAR_A
Contraceptive new acceptors by age 97 150
MAT_CAR_Ag
10 - 14 years
MAT_CAR_Ag
15 - 19 years
MAT_CAR_Ag
20 - 24 years 21 25
MAT_CAR_Ag
25 - 29 years 39 78
MAT_CAR_Ag
30 - 49 years 37 47
MAT_CAR_A
Contraceptive repeat acceptors by age 182 175
MAT_CAR_Ag
10 - 14 years
MAT_CAR_Ag
15 - 19 years
MAT_CAR_Ag
20 - 24 years 25 3
MAT_CAR_Ag
25 - 29 years 83 86
MAT_CAR_Ag
30 - 49 years 74 86
MAT_CAR_Total new and repeat acceptors, disaggregated by method 276 253
MAT_CAR_M
Contraceptive new acceptors by method 94 78
MAT_CAR_Mt
Oral contraceptives 25 28
MAT_CAR_Mt
Injectables 69 50
MAT_CAR_Mt
Implants
MAT_CAR_Mt
IUCD
MAT_CAR_Mt
Vasectomy
MAT_CAR_Mt
Tubal ligation
MAT_CAR_Mt
Others
MAT_CAR_M
Contraceptive repeat acceptors by method 182 175
MAT_CAR_Mt
Oral contraceptives 43 7
MAT_CAR_Mt
Injectables 139 168
MAT_CAR_Mt
Implants
MAT_CAR_Mt
IUCD
MAT_CAR_Mt
Vasectomy
MAT_CAR_Mt
Tubal ligation
MAT_CAR_Mt
Others

MAT_IPPCATotal PPFP 聽acceptors,聽disaggregated by age 30
MAT_IPPCA20 - 24 years 10

MAT_LAFPP
MAT_LAFPPR
Implants
MAT_LAFPPR
IUCD
MAT_LAFPPR
Others
MAT_TLAFPTotal LAFP removal in the reporting period 10

MAT_ANC1_ 64 87
MAT_ANC1_
<= 12 weeks 44 75
MAT_ANC1_
> 12 and <=16 weeks 3
MAT_ANC1_
> 16 weeks 17 12
MAT_ANC1_ 64 87
MAT_ANC1_
10 - 14 years
MAT_ANC1_
15 - 19 years 3
MAT_ANC1_
>= 20 years 61 87
MAT_ANC4Antenatal care (ANC) coverage 鈥

MAT_ANC4+
Total number of pregnant women that received four or more antenatal car 50 72
MAT_ANC4+
10 - 14 years
MAT_ANC4+
15 - 19 years 2
MAT_ANC4+
>= 20 years 48 72
MAT_ANC4+
Total number of pregnant women that received four or more antenatal car 50 72
MAT_ANC4+
<= 30 weeks 25 38
MAT_ANC4+
> 30 weeks 25 34

MAT_ANC8+
MAT_SYPH.Total Number of pregnant women tested for syphilis 60 87
MAT_SYPH.1
Reactive
MAT_SYPH.1
Non-Reactive 60 87
MAT_SYPH.Total Number of pregnant women treated for syphilis
MAT_Hepa Total Number of Pregnant women attending antenatal care tested for hepat 60 87
MAT_Hepa. Reactive
MAT_Hepa. Non-Reactive 60 87
MAT_Prp.1.Total Number of pregnant women who were received prophylaxis for HBV
RMH_L&D_Births attended by skilled health personnel

L&D_SBA.1.Total number of births attended by skilled health personnel 63 79
MAT_PPH.1Total number of women who developed postpartum hemorrhage (PPH) 79
MAT_PPH.1.Facility delivery 79
MAT_UTERPercentage women who received uterotonics in the first one minute after
MAT_UTER.Total number of women who received uterotonics in the first one minute af 63 79
MAT_UTER.1
oxytocin 63 79
MAT_UTER.1
mesoprostol
MAT_UTER.1
ergometrin
MAT_UTER.1
Other uterotonics
MAT_SBR.LNumber of Live births 63 79
B&D_Ntfc
MAT_B&D_INumber of Institutional birth notifications given 63 79
MAT_B&D_INumber of Institutional death notifications given

MAT_EPNC.Number of postnatal visits within 7 days of delivery 63
MAT_EPNC.1
24Hrs (1day) 63
MAT_EPNC.1
25 - 48 hrs (1 - 2 days)
MAT_EPNC.1
49 - 72 hrs (2 - 3 days)
MAT_EPNC.1
73 hrs - 7 days (4 - 7 days)
RMH_L&D_Caesarean section
MAT_CAC Number of women receiving comprehensive abortion care services dis ag 20 16
MAT_CAC_Number of safe abortions performed 11 14
MAT_CAC_S
10 - 14 years
MAT_CAC_S
15 - 19 years 3
MAT_CAC_S
20 - 24 years 1 6
MAT_CAC_S
25 - 29 years 3 4
MAT_CAC_S
>= 30 years 4 4
MAT_CAC_Number of post abortion/emergency care 9 2
MAT_CAC_P
10 - 14 years
MAT_CAC_P
15 - 19 years 3
MAT_CAC_P
20 - 24 years 4
MAT_CAC_P
25 - 29 years 1
MAT_CAC_P
>= 30 years 1 2
MAT_CAC.TNumber of women receiving comprehensive abortion care disaggregated b 20 16
MAT_CAC.Tr
First trimester(<12 Weeks) 20 16
MAT_CAC.Tr
MAT_CAC.M
Number of women receiving post abortion care family planning methods 6
MAT_CAC.MA
Oral contraceptives 1
MAT_CAC.MA
Injectables 5
MAT_CAC.MA
Implants
MAT_CAC.MA
IUCD
MAT_CAC.MA
Vasectomy
MAT_CAC.MA
Tubal ligation
MAT_CAC.MA
Others
MAT_OFC_Id
10 - 14 years
MAT_OFC_Id
15 - 19 years
MAT_OFC_Id
20 - 24 years
MAT_OFC_Id
25 - 29 years
MAT_OFC_Id
>= 30 years
MAT_OFC_T
MAT_OFC_Tr
10 - 14 years
MAT_OFC_Tr
15 - 19 years
MAT_OFC_Tr
20 - 24 years
MAT_OFC_Tr
25 - 29 years
MAT_OFC_Tr
>= 30 years
MAT_TngP Total number of teenage girls tested positive for pregnancy
MAT_TngtstTotal number of women tested positive for pregnancy 41 87
02 - PMTCT | Hospital, Health center, Clinic | Monthly (Hidar 2015)
Gebjiro PHCU
RMCH__PMT
Does health facility provide Monthly PMTCT service? 0 4
MTCT PMTCT
MTCT_TST Pregnant and lactating women who were tested for HIV and know their res 63 108
MTCT_TST.Number of Pregnant women tested and know their HIV result during pregnancy 63 66
MTCT_TST.Number of pregnant women tested and know their HIV result during labour & delivery 42
03 - EPI | Hospital, Health center, Health post, Clinic | Monthly (Hidar 2015)
Gebjiro PHCU
EPI_HepBDNumber of Live births who receive a HepB-Birth dose(BD) 20
EPI_HepBD.Within 24 to 14 days after birth 20
EPI_BCG1. Number of children under one year of age who have received BCG vaccine 67 91
EPI_DPT1.1Number of children under one year of age who have received first dose of pent 73 81
EPI_DPT3.1Number of children under one year of age who have received third dose of pent 73 91
EPI_OPV1.1Number of children under one year of age who have received first dose of polio 73 83
EPI_OPV3.1Number of children under one year of age who have received third dose of Poli 71 91
EPI_PCV1.1Number of children under one year of age who have received first dose of pne 73 86
EPI_PCV3.1Number of children under one year of age who have received third dose of pn 71 71
EPI_IPV.1. Number of children under one year of age who have received one dose of inacti 76 91
EPI_Rota1.1Number of children under one year of age who have received first dose of Rota 73 91
EPI_Rota2.1Number of children under one year of age who have received 2nd dose of Rota 71 86
EPI_MCV1.1Number of children under one year of age who have received first dose of mea 73 71
EPI_FI.1. Number of children received all vaccine doses before 1st birthday 71 91
EPI_MCV2.1Number of children (15-23 ) months of age who have received second dose of 73 71
EPI_PAB Proportion of under one children protected against Neonatal Tetanus(PAB
EPI_PAB.1. Number of infants whose mothers had protective doses of TD against NNT (PA 76 71
EPI_HPV1 HPV 1 (Human Papilloma Virus vaccine (1st dose) Immunization coverage (
EPI_HPV2 HPV 2 (Human Papilloma Virus vaccine (2nd dose) Immunization coverage (
EPI_HPV2.1Number of girls 14 years of age who have received second dose of human papillomavirus vaccine in 6 month interval from the fi
EPI_TD1.1. women who have received TD1 vaccination 38 127
EPI_TD4.1. women who have received TD4 vaccination 5
EPI_VWR_He
HepB-Birth doses given (all ages) 20
EPI_VWR_He
EPI_VWR_He
EPI_VWR_He
BCG Vaccine wastage rate 10.7 7.9
EPI_VWR_BBCG doses given (all ages) 67 129
EPI_VWR_BBCG doses opened 75 140
EPI_VWR_BBCG doses expired
Penta Vaccine wastage rate 0 0
EPI_VWR_Pe
Pentavalent (DPT-HepB-Hib) doses given (all ages) 215 233
EPI_VWR_Pe
Pentavalent (DPT-HepB-Hib) doses opened 215 233
EPI_VWR_PPentavalent (DPT-HepB-Hib) doses damaged
EPI_VWR_Pe
PCV Vaccine wastage rate 4.9 7.2
EPI_VWR_PPneumococcal conjugated vaccine doses given 214 233
EPI_VWR_PPneumococcal conjugated vaccine doses opened 225 251
EPI_VWR_PC
Rota Vaccine wastage rate 0 0
EPI_VWR_RT
Rota doses give (all ages) 144 162
EPI_VWR_RRota doses opened 144 162
EPI_VWR_RT
Rota doses expired
Polio Vaccine wastage rate 1.8 4.9
EPI_VWR_PV
Polio doses given (all ages) 219 233
EPI_VWR_PPolio doses opened 223 245
EPI_VWR_PV
Polio doses expired
Measles Vaccine wastage rate 3.5 5.3
EPI_VWR_M
Measles doses given (all ages) 164 142
EPI_VWR_M
Measles doses opened 170 150
EPI_VWR_M
EPI_VWR_M
TD Vaccine wastage rate 2.9 1.5
EPI_VWR_TD
TD doses given (all ages) 68 64
EPI_VWR_TTD doses opened 70 65
EPI_VWR_TD
TD doses expired
IPV Vaccine wastage rate 2.5 11.3
EPI_VWR_IP
IPV doses given 77 71
EPI_VWR_IP
IPV doses opened 79 80
04.2 - Neonatal and Child Health | Health center, Hospital and clinic | Monthly (Hidar 2015)
Gebjiro PHCU
CH Child Health
CH_TX_PN Under-five children with pneumonia received antibiotic treatment
CH_TX_PNE
Number of under 5 children treated for pneumonia 92 84
CH_TX_SYI.Number of sick young infants 0-2 months treated for Critical illness 10 144
CH_TX_SYI.Treated for Very Severe Diseases
CH_TX_SYI.Treated for Local bacterial infection ( LBI) 25
CH_TX_SYI.Treated for Pneumonia 10 119
CH_TX_DIAChildren treated with Zinc and ORS for diarrhea 99 139
CH_TX_DIAR
Treated by ORS and zinc 99 139
CH_TX_DIAR
Treated by ORS only 5 71
CH_KMC.1.Total number of newborns weighing <2000gm and/or premature newborns for which KMC initiated
CH_KMC.2.Total number of newborns weighing <2000gm and/or premature
CH_ASPH.1Number of neonates resuscitated and survived
CH_ASPH.2Total number of neonates resuscitated
Does the facility provides NICU Service? 0
CH_TX_NICU
Recovered
CH_TX_NICU
Dead
CH_TX_NICU
Transferred
CH_TX_NICU
CH_CHX Newborns that received at least one dose of CHX to the cord on the first day after bir 79
CH_CHX.1. Number of Newborns that received at least one dose of CHX to the cord on the first day after 79
CH_CHDM Children aged 0 to 59 months Assessed for developmental milestone 287
CH_CHDM. 0 to 24 months 152
CH_CHDM. 24 to 59 months 135
CH_CHDMSChildren aged 0 to 59 months Assessed for developmental milestone and there statu 287
CH_CHDMS.
CH_CHDMS.
Developmental Delay
CH_CHDMS.
No Developmental Delay 287
05.2 - Nutrition | Hospital, Health center | Monthly (Hidar 2015)
Gebjiro PHCU
NUT Nutrition
NUT_LBW.2Total number of live births weighed 79
NUT_GMP Proportion of < 2 year children who have participated in growth monitor
NTR_GMP.1Number of children less than 2 yr weighted during GMP session 1265 1941
NTR_GMP.1.
0 - 5 months 166 725
NTR_GMP.1.
6 - 23 months 1099 1216
NUT_GMP.M
Number of weights recorded with moderate malnutrition, by age (Z-score 18 7
NUT_GMP.M
0 - 5 months 2
NUT_GMP.M
6 - 23 months 18 5
NUT_GMP_Number of weights recorded with severe malnutrition, by age (Z-score bel 13 4
NUT_GMP_S
0 - 5 months 1
NUT_GMP_S
6 - 23 months 13 3
NCH_NTR_Children aged 6-59 months who received vitamin A supplementation
NUT_VITA Total number of children aged 6-59 months who received Vitamin A suppl 122 483
NUT_VITA. 6 - 11 months 70 165
NUT_VITA. 12 - 59 months 52 318
NUT_VITA.2Total number of children aged 6-59 months who received Vitamin A suppl 122 483
NUT_VITA.2First dose 122 483
NUT_VITA.2Second dose
NUT_DeW.1Total number of children aged 24 - 59 months dewormed 161 336
NUT_DeW.1.
First dose 161 302
NUT_DeW.1.
Second dose 34
NUT_DeW.2Number of pregnant women De-wormed 138
NUT_IFA Proportion of pregnant women received iron and folic acid (IFA) supplemen
NUT_IFA.1 Total number of Pregnant women received IFA at least 90 plus 64 155
NUT_IFA.1. >= 20 years 64 155
NUT_PreSMProportion of Pregnant and lactating women (PLW) screened for malnutrit
NUT_PreSMTotal number of PLW screened for acute malnutrition by MUAC status 822 166
NUT_PreSMN
MUAC < 23 cm 3
NUT_PreSMN
MUAC >= 23 cm 819 166
NUT_PreSMTotal number of PLW screened for acute malnutrition By maternal status: 844 79
NUT_PreSMN
Pregnant 148 77
NUT_PreSMN
lactating 696 2
NUT_U5SMChildren aged <5 yrs screened for acute malnutrition
NUT_U5SMTotal Number of children < 5 yr screened for acute malnutrition 3561 5562
NUT_U5SMN
0 - 5 months 3 847
NUT_U5SMN
6 - 23 months 1489 1805
NUT_U5SMN
24 - 59 Months 2069 2910
NUT_U5SMN
Number of <5yr children screened and have moderate acute malnutrition 27
NUT_U5SMN
0 - 5 months
NUT_U5SMN
6 - 23 months 20
NUT_U5SMN
24 - 59 Months 7
NUT_U5SMN
Number of <5yr children screened and have severe acute malnutrition 18 3
NUT_U5SMN
0 - 5 months
NUT_U5SMN
6 - 23 months 10 1
NUT_U5SMN
24 - 59 Months 8 2
NUT_TX-U Admission and treatment outcome for management of severe acute malnutri
NUT_TX-U Total SAM at the beginning of the month 3
NUT_TX-U56 - 23 months 1
NUT_TX-U524 - 59 Months 2
NUT_TX-U5Total number of children with SAM admitted to SC during the reporting period(new a 18
NUT_TX-U5Number of children stablized 15
NUT_TX-U5Number of children cured 3
NUT_TX-U Number of children -non-respondent
NUT_TX-U5Number of children Medical transfer 15
NUT_TX-U5Number of children who exit from severe acute malnutrition treatment during the rep 287
NUT_TX-U5Admission and treatment outcome for management of severe acute malnutr
NUT_TX-U5Total SAM at the beginning of the month for OTP 7
NUT_TX-U5OTP_Number of children stabilized 7
NUT_TX-U5OTP_Number of children cured 4
NUT_TX-U5OTP_Number of children Medical transfer 8
NUT_TX-U5OTP_Number of children unknown status 3
NUT_TX-U5Total number of children with SAM admitted to OTP during the reporting period 15
NUT_TX-U5Number of children who exit from severe acute malnutrition treatment during the reporting 15
NUT_TX-U Admission and treatment outcome for management of MAM for childern 6
NUT_TX-U5MAM_Number of children stabilized 8
NUT_TX-U5MAM_Number of children cured 3
NUT_TX-U5MAM_Number of children -non-respondent
NUT_Adl&YTotal number of Adolescent girls Aged 14-19 years screened for malnutrition 204
NUT_Adl&Yo
10 - 14 years, Male
NUT_Adl&Yo
NUT_Adl&Yo
15 - 19 years, Male
NUT_Adl&Yo
NUT_Adl& Adolescent and Youth Aged 10-19 screened for nutrition-underweight
NUT_Adl&Y10 - 14 years, Male
NUT_Adl&Y10 - 14 years, Female
NUT_Adl&Y15 - 19 years, Male
NUT_Adl&Y15 - 19 years, Female
NUT_Adl& Adolescent and Youth Aged 10-19 screened for nutrition-overweight 204
NUT_Adl&Y10 - 14 years, Male 50
NUT_Adl&Y10 - 14 years, Female 90
NUT_Adl&Y15 - 19 years, Male 64
06 - HIV | Hospital, Health center, Clinic | Monthly (Hidar 2015)
Gebjiro PHCU
HIV_HTS_TClients receiving HIV test results (at VCT)
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TClients testing positive for HIV (at VCT)
HIV_HTS_T>= 50 years, Male
HIV_HTS_T>= 50 years, Female
HIV_HTS_TClients receiving HIV test results (at PITC) 262 82
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male 2
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
10 - 14 years, Female 2
HIV_HTS_TS
15 - 19 years, Male 27
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male 62 1
HIV_HTS_TS
20 - 24 years, Female 1 12
HIV_HTS_TS
25 - 29 years, Male 40 1
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male 69 1
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male 49 1
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male 3 2
HIV_HTS_TS
>= 50 years, Female 1
HIV_HTS_TClients testing positive for HIV (at PITC)
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_THIV testing service - HTS who received result by population group
HIV_HTS_THIV testing service - HTS who tested positive by population group
HIV_TST_PFemale comercial Sex workers : Received result
HIV_HTS_TFemale comercial Sex workers :Positive
HIV_HTS_TLong distance drivers: Received result
HIV_HTS_TLong distance drivers :Positive
HIV_HTS_TMobile/Daily Laborers: Received result
HIV_HTS_TMobile/Daily Laborers: Positive
HIV_HTS_TOVC of PLHIV :Received result
HIV_HTS_TOVC of PLHIV: Positive
HIV_HTS_TChildren of PLHIV: Received result
HIV_HTS_TChildren of PLHIV: Positive
HIV_HTS_TPrisoners :Received result
HIV_HTS_TPrisoners : Positive
HIV_HTS_TPartners of PLHIV: Received result
HIV_HTS_TPartners of PLHIV: Positive
HIV_HTS_TOther MARPs:Received result
HIV_HTS_TOther MARPs: Positive
HIV_HTS_TGeneral population: Received result 262
HIV_HTS_TGeneral population: Positive
HIV_HTS_TNumber of individuals who were identified and tested using Index testing s
HIV_HTS_TNumber of index cases offered
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TNumber of contacts elicited
HIV_HTS_TS
< 15 years, Male
HIV_HTS_TS
< 15 years, Female
HIV_HTS_TS
>= 15 years, Male
HIV_HTS_TS
>= 15 years, Female
HIV_HTS_TNumber of contacts tested
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TNumber of contacts by test result (Positive)
HIV_HTS_TNew positive
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TKnown positive
HIV_HTS_TS
< 1 year, Male
HIV_HTS_TS
< 1 year, Female
HIV_HTS_TS
1 - 4 years, Male
HIV_HTS_TS
1 - 4 years, Female
HIV_HTS_TS
5 - 9 years, Male
HIV_HTS_TS
5 - 9 years, Female
HIV_HTS_TS
10 - 14 years, Male
HIV_HTS_TS
HIV_HTS_TS
15 - 19 years, Male
HIV_HTS_TS
HIV_HTS_TS
20 - 24 years, Male
HIV_HTS_TS
HIV_HTS_TS
25 - 29 years, Male
HIV_HTS_TS
HIV_HTS_TS
30 - 34 years, Male
HIV_HTS_TS
HIV_HTS_TS
35 - 39 years, Male
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TNumber of Individual HIV self test KIT distribued
HIV_HTS_TDirectly assisted
HIV_HTS_TS
HIV_HTS_TS
40 - 44 years, Male
HIV_HTS_TS
HIV_HTS_TS
45 - 49 years, Male
HIV_HTS_TS
HIV_HTS_TS
>= 50 years, Male
HIV_HTS_TS
>= 50 years, Female
HIV_HTS_TUnassisted
HIV_HTS_TMale
HIV_HTS_TFemale
HIV_HIV_TrDoes health facility provide Monthly PMTCT / ART Treatment Service? 0
HIV_TX_CUChildren聽currently on ART aged <1 yr
HIV_TX_CUChildren currently on ART aged <1 yr on First line聽 regimen by sex
HIV_TX_CUMale
HIV_TX_CUFemale
HIV_TX_CUChildren currently on ART aged <1 yr on Second line聽 regimen by sex
HIV_TX_CUMale
HIV_TX_CUFemale
HIV_TX_CUMale
HIV_TX_CUFemale
HIV_TX_CUChildren currently on ART aged 1-4 yr on First line聽 regimen by sex

HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren currently on ART aged 1-4 yr on Second-line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren聽currently on ART aged 5-9 yr on First line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren聽currently on ART aged 5-9 yr on Second line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren聽currently on ART aged 5-9 yr on Third line regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren聽 currently on ART aged 10-14 year
HIV_TX_CUChildren聽 currently on ART aged 10-14 year on First line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUChildren currently on ART aged 10-14 year on Second line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUR
Male
HIV_TX_CUR
Female

HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUAdult currently on ART aged 50+ on First line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUAdult currently on ART aged 50+ on Second line聽 regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_CUAdult currently on ART aged 50+ on Third line regimen by sex
HIV_TX_CUR
Male
HIV_TX_CUR
Female
HIV_TX_C Currently on ART by pregnancy status
HIV_TX_CUPregnant
HIV_TX_CUChildren currently on ART aged <1 yr on First line聽 regimen by regimen type
HIV_TX_CU聽Children currently on ART aged 1-4 yr on First line regimen by regimen type

HIV_TX_CUChildren currently on ART aged 10-14 year on 聽First line regimen by regimen type
HIV_TX_CUAdult currently on ART aged 15-19 on聽First line regimen by regimen type
HIV_TX_CU1d = AZT-3TC-EFV
HIV_TX_CU1e = TDF-3TC-EFV
HIV_TX_CU1g= ABC + 3TC + EFV
HIV_TX_CU1j=TDF + 3TC + DTG
HIV_TX_CU1k= AZT +3TC +DTG
HIV_TX_CU1i = Other specify
HIV_TX_CU2e= AZT+3TC+LPV/r
HIV_TX_CU2f=AZT+3TC+ATV/r
HIV_TX_CU2g= TDF-3TC-LPV/r
HIV_TX_CU2h =TDF-3TC-ATV/r
HIV_TX_CU2i = ABC + 3TC + LPV/r
HIV_TX_CU2j = TDF + 3TC + DTG
HIV_TX_CU2k = AZT + 3TC + DTG
HIV_TX_CU2l=other secondline
HIV_TX_CU3a=DRV/r+DTG+AZT/3TC
HIV_TX_CU3b=DRV/r+DTG+TDF/3TC
HIV_TX_CU3c=DRV/r+ABC+3TC+DTG
HIV_TX_CU3e= DRV/r+TDF+3TC+EFV
HIV_TX_CU3f= DRV/r+AZT+3TC +EFV
HIV_TX_CU3d=Other thirdline
HIV_TX_CUAdults >=20 years currently on First line聽 regimen by regimen type
HIV_TX_CU1d = AZT-3TC-EFV, Male
HIV_TX_CU1d = AZT-3TC-EFV, Female - pregnant
HIV_TX_CU1d = AZT-3TC-EFV, Female - non-pregnant
HIV_TX_CU1e = TDF-3TC-EFV, Male
HIV_TX_CU1e = TDF-3TC-EFV, Female - pregnant
HIV_TX_CU1e = TDF-3TC-EFV, Female - non-pregnant
HIV_TX_CU1g= ABC + 3TC + EFV, Male
HIV_TX_CU1g= ABC + 3TC + EFV, Female - pregnant
HIV_TX_CU1g= ABC + 3TC + EFV, Female - non-pregnant
HIV_TX_CU1j=TDF + 3TC + DTG, Male
HIV_TX_CU1j=TDF + 3TC + DTG, Female - pregnant
HIV_TX_CU1j=TDF + 3TC + DTG, Female - non-pregnant
HIV_TX_CU1k= AZT +3TC +DTG, Male
HIV_TX_CU1k= AZT +3TC +DTG, Female - pregnant
HIV_TX_CU1k= AZT +3TC +DTG, Female - non-pregnant
HIV_TX_CU1i = Other specify, Male
HIV_TX_CU1i = Other specify, Female - pregnant
HIV_TX_CU1i = Other specify, Female - non-pregnant
HIV_TX_CU聽Adults >=20 years currently on Second line regimen by regimen type
HIV_TX_CU2e= AZT+3TC+LPV/r, Male
HIV_TX_CU2e= AZT+3TC+LPV/r, Female - pregnant
HIV_TX_CU2e= AZT+3TC+LPV/r, Female - non-pregnant
HIV_TX_CU2f=AZT+3TC+ATV/r, Male
HIV_TX_CU2f=AZT+3TC+ATV/r, Female - pregnant
HIV_TX_CU2f=AZT+3TC+ATV/r, Female - non-pregnant
HIV_TX_CU2g= TDF-3TC-LPV/r, Male
HIV_TX_CU2g= TDF-3TC-LPV/r, Female - pregnant
HIV_TX_CU2g= TDF-3TC-LPV/r, Female - non-pregnant
HIV_TX_CU2h =TDF-3TC-ATV/r, Male
HIV_TX_CU2h =TDF-3TC-ATV/r, Female - pregnant
HIV_TX_CU2h =TDF-3TC-ATV/r, Female - non-pregnant
HIV_TX_CU2i = ABC + 3TC + LPV/r, Male
HIV_TX_CU2i = ABC + 3TC + LPV/r, Female - pregnant
HIV_TX_CU2i = ABC + 3TC + LPV/r, Female - non-pregnant
HIV_TX_CU2j = TDF + 3TC + DTG, Male
HIV_TX_CU2j = TDF + 3TC + DTG, Female - pregnant
HIV_TX_CU2j = TDF + 3TC + DTG, Female - non-pregnant
HIV_TX_CU2k = AZT + 3TC + DTG, Male
HIV_TX_CU2k = AZT + 3TC + DTG, Female - pregnant
HIV_TX_CU2k = AZT + 3TC + DTG, Female - non-pregnant
HIV_TX_CU2l=other secondline, Male
HIV_TX_CU2l=other secondline, Female - pregnant
HIV_TX_CU2l=other secondline, Female - non-pregnant
HIV_TX_CU3a=DRV/r+DTG+AZT/3TC, Male
HIV_TX_CU3a=DRV/r+DTG+AZT/3TC, Female - pregnant
HIV_TX_CU3a=DRV/r+DTG+AZT/3TC, Female - non-pregnant
HIV_TX_CU3b=DRV/r+DTG+TDF/3TC, Male
HIV_TX_CU3b=DRV/r+DTG+TDF/3TC, Female - pregnant
HIV_TX_CU3b=DRV/r+DTG+TDF/3TC, Female - non-pregnant
HIV_TX_CU3c=DRV/r+ABC+3TC+DTG, Male
HIV_TX_CU3c=DRV/r+ABC+3TC+DTG, Female - pregnant
HIV_TX_CU3c=DRV/r+ABC+3TC+DTG, Female - non-pregnant
HIV_TX_CU3e= DRV/r+TDF+3TC+EFV, Male
HIV_TX_CU3e= DRV/r+TDF+3TC+EFV, Female - pregnant
HIV_TX_CU3e= DRV/r+TDF+3TC+EFV, Female - non-pregnant
HIV_TX_CU3f= DRV/r+AZT+3TC +EFV, Male
HIV_TX_CU3f= DRV/r+AZT+3TC +EFV, Female - pregnant
HIV_TX_CU3f= DRV/r+AZT+3TC +EFV, Female - non-pregnant
HIV_TX_CU3d=Other thirdline, Male
HIV_TX_CU3d=Other thirdline, Female - pregnant
HIV_TX_CU3d=Other thirdline, Female - non-pregnant
HIV_TX_NENumber of adults and children with HIV infection newly started on ART
HIV_TX_NE< 1 year, Male
HIV_TX_NE< 1 year, Female - non-pregnant
HIV_TX_NE>= 50 years, Male
HIV_TX_NE>= 50 years, Female - non-pregnant
HIV_ART_RART retention rate (Percentage of adult and children on ART treatment afte
HIV_ART_RE
< 1 year, Male
HIV_ART_RE
HIV_ART_RE
1 - 4 years, Male
HIV_ART_RE
HIV_ART_RE
5 - 9 years, Male
HIV_ART_RE
HIV_ART_RE
10 - 14 years, Male
HIV_ART_RE
HIV_ART_RE
15 - 19 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
20 - 24 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
25 - 29 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
30 - 34 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
35 - 39 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
40 - 44 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
45 - 49 years, Male
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
>= 50 years, Male
HIV_ART_RE
HIV_ART_R< 1 year, Male
HIV_ART_R< 1 year, Female - non-pregnant
HIV_ART_R>= 50 years, Female - non-pregnant
HIV_ART_ Linkage outcome of of newly identified Hiv positive individuals in the reporting period
HIV_ART_NDied
HIV_ART_NOthers
HIV_TX_PVViral load Suppression (Percentage of ART clients with a suppressed viral
HIV_TX_PVNumber of adult and pediatric ART patients for whom viral load test result received in the reporting period
HIV_TX_PVL
< 1 year, Male
HIV_TX_PVL
HIV_TX_PVL
1 - 4 years, Male
HIV_TX_PVL
HIV_TX_PVL
5 - 9 years, Male
HIV_TX_PVL
HIV_TX_PVL
10 - 14 years, Male
HIV_TX_PVL
HIV_TX_PVL
15 - 19 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
20 - 24 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
25 - 29 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
30 - 34 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
35 - 39 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
40 - 44 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
45 - 49 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
>= 50 years, Male
HIV_TX_PVL
HIV_TX_PVTotal number of adult and paediatric ART patients with an undetectable viral load(<50 copies/ml) in the reporting period
HIV_TX_PVL
< 1 year, Male
HIV_TX_PVL
HIV_TX_PVL
1 - 4 years, Male
HIV_TX_PVL
HIV_TX_PVL
5 - 9 years, Male
HIV_TX_PVL
HIV_TX_PVL
10 - 14 years, Male
HIV_TX_PVL
HIV_TX_PVL
15 - 19 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
20 - 24 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
25 - 29 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
30 - 34 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
35 - 39 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
40 - 44 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
45 - 49 years, Male
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
>= 50 years, Male
HIV_TX_PVL
HIV_TX_DSTotal number of adult and paediatric ART patients with low level viremia (50 -1000 copies/ml) in the reporting period
HIV_TX_DSD
< 1 year, Male
HIV_TX_DSD
HIV_TX_DSD
1 - 4 years, Male
HIV_TX_DSD
HIV_TX_DSD
5 - 9 years, Male
HIV_TX_DSD
HIV_TX_DSD
10 - 14 years, Male
HIV_TX_DSD
HIV_TX_DSD
15 - 19 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
20 - 24 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
25 - 29 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
30 - 34 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
35 - 39 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
40 - 44 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
45 - 49 years, Male
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
>= 50 years, Male
HIV_TX_DSD
HIV_TX_DSProportion of PLHIV currently on differentiated service Delivery model (D
HIV_TX_3MTotal number of clients on 3MMD
HIV_TX_3M< 1 year, Male
HIV_TX_3M< 1 year, Female
HIV_TX_3M>= 50 years, Male
HIV_TX_3M>= 50 years, Female
HIV_TX_ASTotal number of clients on ASM(6MMD)
HIV_TX_ASM
15 - 19 years, Male
HIV_TX_ASM
HIV_TX_ASM
20 - 24 years, Male
HIV_TX_ASM
HIV_TX_ASM
25 - 49 years, Male
HIV_TX_ASM
HIV_TX_ASM
>= 50 years, Male
HIV_TX_ASM
>= 50 years, Female
HIV_TX_FTA
15 - 19 years, Male
HIV_TX_FTA
HIV_TX_FTA
20 - 24 years, Male
HIV_TX_FTA
HIV_TX_FTA
25 - 49 years, Male
HIV_TX_FTA
HIV_TX_FTA
>= 50 years, Male
HIV_TX_FTA
>= 50 years, Female
HIV_TX_CAG
15 - 19 years, Male
HIV_TX_CAG
HIV_TX_CAG
20 - 24 years, Male
HIV_TX_CAG
HIV_TX_CAG
25 - 49 years, Male
HIV_TX_CAG
HIV_TX_CAG
>= 50 years, Male
HIV_TX_CAG
>= 50 years, Female
HIV_TX_PCTotal number of clients on PCAD
HIV_TX_PCA
15 - 19 years, Male
HIV_TX_PCA
HIV_TX_PCA
20 - 24 years, Male
HIV_TX_PCA
HIV_TX_PCA
25 - 49 years, Male
HIV_TX_PCA
HIV_TX_PCA
>= 50 years, Male
HIV_TX_PCA
>= 50 years, Female
.
HIV_TX_AdoTotal number of clients on Adolescent DSD
HIV_TX_KPTotal number of clients on KP DSD
HIV_TX_ othTotal number of clients on other types of DSD
HIV_TX_A Total number of clients on "Advanced HIV Disease Care Model"
HIV_TX_AH< 1 year, Male
HIV_TX_AH< 1 year, Female
HIV_TX_AH>= 50 years, Male
HIV_TX_AH>= 50 years, Female
HIV_ART_I Transferred out
HIV_ART_I Refused (stopped) treatement
HIV_ART_I Died
HIV_ART_R< 15 years, Male
HIV_ART_R< 15 years, Female
HIV_ART_R>= 15 years, Female
HIV_PrEP.1PrEP (New Number of individuals who were newly enrolled on PrEP)
HIV_PrEP.1By age and Sex
HIV_PrEP.1By Client Category
HIV_PrEP.1PrEP Curr (Number of individuals that received oral PrEP during the repor
HIV_PEP. 1Occupational
HIV_PEP. 2Sexual violence
HIV_PEP. 3Other Non occupational
HIV_PLHIV Proportion of clinically undernourished People Living with HIV (PLHIV) who received therapeutic or supplementary food
HIV_PLHIV Number of PLHIV that were nutritionally assessed and found to be clinically undernourished (disaggregated by Age, Se
HIV_PLHIV Total MAM
HIV_PLHIV Total SAM
HIV_PLHIV Clinically undernourished PLHIV who received therapeutic or supplementary food (disaggregated by age, sex and preg
HIV_PLHIV Total MAM who received therapeutic or supplementary food
HIV_PLHIV Total SAM who received therapeutic or supplementary food
HIV_STI_SCMale
HIV_STI_SCFemale
HIV_STI_SCMale
HIV_STI_SCFemale
HIV_ART_FP
10 - 14 years
HIV_ART_FP
15 - 19 years
HIV_ART_FP
20 - 24 years
HIV_ART_FP
25 - 29 years
HIV_ART_FP
30 - 49 years
HIV_ART_FOral contraceptives
HIV_ART_FInjectables
HIV_ART_FImplants
HIV_ART_FIUCD
HIV_ART_FOthers
HIV_TB.1. 1< 15 years, Male
HIV_TB.1. 2< 15 years, Female
HIV_TB.1. 3>= 15 years, Male
HIV_TB.1. 4>= 15 years, Female
HIV_ART_TNumber of ART patients who started on a standard course of TB Preventive Treatment (TPT) in the reporting period
HIV_TB_TPPatients on 6H
HIV_TB_TPT
< 15 years, Male
HIV_TB_TPT
< 15 years, Female
HIV_TB_TPT
>= 15 years, Male
HIV_TB_TPT
>= 15 years, Female
HIV_ART_TPatients on 3HP
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_TPatients on 3HR
HIV_ART_T< 15 years, Male
HIV_ART_T< 15 years, Female
HIV_ART_T>= 15 years, Male
HIV_ART_T>= 15 years, Female
HIV_ART_TNumber of ART patients who were initiated on any course of TPT 12 months before the reporting period
HIV_ART_TPatients on 3HP 12 months prior to the reporting period
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_TPatients on 3HR 12 months prior to the reporting period
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_TNumber of ART patients who started TPT 12 months prior to the reproting period that completed a full course of therapy
HIV_ART_TPatients who completed 6H
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_TPatients who completed 3HP
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_ART_TPatients who completed 3HR
HIV_ART_TP
< 15 years, Male
HIV_ART_TP
< 15 years, Female
HIV_ART_TP
>= 15 years, Male
HIV_ART_TP
>= 15 years, Female
HIV_CXCA Cervical Cancer screening by type of test
HIV_CXCA_S
15 - 19 years
HIV_CXCA_S
20 - 24 years
HIV_CXCA_S
25 - 29 years
07 - TB/Leprosy | Hospital, Health center, clinic | Monthly (Hidar 2015)
Gebjiro PHCU
TB_TX_PTBNumber of all forms of TB (New and Relapse) cases that were notified and 24.3
TB Number of bacteriologically confirmed New Pulmonary TB cases detected and enrolled in the rep
TB_TX_PTBNumber of clinically diagnosed New pulmonary TB cases detected and enro 1
TB_TX_PTB.
0 - 4 years, Male
TB_TX_PTB.
0 - 4 years, Female
TB_TX_PTB.
5 - 9 years, Male
TB_TX_PTB.
5 - 9 years, Female
TB_TX_PTB.
10 - 14 years, Male
TB_TX_PTB.
TB_TX_PTB.
15 - 19 years, Male
TB_TX_PTB.
TB_TX_PTB.
20 - 24 years, Male
TB_TX_PTB.
TB_TX_PTB.
25 - 34 years, Male
TB_TX_PTB.
TB_TX_PTB.
35 - 44 years, Male
TB_TX_PTB.
TB_TX_PTB.
45 - 54 years, Male
TB_TX_PTB.
TB_TX_PTB.
55 - 64 years, Male
TB_TX_PTB.
TB_TX_PTB.
>=65 yr, Male
TB_TX_PTB.
>=65 yr, Female
TB_TX_EPTNumber of clinically diagnosed and bacteriological confirmed new EPTB ca 1
TB_TX_EPTB
0 - 4 years, Male
TB_TX_EPTB
0 - 4 years, Female
TB_TX_EPTB
5 - 9 years, Male
TB_TX_EPTB
5 - 9 years, Female
TB_TX_EPTB
10 - 14 years, Male
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
20 - 24 years, Male
TB_TX_EPTB
TB_TX_EPTB
25 - 34 years, Male
TB_TX_EPTB
TB_TX_EPTB
35 - 44 years, Male
TB_TX_EPTB
TB_TX_EPTB
45 - 54 years, Male
TB_TX_EPTB
TB_TX_EPTB
55 - 64 years, Male
TB_TX_EPTB
TB_TX_EPTB
>=65 yr, Male
TB_TX_EPTB
>=65 yr, Female
TB_TX_RTB.
0 - 4 years, Male
TB_TX_RTB.
0 - 4 years, Female
TB_TX_RTB.
5 - 9 years, Male
TB_TX_RTB.
5 - 9 years, Female
TB_TX_RTB.
10 - 14 years, Male
TB_TX_RTB.
TB_TX_RTB.
15 - 19 years, Male
TB_TX_RTB.
TB_TX_RTB.
20 - 24 years, Male
TB_TX_RTB.
TB_TX_RTB.
25 - 34 years, Male
TB_TX_RTB.
TB_TX_RTB.
35 - 44 years, Male
TB_TX_RTB.
TB_TX_RTB.
45 - 54 years, Male
TB_TX_RTB.
TB_TX_RTB.
55 - 64 years, Male
TB_TX_RTB.
TB_TX_RTB.
>=65 yr, Male
TB_TX_RTB.
>=65 yr, Female
TB_KEY_P Number of notified TB cases from key affected population group during the reporting period
TB_KEY_POHealth care workers including HEWs
TB_KEY_PODiabetes
TB_KEY_POHomeless
TB_KEY_PORefugee
TB_KEY_POPrisoners
TB_KEY_POMiners
TB_KEY_POCongregated Settings
TB_KEY_POTB Contacts
TB_KEY_POOther key affected population
CDC_TB_RTB Treatment-outcome
TB_TX_OUTTotal number of bacteriologically confirmed new Pulmonary TB cases enrolled in cohort (PTB+) in the same month of the previ
TB_CR_PTB
TB_CR_PTB.
Completed
TB_CR_PTB.
Cured
TB_CR_PTB.
Lost to follow-up
TB_CR_PTB.
Dead
TB_CR_PTB.
Failed
TB_CR_PTB.
Not evaluated
TB_CR_PTB.
TB_CR_PNTTotal number of new clinically diagnosed pulmonary TB cases enrolled in the cohort (P/Neg) in the same month of
TB_CR_PNT
TB_CR_PNTB
Completed
TB_CR_PNTB
Lost to follow-up
TB_CR_PNTB
Deaths
TB_CR_PNTB
Failed
TB_CR_PNTB
TB_CR_PNTB
Not evaluated
TB_CR_EPTTotal number of new EPTB cases enrolled in the cohort (EPTB) in the same month of previous EFY
TB_CR_EPTTreatment outcome of cohort of new extra pulmonary TB (EPTB)cases
TB_CR_EPTB
Completed
TB_CR_EPTB
Lost to follow-up
TB_CR_EPTB
Deaths
TB_CR_EPTB
Failed
TB_CR_EPTB
TB_CR_EPTB
Not evaluated
TB_CR_RTBTotal number of all Relapse cases enrolled in the cohort in the same month of previous EFY
TB_CR_RTB
TB_CR_RTB.
Completed
TB_CR_RTB.
Cured
TB_CR_RTB.
Lost to follow-up
TB_CR_RTB.
Dead
TB_CR_RTB.
Failed
TB_CR_RTB.
Not evaluated
TB_CR_RTB.
TB_COMM. Number of all forms TB cases detected and registered on TB unit register who are initially referred by the communit
TB_CBTSR.Number of cohort TB patients (all forms) who were successfully treated (cured plus completed treatment) who received support f
TB_CBTSR.Total number of patients who started TB treatment in same reporting month of pervious year and who received any
TB_DX_PRINumber of TB cases (all forms) notified in public health facilities with initial referral by PPM sites for TB diagnosis or
TB_CI.1.1 Total number of contacts with index bacteriologically confirmed drug susceptible TB cases during the repo
TB_CI.1.1. 10 - 4 years
TB_CI.1.1. 25 - 14 years
TB_CI.1.1. 3>= 15 years
TB_CI.1.2. 10 - 4 years
TB_CI.1.2. 25 - 14 years
TB_CI.1.2. 3>= 15 years
TB_CI_SCRContacts of drug susceptible TB cases screened for TB
TB_CI_SCRContacts of drug Resistant TB cases screened for TB
TB_CI_SCRNumber of contacts with index bacteriologically confirmed TB (drug susceptible) cases screened
TB_CI_SCR_
0 - 4 years
TB_CI_SCR_
5 - 14 years
TB_CI_SCR_
>= 15 years
TB_TPT Number of contacts screened negative for TB and others eligible and put on TB Preventive Thera
TB_TPT.1.4.3HP
TB_TPT.1.4.3RH
TB_TPT.1.4.6H
TB_TPT.2.1Number of cohort of individuals started TPT 12 months prior to the reporting period by Age Group
TB_TPT.2.5.3HP
TB_TPT.2.5.3RH
TB_TPT.2.5.6H
TB_IPT.3. 3>= 15 years
TB_IPT.3.4.3HP
TB_IPT.3.4.3RH
TB_IPT.3.4.6H
TB_TST-W Number of new and relapse bacteriologically confirmed pulmonary TB patients initially tested using a WHO recommend
TB_TST-WH>= 15 years, Male
TB_TST-WH>= 15 years, Female
TB_DST.1 Number of notified bacteriologically confirmed TB cases evaluated for drug susceptibility testin
TB_DST.1. New
TB_DST.2. New
TB_DR_DRNumber of Hr-TB TB cases
TB_DR_DR.7
< 15 years, Male
TB_DR_DR.7
< 15 years, Female
TB_DR_DR.7
>= 15 years, Male
TB_DR_DR.7
>= 15 years, Female
TB_DR_DR.1
< 15 years, Male
TB_DR_DR.1
< 15 years, Female
TB_DR_DR.1
>= 15 years, Male
TB_DR_DR.1
>= 15 years, Female
TB_DR_DR.1
< 15 years, Male
TB_DR_DR.1
< 15 years, Female
TB_DR_DR.1
>= 15 years, Male
TB_DR_DR.1
>= 15 years, Female
TB_DR_DR.2
< 15 years, Male
TB_DR_DR.2
< 15 years, Female
TB_DR_DR.2
>= 15 years, Male
TB_DR_DR.2
>= 15 years, Female
Is the health facility a DR TB Treatment initiating center? 1
TB_DR_TX.Positive
TB_DR_TX.Negative
TB_DR_TX.Unknown
TB_DR_TX.By Registration Group
TB_DR_TX.5
New
TB_DR_TX.5
TB_DR_TX.5
TB_DR_TX.5
Unknown
TB_DR_DST
TB_DR_DST.
Shorter regimen
TB_DR_DST.
Longer regimen
TB_DR_DST.
TB_DR_DST
TB_DR_DST.
Positive
TB_DR_DST.
Negative
TB_DR_DST.
Unknown
TB_DR_DST
TB_DR_DST.
New
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
Unknown
TB_DR_DST
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DS RR/MDR-TB cases with DST result at least for fluoroquinolone during the reporting month
TB_DR_DSTwith susceptibility result
TB_DR_DSTwith resistant strain
TB_DR_DSTwhom Susceptibility result unknown
TB_DR_CT Total Number of聽 cohort聽 DR-TB cases initiated on second-line anti-TB the same month of the previous year (12 mon
TB_DR_CTXShort term regimen
TB_DR_CTXLong term
TB_DR_CTX
Number of cohort DR-TB cases started short term second-line anti-TB treatment regimen the same month of the previou
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
Number of聽 cohort DR-TB cases started聽 long term second-line anti-TB treatment regimen the same month of the pre
TB_DR_CTX
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_TxO.
Cured
TB_DR_TxO.
Completed
TB_DR_TxO.
Died
TB_DR_TxO.
Failed
TB_DR_TxO.
Lost to follow-up
TB_DR_TxO.
Not evaluated
TB_DR_CTX
TB_DR_CTX.
Cured
TB_DR_CTX.
Completed
TB_DR_CTX.
Died
TB_DR_CTX.
Failed
TB_DR_CTX.
Lost to follow-up
TB_DR_CTX.
Not evaluated
TB_DR_CTX
TB_DR_CTX.
Cured
TB_DR_CTX.
Completed
TB_DR_CTX.
Died
TB_DR_CTX.
Failed
TB_DR_CTX.
Lost to follow-up
TB_DR_CTX.
Not evaluated
TB_DR_NUT
TB_DR_NUT.
Normal
TB_DR_NUT.
MAM
TB_DR_NUT.
SAM
TB_MN. 1 Normal
TB_MN. 2 MAM
TB_MN. 3 SAM
TB_HIV_N Total number of new and relapse TB patients registered during the reporting period having a documented HIV
TB_ART.1. >= 15 years, Male
TB_ART.1. >= 15 years, Female
TB_NEW_AR
TB_NEW_AR
0 - 4 years, Male
TB_NEW_AR
0 - 4 years, Female
TB_NEW_AR
5 - 14 years, Male
TB_NEW_AR
TB_NEW_AR
>= 15 years, Male
TB_NEW_AR
>= 15 years, Female
LEP_NOT_.1
LEP_NOT_.1
< 15 years, Male
LEP_NOT_.1
< 15 years, Female
LEP_NOT_.1
>= 15 years, Male
LEP_NOT_.1
>= 15 years, Female
LEP_NOT_.1
LEP_NOT_.1.
< 15 years, Male
LEP_NOT_.1.
< 15 years, Female
LEP_NOT_.1.
>= 15 years, Male
LEP_NOT_.1.
>= 15 years, Female
LEP_NOT_.1
LEP_NOT_.1
LEP_CSCR.Total number of household contacts of leprosy patients that are screened for Leprosy in the reporting period
LEP_CSCR.Total number of household contacts diagnosed with Leprosy cases in the reporting month
TB_LB_GenTB_Total Number of tests performed using GeneXpert MTB/RIF/Ultra for MTB detection
TB_LB_Gene
MTB Detected Rif Resistance not detected
08.2 - Malaria, NTD, NCD | Hospital, Health center, Clinic | Monthly (Hidar 2015)
Gebjiro PHCU
MAL Total number of slides or RDT performed for malaria diagnosis 115 51
MAL. 1 < 5 years, Male 9
MAL. 2 < 5 years, Female 27
MAL. 3 5 - 14 years, Male 16
MAL. 4 5 - 14 years, Female 7 2
MAL. 5 >= 15 years, Male 29 39
MAL. 6 >= 15 years, Female 27 10
MAL_POS.1Total number of slides or RDT Positive 7 6
MAL_POS.1.>= 15 years, Male 7 6
Is the woreda elimination district? 6 5
MAL_FULL.1
MAL_FULL.2
NTD. Does the facility provide leishmaniasis treatment? 0 0
NTD_VL.1. < 5 years, Male
NTD_VL.1. < 5 years, Female
NTD_VL.1. >= 15 years, Male
NTD_VL.1. >= 15 years, Female
NTD_VL.2. Primary visceral leishmaniasis
NTD_VL.2. Relapse visceral leishmaniasis
NTD_VL.2. Post Kala-azar dermal leishmaniasis (PKDL)
NTD_VL.3. Cured
NTD_VL.3. Defaulted
NTD_VL.3. Failed
NTD_VL.3. Dead
NTD_VL.3. Referred
NTD_VL.4. Positive
NTD_VL.4. Negative
NTD_CL.1. < 5 years, Male
NTD_CL.1. < 5 years, Female
NTD_CL.1. >= 15 years, Male
NTD_CL.1. >= 15 years, Female
NTD_CL.2. Primary cutaneous leishmaniasis
NTD_CL.2. Relapse cutaneous leishmaniasis
NTD_CL.3. Cured
NTD_CL.3. Defaulted
NTD_CL.3. Failed
NTD_CL.3. Dead
NTD_CL.3. Referred
NTD_TT.1. < 15 years, Male
NTD_TT.1. < 15 years, Female
NTD_TT.1. >= 15 years, Male
NTD_TT.1. >= 15 years, Female
NTD_HYD. < 15 years, Male
NTD_HYD. >= 15 years, Male
NTD_POD. < 15 years, Male
NTD_POD. < 15 years, Female
NTD_POD. >= 15 years, Male
NTD_POD. >= 15 years, Female
NCT_HTN Number of Individuals screened for hypertension 210
NCT_HTN. 18 - 29 years, Male 10
NCT_HTN. 18 - 29 years, Female 10
NCT_HTN. >=70 years, Male 12
NCT_HTN. >=70 years, Female 13
NCD_HTNDX
Number of Individuals screened for hypertension by result of screening 210
NCD_HTNDX.
Raised BP 5
NCD_HTNDX.
Normal BP 205
NCD_HTNDX
Hypertensive patients enrolled to care by Type of Treatment 5
NCD_HTNDX
NCD_HTNDX
Pharmacological management and HLC 5
NCD_HTNDX
Hypertensive patients enrolled to care by age and sex 5
NCD_HTNDX.
18 - 29 years, Male
NCD_HTNDX.
NCD_HTNDX.
30 - 39 years, Male
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
>=70 years, Male
NCD_HTNDX.
>=70 years, Female
NCD_HTNDX
Hypertensive patients by timing of enrollment 3
NCD_HTNDX.
Newly enrolled to care 1
NCD_HTNDX.
Previously in care 2
NCD_HTNTX
NCD_HTNTTreatment outcome for cohort of patient registered for hypertension treatment six months prior to the reporting peridod
NCD_HTNTX
Controlled
NCD_HTNTX
Uncontrolled
NCD_HTNTX
Lost to follow-up
NCD_HTNTX
Died
NCD_HTNTX
Transferred out
NCD_HTNTX
Not evaluated
NCD_CVD.2.
40 - 59 Years, Male
NCD_CVD.2.
NCD_CVD.2.
60 - 74 Years, Male
NCD_CVD.2.
NCD_CVD.3.
With Statin
NCD_CVD.3.
Without Statin
NCD_CVD.4.
40 - 59 Years, Male
NCD_CVD.4.
NCD_CVD.4.
60 - 74 Years, Male
NCD_CVD.4.
NCD_DMDX.
NCD_DMDX.1
< 40 years, Male
NCD_DMDX.1
< 40 years, Female
NCD_DMDX.1
>= 40 years, Male
NCD_DMDX.1
>= 40 years, Female
NCD_DMDX.
NCD_DMDX.1
Raised blood sugar
NCD_DMDX.1
Normal blood sugar
NCD_DMDXDiabetic patients enrolled to care by types of Diabete
NCD_DMDX.
Type I
NCD_DMDX.
Type II
NCD_DMDX.
Gestational DM
NCD_DMDX.
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.
NCD_DMDX.2
< 15 years, Male
NCD_DMDX.2
< 15 years, Female
NCD_DMDX.2
15 - 29 years, Male
NCD_DMDX.2
NCD_DMDX.2
30 - 39 years, Male
NCD_DMDX.2
NCD_DMDX.2
>= 40 years, Male
NCD_DMDX.2
>= 40 years, Female
NCD_DMDX.
NCD_DMDX.2
NCD_DMDX.2
Previously in care
NCD_DMTX.Total number of cohort of hypertensive pateints registered for diabetes treatment six months prior to the reporting period
NCD_DMTXTreatment outcome for cohort of patient registered for diabetes treatment six months prior to the reporting period
NCD_DMTX.Controlled
NCD_DMTX.Died
NCD_DMTX.Treatment outcome for cohort of patient registered for diabetes treatment six months prior to the reporting period by a
NCD_DMTX.< 15 years, Male
NCD_DMTX.< 15 years, Female
NCD_DMTX.>= 40 years, Male
NCD_DMTX.>= 40 years, Female
NCD_CV_SC
NCD_CV_SC
Screened by VIA
09.2 - Medical services | Health center | Monthly (Hidar 2015)
Gebjiro PHCU
MS Number of outpatient visits 455 2175
MS. 1 < 5 years, Male 70 277
MS. 2 < 5 years, Female 79 222
MS. 3 5 - 10 years, Male 27 230
MS. 4 5 - 10 years, Female 12 160
MS. 5 11 - 19 years, Male 10 195
MS. 6 11 - 19 years, Female 145
MS. 7 20 - 29 years, Male 15 194
MS. 8 20 - 29 years, Female 74 154
MS. 10 30 - 45 years, Female 111 140
MS. 11 46 - 65 years, Male 2 100
MS. 12 46 - 65 years, Female 12 50
MS. 14 >= 66 years, Female 20
MS_OPD_Nu
Number of health insurance beneficiaries that visited HF in the reporting period 1247
MS_IPD_BOTotal length of stay (in days) in the reporting period 20
MS_IPD_BOTotal Number of beds in the reporting period 3
MS_ALS.1. Total length of stay (in days) during discharge 20
MS_ALS.2. Number of inpatient discharges 13
MS_LaBT.1.Monthly score of essential laboratorial tests of the facility 0
MS_RoR.1 Number of people referred to other health facility 22
MS_RoR.1. Emergency referral 16
MS_RoR.1. Non-emergency referral 6
MS_RI Referral-ins
MS_NumRI.Emergency referral
MS_NumRI.Non-emergency referral
MS_AMBU Ambulance service utilization for emergency referral
MS_AMBU.Number of clients that came to health facility using ambulance 1
MS_AMBU.1Pre-facility
MS_AMBU.1Between facility 1
MS_AMBUR1
MS_AMBUR1
MS_AMBURe
Total number of ambulance requests made during the reporting period 1
MS_AMBUR2
MS_AMBUR2
MS_AMBUR2
Trauma
MS_AMBUR2
Burn & Poisoning
MS_AMBUR2
Others
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
HSQI_IPD_ Admission rate
MS_IPD_AR.
Number of inpatient admissions 13
HSQI_IPD_ Inpatient mortality rate
MS_IPIMR.1< 24 hours
MS_IPIMR.1>= 24 hours
MS_UBDT.1.
MS_UBDT.1.
from blood bank
MS_RTI.1. 4Others
PMS. Medroxyprogesterone Injection 1
PMS_AVAIL.Pentavalent vaccine 1
PMS_AVAIL.Magnesium Sulphate injection 1
PMS_AVAIL.Oxytocine inj 1
PMS_AVAIL.Gentamycin injection 1
PMS_AVAIL.ORS+/- Zinc sulphate 1
PMS_AVAIL.Amoxcillin dispersable/suspension/capsule 1
PMS_AVAIL.Iron + folic acid 1
PMS_AVAIL.Albendazole/Mebendazole tablet/suspension 1
PMS_AVAIL.TTC eye ointment 1
PMS_AVAIL.RHZE/RH 0
PMS_AVAIL.TDF/3TC/DTG 1
PMS_AVAIL.Co-trimoxazole 240mg/5ml suspension 1
PMS_AVAIL.Arthmeter + Lumfanthrine tablet 1
PMS_AVAIL.Amlodipine tablet 1
PMS_AVAIL.Frusamide tablets 0
PMS_AVAIL.Metformin tablet 1
PMS_AVAIL.Normal Saline 0.9% 1
PMS_AVAIL.40% glucose 1
PMS_AVAIL.Adrenaline injection 1
PMS_AVAIL.Tetanus Anti Toxin (TAT) injection 0
PMS_AVAIL.Omeprazole capsule 1
PMS_AVAIL.Metronidazole capsule 0
PMS_AVAIL.Ciprofloxcaxillin tablet 0
PMS_AVAIL.Hydralizine injection 0
PMS_ABIOTI
PMS_ABIOTI
PMS_FILL1Clients with 100% prescribed drugs filled
PMS_FILL10Number of clients who received 100% of prescribed drugs 100
PMS_FILL10Total number of clients who received prescriptions 100
PMS_FSMLPercentage of medicines prescribed from the facility’s medicines list 100
PMS_MPFMTotal number of medicines prescribed from Health facility medicine list 1247
PMS_MP_NTotal number of medicine prescribed 1247
EIDM_LQA Proportion of health facilities that conduct reporting consistency check
EBDM. Did the HF conduct LQAS for service report? 5 6
DQ_DA.1.1.LQAS first score for service report 95 85.8
DQ_DA.1.2.LQAS last score for service report 95 90.8
DQ_DA2. Did the HF conduct LQAS for OPD report? 5 6
DQ_DA.2.1.LQAS first score for OPD report 95 91.7
DQ_DA.2.2.LQAS last score for OPD report 95 92.5
DQ_DA3. Did the HF conduct LQAS for IPD report? 1
DQ_DA.3.1.LQAS first score for IPD report 95
DQ_DA.3.1.LQAS last score for IPD report 95
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
144 354 371 436 1909

83 115 80 85 610
3 19 7 15 44
21 26 25 24 142
36 37 22 23 235
23 33 26 23 189
61 239 291 351 1299
5 14 6 14 39
15 64 44 108 259
18 77 140 130 534
23 84 101 99 467
143 265 280 436 1653
83 82 57 85 479
11 6 6 2 78
72 76 51 74 392
9 9
60 183 223 351 1174

13 10 7 6 86
47 173 216 265 1008
72 72
8 8
9 39
4 14
3 18
2 7
8 6 24
83 114 71 78 497
67 33 48 33 300
4 11 9 1 28
12 70 14 44 169
83 114 71 78 497
6 21 16 12 58
77 93 55 66 439
65 44 59 54 344
7 8 10 10 37
58 36 49 44 307
65 44 59 54 344
28 54 145
65 16 59 199
83 114 71 78 493
114 114
83 71 78 379
83 114 71 78 493
114 114
83 71 78 379
68 96 80 84 470
79
79
68 96 80 87 473
68 96 80 84 470
3 3
11.9 11.9
1 1
68 96 80 83 469
68 96 80 83 469
84 147
84 147
1 1
6 8 13 6 69
6 5 4 5 45
2 2 2 3 12
3 1 2 13
1 1 9
3 11
3 9 1 24
2 5
2 1 7
4 5
1 2 1 7
6 8 13 6 69
6 8 13 6 69
5 6 17
1
5 4 14
2 2
8 10 7 25
8 10 7 25
34 62 63 287
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
1 8 0 1 14
67 114 71 78 501
67 114 71 78 459
42
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
20
20
96 113 88 104 559
85 134 91 102 566
85 134 91 100 574
85 134 91 102 568
85 134 91 100 572
88 134 91 102 574
85 134 91 100 552
85 134 91 100 577
85 134 91 102 576
85 133 90 100 565
77 132 83 100 536
77 132 83 100 554
48 88 68 100 448
80 134 91 101 553
s vaccine in 6 month interval from the first dose
46 102 71 38 422
43 69 71 34 316
24 33 4 19 115
9 3 8 25
2 1 2 5
20
0 26.5 60 35 140.1
120 147 88 104 655
120 200 220 160 915
0 0 0 0 0
239 401 272 302 1662
239 401 272 302 1662
0 0.25 6.8 1.9 21.05

170 401 272 302 1592
170 402 292 308 1648
0 2.6 0 0 2.6
170 267 181 202 1126
170 274 181 202 1133
0 6.2 17.6 11.2 41.7

170 319 272 302 1515
170 340 330 340 1648
0 8.7 16.1 8.2 41.8

144 242 151 202 1045
144 265 180 220 1129
0 6.2 0 4.3 14.9

140 197 150 110 729
140 210 150 115 750
0 20.2 20.9 13 67.9
152 134 91 100 625
152 168 115 115 709
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
99 156 159 95 685

3 156 2 315
1 2 28
2 156 287
111 139 91 74 653
111 139 91 74 653
25 7 20 6 134
0 0 0 0
80 159
80 159
287
152
135
287
287
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
68 96 80 83 406
1378 2262 1660 3048 11554

115 117 287 296 1706
1263 2145 1373 2752 9848
337 4 10 4 380
12 14
325 4 10 4 366
3 2 22
1
3 2 21
240 1101 180 410 2536

50 236 50 80 651
190 865 130 330 1885
240 1101 180 410 2536
240 1101 178 410 2534
2 2
150 772 810 2229

150 772 810 2195
34
68 80 286
68 114 71 54 526
8 21 16 10 55
60 93 55 44 471
225 354 71 94 1732

23 26
225 331 71 94 1706
528 354 71 94 1970
261 182 71 94 833
267 172 1137
2086 5426 3483 6205 26323

1 88 91 1030
579 1534 1373 3243 10023
1506 3804 2110 2871 15270
539 6 15 19 606
312 4 10 15 361
227 2 5 4 245
152 3 176
130 3 144
22 32
1 47 51
1 44 46
3 5
18
14
4
15
12
3
6 9
4 7
2 2
15
12
3
287
44
108
135
3 7 47 10 74
3 10
4 3 4 10 25
8
3
1 10 3 10 39
3 4 10 32
3 1 10 14
4 10 14
8
4 10 17
6 10 16
204
204
50
90
64
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
170 228 244 337 1323
5 5
6 6
2
2 7 11
5 1 9 42
20 51 42 27 141
15 4 82
31 55 84 74 257
10 4 55
27 83 89 73 301
5 1 5 81
20 35 29 64 177
5 1 14 70
20 12 39
2 1 13 18
1 4 7
7 6 13
4 4
4 9
2 3
2 2
1 1
1 1
23 23
228 244 314 1048

2 2
0 0 1 1
2 2
1 1
1 1
10 10
6 6
4 4
4 4
2 2
2 2
3 3
1 1
2 2
20 20
8 8
12 12
46 46
16 16
30 30
2 2
2 2
47 47
12 12
35 35
2 2
2 2
36 36
12 12
24 24
12 12
5 5
7 7
16 16
5 5
11 11
9 9
8 8
1 1
2 2
2 2
10 10
9 9
1 1
4 4
4 4
177 177
74 74
8 8
95 95
4 4
2 2
2 2
2 2
1 1
1 1
nus those transferred out (net current cohort) 197 197
1 1
2 2
8 8
2 2
2 2
2 2
2 2
7 7
12 12
16 16
1 1
29 29
14 14
35 35
12 12
24 24
5 5
7 7
5 5
11 11
2 2
2 2
in the reporting period 30 30
4 4
4 4
7 7
5 5
6 6
4 4
50 copies/ml) in the reporting period 30 30
4 4
4 4
7 7
5 5
6 6
4 4
copies/ml) in the reporting period

82 82
1 1
3 3
2 2
6 6
2 2
2 2
1 1
3 3
21 21
29 29
5 5
7 7
120 120
10 10
14 14
28 28
56 56
4 4
8 8
6 6
6 6
nfection by exposure type
ed therapeutic or supplementary food

44 44
8 8
8 8
7 7
21 21
nourished (disaggregated by Age, Sex and Pregnancy)
disaggregated by age, sex and pregnancy status)

se of any method of modern family planning by 57 57
3 3
12 12
42 42
se of any method of modern family planning by 57 57
55 55
2 2
2 2
2 2
ent (TPT) in the reporting period
the reporting period
at completed a full course of therapy

5 5
3 3
2 2
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
12.2 48.7 36.5 121.7

1 1 2 4
1 1
1 1
1 1
1 1
1 2
1 1
1
2 3
1 1
1 1
1 1
1 1
3 3
3 3
PTB+) in the same month of the previ 1 1
eg) in the same month of 1 1

referred by the communit 1 1
eted treatment) who received support for treatment adherence by HEWs during in the same month of previous EFY
ear and who received any 1 1
M sites for TB diagnosis or 1 1
B cases during the repo 5 7 12
5 7 12
ng the reporting Month
23 23
2 2
21 21
12 12
4 4
8 8
12 5 7 24
4 4
8 5 7 20
12 12
4 4
8 8
4 4
4 4
d by Age Group
arted 12 months prior to the reporting period by Age Group
ally tested using a WHO recommende 2 2
1 1
1 1
5 1 6
1 1 2
4 4
ring the reporting period

0 0 1
vious year (12 month earlier)
gimen the same month of the previous year (12 month earlier)
t regimen the same month of the previous year (12 month earlier)
tment regimen 24 months earlier.
ment regimen 24 months earlier.

dualized) second-line anti-TB treatment regimen 36 months earlier.
ring the reporting period
d having a documented HIV positive t 1 1

1 1
d having a documented HIV 4 2 6

3 1 4
1 1 2
1 1
1 1
eporting month
he reporting period
46 8 54
46 46
8 8
2 2
1 1
1 1
2 2
2 2
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
110 602 316 280 1474
5 96 21 43 174
10 112 21 51 221
34 70 35 30 185
32 72 24 18 155
18 96 150 62 394
11 156 65 76 345
3 78 81 49 224
5 3 1 9
3 2 5
2 14 10 2 28
1 12 4 2 19
28 55 19 115
16 7 25 48
6 8 25
0 5 0 0 5
418 157 1172 1957
50 6 86 152
36 8 172 226
27 10 216 283
36 13 224 313
68 21 248 382
79 28 169 326
44 32 36 124
78 39 21 151
261 157 1172 1800
6 2 5 18
255 155 1167 1782
6 2 17 30
5 17 22
1 2 8
1 2 8
1 1
3
1 3
1 1
35 2 17 57
1 2 5 9
34 12 48
20 3 5 28
months prior to the reporting peridod 3 5 8
3 5 8
1 1
1 1
1 1
1 1
33 33
6 6
4 4
10 10
13 13
32 32
1 1
31 31
1 1
1 1
1 1
1 1
32 32
2 2
6 6
18 18
6 6
1 1
1 1
ths prior to the reporting period 1 2 3

hs prior to the reporting period 1 2 3
1 2 3
hs prior to the reporting period by a 1 2 3
1 1
1 1
1 1
30 30
30 30
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
2742 8002 5719 1232 20325
287 1451 1728 47 3860
320 1673 1800 65 4159
167 293 120 203 1040
227 323 113 140 975
224 445 198 80 1152
137 552 154 92 1080
123 553 310 62 1257
102 674 390 10 1404
297 660 308 108 1624

220 262 170 37 791
123 274 201 109 769
266 121 23 154 584

1009 5449 1998 9703
32 52 22 126
3 3 3 12
24 22 66
16 24 11 64
0 0 100 100
21 57 6 106
10 34 60
11 23 6 46
57 57
34 34
23 23
12 57 70
34 34
12 23 36
12 57 69
12 34 46
23 23
13 57 71
8 33 41
5 5
1 21 22
12 12
2 2
11 24
45 45
20 20
13 13
12 12
1 1 1 4
1 1 1 4
1 1 1 4
1 1 1 4
1 1 1 4
1 1 1 4
1 1 1 4
1 1 1 4
1 1 1 4
1 1 1 4
0 1 1 2
1 1 1 4
1 1 1 4
0 1 1 3
1 1 1 4
1 1 1 3
1 1 1 4
1 1 1 4
1 1 1 4
1 1 1 4
0 1 1 2
1 1 1 4
1 1 1 3
0 1 1 2
0 1 1 2
100 100
2293 2293
2293 2293
4389 2293 6782

4473 2293 6866
100 100 300
156 6879 8282
156 6879 8282
6 7 12 6 42
87.5 95 79.2 93.3 535.8
85.8 95 90 93.3 549.9
6 6 12 6 41
85 95 80.8 90 537.5
89.2 95 90 90.8 552.5
1 1 1 4
90 95 90 370
90 95 90 370
01.2 - Reproductive and Maternal Health | Hospital, Health center, Clinic | Monthly (Hidar 2015; Tikemet 2015; Meskerem
S.No
RMH
MAT_CAR
MAT_CAR_A
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_A
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_Ag
MAT_CAR_
MAT_CAR_M
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_M
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
MAT_CAR_Mt
RMH_FP_IP
MAT_IPPCA
MAT_IPPCA
MAT_IPPCA
MAT_IPPCA
MAT_IPPCA
MAT_IPPCA
RMH_FP_L
MAT_LAFPP
MAT_LAFPPR
MAT_LAFPPR
MAT_LAFPPR
MAT_TLAFP
MAT_ANC1
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC1_
MAT_ANC4
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC4+
MAT_ANC8
MAT_ANC8+
RMH_ANC_
MAT_SYPH.
MAT_SYPH.1
MAT_SYPH.1
MAT_SYPH.
MAT_Hepa
MAT_Hepa.
MAT_Hepa.
MAT_Prp.1.
RMH_L&D_
L&D_SBA.1.
MAT_PPH.1
MAT_PPH.1.
MAT_PPH.1.
MAT_UTER
MAT_UTER.
MAT_UTER.1
MAT_UTER.1
MAT_UTER.1
MAT_UTER.1
MAT_SBR
MAT_SBR.S
MAT_SBR.L
B&D_Ntfc
MAT_B&D_I
MAT_B&D_I
MAT_EPNC.
MAT_EPNC.
MAT_EPNC.1
MAT_EPNC.1
MAT_EPNC.1
MAT_EPNC.1
RMH_L&D_
MAT_CS.1.
MAT_CAC
MAT_CAC_
MAT_CAC_S
MAT_CAC_S
MAT_CAC_S
MAT_CAC_S
MAT_CAC_S
MAT_CAC_
MAT_CAC_P
MAT_CAC_P
MAT_CAC_P
MAT_CAC_P
MAT_CAC_P
MAT_CAC.T
MAT_CAC.Tr
MAT_CAC.Tr
MAT_CAC.M
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_CAC.MA
MAT_OFC_I
MAT_OFC_Id
MAT_OFC_Id
MAT_OFC_Id
MAT_OFC_Id
MAT_OFC_Id
MAT_OFC_T
MAT_OFC_Tr
MAT_OFC_Tr
MAT_OFC_Tr
MAT_OFC_Tr
MAT_OFC_Tr
MAT_IMD
MAT_IMD.1.
MAT_TngP
MAT_TngP_
MAT_TngP_
MAT_Tngtst
02 - PMTCT | Hospital, Health center, Clinic | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 2014; Nehase 2
S.No
RMCH__PMT
MTCT
MTCT_TST
MTCT_TST.
MTCT_TST.
MTCT_TST.
MTCT_Test.
MTCT_NWpo
MTCT_ART
MTCT_ART.
MTCT_ART.
MTCT_ART.
MTCT_ART.
MTCT_HEI_
MTCT_HEI_E
MTCT_HEI_E
03 - EPI | Hospital, Health center, Health post, Clinic | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 2014; N
S.No
EPI
EPI_HepBD
EPI_HepBD.
EPI_HepBD.
EPI_BCG1.
EPI_DPT1.1
EPI_DPT3.1
EPI_OPV1.1
EPI_OPV3.1
EPI_PCV1.1
EPI_PCV3.1
EPI_IPV.1.
EPI_Rota1.1
EPI_Rota2.1
EPI_MCV1.1
EPI_FI.1.
EPI_MCV2
EPI_MCV2.1
EPI_PAB
EPI_PAB.1.
EPI_HPV1
EPI_HPV1.1
EPI_HPV2
EPI_HPV2.1
EPI_TD
EPI_TD1.1.
EPI_TD2.1.
EPI_TD3.1.
EPI_TD4.1.
EPI_TD5.1.
EPI_VWR
EPI_VWR_He
EPI_VWR_He
EPI_VWR_He
EPI_VWR_He
EPI_VWR_B
EPI_VWR_B
EPI_VWR_B
EPI_VWR_B
EPI_VWR_Pe
EPI_VWR_Pe
EPI_VWR_P
EPI_VWR_Pe
EPI_VWR_P
EPI_VWR_P
EPI_VWR_P
EPI_VWR_PC
EPI_VWR_RT
EPI_VWR_R
EPI_VWR_R
EPI_VWR_RT
EPI_VWR_PV
EPI_VWR_P
EPI_VWR_P
EPI_VWR_PV
EPI_VWR_M
EPI_VWR_M
EPI_VWR_M
EPI_VWR_M
EPI_VWR_TD
EPI_VWR_T
EPI_VWR_T
EPI_VWR_TD
EPI_VWR_IP
EPI_VWR_IP
EPI_VWR_I
EPI_VWR_IP
EPI_VWR_H
EPI_VWR_H
EPI_VWR_H
EPI_VWR_H
04.2 - Neonatal and Child Health | Health center, Hospital and clinic | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015
S.No
CH
CH_IND
CH_IND. 1
CH_IND. 2
CH_IND. 3
CH_TX_PN
CH_TX_PNE
CH_TX_SYI.
CH_TX_SYI.
CH_TX_SYI.
CH_TX_SYI.
CH_TX_DIA
CH_TX_DIAR
CH_TX_DIAR
CH_KMC
CH_KMC.1.
CH_KMC.2.
CH_ASPH
CH_ASPH.1
CH_ASPH.2
CH_TX_NIC
CH_TX_NIC
CH_TX_NIC
CH_TX_NICU
CH_TX_NICU
CH_TX_NICU
CH_TX_NICU
CH_CHX
CH_CHX.1.
CH_CHDM
CH_CHDM.
CH_CHDM.
CH_CHDMS
CH_CHDMS.
CH_CHDMS.
CH_CHDMS.
05.2 - Nutrition | Hospital, Health center | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 2014; Nehase 2014
S.No
NUT
NUT_LBW
NUT_GMP.
NUT_LBW.2
NUT_GMP
NTR_GMP.1
NTR_GMP.1.
NTR_GMP.1.
NUT_GMP.M
NUT_GMP.M
NUT_GMP.M
NUT_GMP_
NUT_GMP_S
NUT_GMP_S
NCH_NTR_
NUT_VITA
NUT_VITA.
NUT_VITA.
NUT_VITA.2
NUT_VITA.2
NUT_VITA.2
NUT_DeW
NUT_DeW.1
NUT_DeW.1.
NUT_DeW.1.
NUT_DeW.2
NUT_IFA
NUT_IFA.1
NUT_IFA.1.
NUT_IFA.1.
NUT_IFA.1.
NUT_PreSM
NUT_PreSM
NUT_PreSMN
NUT_PreSMN
NUT_PreSM
NUT_PreSMN
NUT_PreSMN
NUT_U5SM
NUT_U5SM
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_U5SMN
NUT_TX-U
NUT_TX-U
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_TX-U5
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&Yo
NUT_Adl&Yo
NUT_Adl&Yo
NUT_Adl&Yo
NUT_Adl&
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&Y
NUT_Adl&Y
06 - HIV | Hospital, Health center, Clinic | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 2014; Nehase 2014)
S.No
HIV
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HCT_P
HIV_HTS_T
HIV_HTS_T
HIV_TST_P
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_TS
HIV_HTS_T
HIV_HTS_T
HIV_HTS_T
HIV_HIV_Tr
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_CU
HIV_TX_CUR
HIV_TX_CUR
HIV_TX_C
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_CU
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_TX_NE
HIV_ART_R
HIV_ART_R
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_RE
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_
HIV_ART_N
HIV_ART_N
HIV_ART_N
HIV_ART_N
HIV_ART_N
HIV_ART_N
HIV_TX_PV
HIV_TX_PV
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PV
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_PVL
HIV_TX_DS
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DSD
HIV_TX_DS
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_3M
HIV_TX_AS
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_ASM
HIV_TX_FT
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_FTA
HIV_TX_CA
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_CAG
HIV_TX_PC
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
HIV_TX_PCA
.
HIV_TX_Ado
HIV_TX_KP
HIV_TX_MC
HIV_TX_ oth
HIV_TX_A
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_TX_AH
HIV_ART_I
HIV_ART_I
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_I
HIV_ART_I
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_IN
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_ART_R
HIV_PrEP
HIV_PrEP.1
HIV_PrEP.1
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1
HIV_PrEP.1.
HIV_PrEP.1.
HIV_PrEP.1
HIV_PrEP_
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_C
HIV_PrEP_
HIV_PrEP_C
HIV_PrEP_C
HIV_PEP
HIV_PEP. 1
HIV_PEP. 2
HIV_PEP. 3
HIV_PLHIV
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_PLHIV_
HIV_STI_S
HIV_STI_SC
HIV_STI_SC
HIV_STI_SC
HIV_STI_S
HIV_STI_SC
HIV_STI_SC
HIV_STI_S
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_STI_SY
HIV_ART_F
HIV_ART_FP
HIV_ART_FP
HIV_ART_FP
HIV_ART_FP
HIV_ART_FP
HIV_ART_F
HIV_ART_F
HIV_ART_F
HIV_ART_F
HIV_ART_F
HIV_ART_F
HIV_TB_SC
HIV_TB.1
HIV_TB.1. 1
HIV_TB.1. 2
HIV_TB.1. 3
HIV_TB.1. 4
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_TB_SC
HIV_ART_T
HIV_TB_TP
HIV_TB_TPT
HIV_TB_TPT
HIV_TB_TPT
HIV_TB_TPT
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_T
HIV_ART_T
HIV_ART_T
HIV_ART_T
HIV_ART_T
HIV_TPT
HIV_TPT. 1
HIV_TPT. 2
HIV_TPT. 3
HIV_TPT. 4
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_T
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_ART_TP
HIV_CXCA
HIV_CXCA_
HIV_CXCA_
HIV_CXCA_
HIV_CXCA_
HIV_CXCA_S
HIV_CXCA_S
HIV_CXCA_S
HIV_CXCA_S
07 - TB/Leprosy | Hospital, Health center, clinic | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 2014; Neha
S.No
TB_COMM
TB_TX_PTB
TB
TB. 1
TB. 2
TB. 3
TB. 4
TB. 5
TB. 6
TB. 7
TB. 8
TB. 9
TB. 10
TB. 11
TB. 12
TB. 13
TB. 14
TB. 15
TB. 16
TB. 17
TB. 18
TB. 19
TB. 20
TB_TX_PTB
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_PTB.
TB_TX_EPT
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_EPTB
TB_TX_RTB
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_TX_RTB.
TB_RET
TB_RET. 1
TB_RET. 2
TB_RET. 3
TB_RET. 4
TB_RET. 5
TB_RET. 6
TB_RET. 7
TB_RET. 8
TB_KEY_P
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
TB_KEY_PO
CDC_TB_R
TB_TX_OUT
TB_CR_PTB
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PTB.
TB_CR_PNT
TB_CR_PNT
TB_CR_PNTB
TB_CR_PNTB
TB_CR_PNTB
TB_CR_PNTB
TB_CR_PNTB
TB_CR_PNTB
TB_CR_EPT
TB_CR_EPT
TB_CR_EPTB
TB_CR_EPTB
TB_CR_EPTB
TB_CR_EPTB
TB_CR_EPTB
TB_CR_EPTB
TB_CR_RTB
TB_CR_RTB
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_CR_RTB.
TB_COMM.
TB_CBTSR.
TB_CBTSR.
TB_DX_PRI
TB_CI
TB_CI.1.1
TB_CI.1.1. 1
TB_CI.1.1. 2
TB_CI.1.1. 3
TB_CI.1.2
TB_CI.1.2. 1
TB_CI.1.2. 2
TB_CI.1.2. 3
TB_CI_SCR
TB_CI_SCR.
TB_CI_SCR.
TB_CI_SCR.
TB_CI_SCR
TB_CI_SCR.
TB_CI_SCR.
TB_CI_SCR.
TB_CI_SCR
TB_CI_SCR_
TB_CI_SCR_
TB_CI_SCR_
TB_TPT
TB_TPT
TB_TPT. 1
TB_TPT. 2
TB_TPT. 3
TB_TPT.1.4
TB_TPT.1.4.
TB_TPT.1.4.
TB_TPT.1.4.
TB_TPT.2.1
TB_TPT.2.1.
TB_TPT.2.1.
TB_TPT.2.1.
TB_TPT.2.5
TB_TPT.2.5.
TB_TPT.2.5.
TB_TPT.2.5.
TB_TPT.3
TB_IPT.3
TB_IPT.3. 1
TB_IPT.3. 2
TB_IPT.3. 3
TB_IPT.3.4
TB_IPT.3.4.
TB_IPT.3.4.
TB_IPT.3.4.
TB_TST-W
TB_TST-WH
TB_TST-WH
TB_TST-WH
TB_TST-WH
TB_TST-WH
TB_TST-WH
TB_DST.1
TB_DST.1.
TB_DST.1.
TB_DST.1.
TB_DST.2
TB_DST.2.
TB_DST.2.
TB_DST.2.
TB_DR_DR.
TB_DR_DR
TB_DR_DR.
TB_DR_DR.
TB_DR_DR.
TB_DR_DR.
TB_DR_DR.
TB_DR_DR.7
TB_DR_DR.7
TB_DR_DR.7
TB_DR_DR.7
TB_DR_DR.
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.1
TB_DR_DR.
TB_DR_DR.2
TB_DR_DR.2
TB_DR_DR.2
TB_DR_DR.2
TB_DR_TX
TB_DR_TX
TB_DR_TX.
TB_DR_TX.
TB_DR_TX.
TB_DR_TX.
TB_DR_TX.5
TB_DR_TX.5
TB_DR_TX.5
TB_DR_TX.5
TB_DR_DST
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DST
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DST
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DST
TB_DR_DST.
TB_DR_DST.
TB_DR_DST.
TB_DR_DS
TB_DR_DST
TB_DR_DST
TB_DR_DST
TB_DR_CTX
TB_DR_CT
TB_DR_CTX
TB_DR_CTX
TB_DR_CTX
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_TxO
TB_DR_TxO.
TB_DR_TxO.
TB_DR_TxO.
TB_DR_TxO.
TB_DR_TxO.
TB_DR_TxO.
TB_DR_CTX
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_CTX.
TB_DR_NUT
TB_DR_NUT.
TB_DR_NUT.
TB_DR_NUT.
TB_MN
TB_MN. 1
TB_MN. 2
TB_MN. 3
TBHIV
TBHIV. 1
TBHIV. 2
TBHIV. 3
TBHIV. 4
TB_HIV_N
TB_HIV_N.
TB_HIV_N.
TB_HIV_N.
TB_HIV_N.
TB_ART.1
TB_ART.1.
TB_ART.1.
TB_ART.1.
TB_ART.1.
TB_ART.1.
TB_ART.1.
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
TB_NEW_AR
LEP_NOT_1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1
LEP_NOT_.1.
LEP_NOT_.1.
LEP_NOT_.1.
LEP_NOT_.1.
LEP_NOT_.1
LEP_NOT_.1
LCS
LEP_CSCR.
LEP_CSCR.
LEP_CSCR.
LEP_DIS.1
LEP_DIS.1.
LEP_DIS.1.
LEP_DIS.1.
LEP_DIS.1.
LEP_TX.r
LEP_TX.r.
LEP_TX.2.
LEP_TX.3.
LEP_TX.4.
LEP_TX.5.
TB_LB
TB_LB. 1
TB_LB. 2
TB_LB_AFB
TB_LB_AFB.
TB_LB_AFB.
TB_LB_Gen
TB_LB_Gene
08.2 - Malaria, NTD, NCD | Hospital, Health center, Clinic | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 20
S.No
MAL
MAL. 1
MAL. 2
MAL. 3
MAL. 4
MAL. 5
MAL. 6
MAL_POS.1
MAL_POS.1.
MAL_POS.1.
MAL_POS.1.
MAL_POS.1.
MAL_POS.1.
MAL_POS.1.
Mal_Travel.
Mal_Noti.
MAL_FULL.1
MAL_FULL.2
MAL_FOCI.1
NTD.
NTD_VL.1
NTD_VL.1.
NTD_VL.1.
NTD_VL.1.
NTD_VL.1.
NTD_VL.1.
NTD_VL.1.
NTD_VL.2
NTD_VL.2.
NTD_VL.2.
NTD_VL.2.
NTD_VL.3
NTD_VL.3.
NTD_VL.3.
NTD_VL.3.
NTD_VL.3.
NTD_VL.3.
NTD_VL.4
NTD_VL.4.
NTD_VL.4.
NTD_CL.1
NTD_CL.1.
NTD_CL.1.
NTD_CL.1.
NTD_CL.1.
NTD_CL.1.
NTD_CL.1.
NTD_CL.2
NTD_CL.2.
NTD_CL.2.
NTD_CL.3
NTD_CL.3.
NTD_CL.3.
NTD_CL.3.
NTD_CL.3.
NTD_CL.3.
NTD_TT.1
NTD_TT.1.
NTD_TT.1.
NTD_TT.1.
NTD_TT.1.
NTD_HYD
NTD_HYD.
NTD_HYD.
NTD_POD
NTD_POD.
NTD_POD.
NTD_POD.
NTD_POD.
NCT_HTN
NCT_HTN
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCT_HTN.
NCD_HTNDX
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX
NCD_HTNDX
NCD_HTNDX
NCD_HTNDX
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNDX
NCD_HTNDX.
NCD_HTNDX.
NCD_HTNTX
NCD_HTNT
NCD_HTNTX
NCD_HTNTX
NCD_HTNTX
NCD_HTNTX
NCD_HTNTX
NCD_HTNTX
CVD
CVD
CVD. 1
CVD. 2
NCD_CVD.2
NCD_CVD.2.
NCD_CVD.2.
NCD_CVD.2.
NCD_CVD.2.
NCD_CVD.3
NCD_CVD.3.
NCD_CVD.3.
NCD_CVD.4
NCD_CVD.4.
NCD_CVD.4.
NCD_CVD.4.
NCD_CVD.4.
DM
NCD_DMDX.
NCD_DMDX.1
NCD_DMDX.1
NCD_DMDX.1
NCD_DMDX.1
NCD_DMDX.
NCD_DMDX.1
NCD_DMDX.1
NCD_DMDX
NCD_DMDX.
NCD_DMDX.
NCD_DMDX.
NCD_DMDX.
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.2
NCD_DMDX.
NCD_DMDX.2
NCD_DMDX.2
NCD_DMTX
NCD_DMTX.
NCD_DMTX
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_DMTX.
NCD_CV_SC
NCD_CV_SC
NCD_CV_SC
NCD_CV_SC
NCD_CV_SCR
NCD_CV_SCR
NCD_CV_SCR
NCD_CV_SCR
NCD_CV_SC
NCD_CV_SCR
NCD_CV_SCR
NCD_CV_TX
NCD_CV_TX.
NCD_CV_TX.
NCD_CV_TX.
NCD_CV_TX
NCD_CV_TX.
NCD_CV_TX.
NCD_CV_TX
NCD_CV_TX.
09.2 - Medical services | Health center | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 2014; Nehase 2014)
S.No
MS
MS. 1
MS. 2
MS. 3
MS. 4
MS. 5
MS. 6
MS. 7
MS. 8
MS. 9
MS. 10
MS. 11
MS. 12
MS. 13
MS. 14
MS_OPD_Nu
MS_BOR
MS_IPD_BO
MS_IPD_BO
MS_ALOS
MS_ALS.1.
MS_ALS.2.
MS_LaBT
MS_LaBT.1.
MS_RoR
MS_RoR.1
MS_RoR.1.
MS_RoR.1.
MS_RI
MS_AMBU
MS_NumRI
MS_NumRI.
MS_NumRI.
MS_AMBU
MS_AMBU.
MS_AMBU.1
MS_AMBU.1
MS_AMBUR
MS_AMBUR
MS_AMBUR1
MS_AMBUR1
MS_AMBURe
MS_AMBUR
MS_AMBUR2
MS_AMBUR2
MS_AMBUR2
MS_AMBUR2
MS_AMBUR2
MS_EMERG
MS_EMERG
MS_EMERG
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG_
MS_EMERG
MS_NumEM
MS_EMERG
MS_EMERG_
HSQI_IPD_
MS_IPD_AR.
HSQI_IPD_
MS_IPIMR.1
MS_IPIMR.1
MS_IPIMR.1
MS_UBDR.1
MS_UBDT.1
MS_UBDT.1.
MS_UBDT.1.
MS_SATIR.1
MS_RTI.1
MS_RTI.1. 1
MS_RTI.1. 2
MS_RTI.1. 3
MS_RTI.1. 4
PMS
PMS.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_AVAIL.
PMS_ABIOT
PMS_ABIOTI
PMS_ABIOTI
PMS_FILL1
PMS_FILL10
PMS_FILL10
PMS_FSML
PMS_MPFM
PMS_MP_N
EIDM_LQA
EIDM_LQA
EBDM.
DQ_DA.1.1.
DQ_DA.1.2.
DQ_DA2.
DQ_DA.2.1.
DQ_DA.2.2.
DQ_DA3.
DQ_DA.3.1.
DQ_DA.3.1.
01.2 - Reproductive and Maternal Health | Hospital, Health center, Clinic | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Ham
Activity

10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
30 - 49 years
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
30 - 49 years
Oral contraceptives
Injectables
Implants
IUCD
Vasectomy
Tubal ligation
Others
Oral contraceptives
Injectables
Implants
IUCD
Vasectomy
Tubal ligation
Others

10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
30 - 49 years

Implants
IUCD
Others

<= 12 weeks
> 12 and <=16 weeks
> 16 weeks
10 - 14 years
15 - 19 years
>= 20 years

10 - 14 years
15 - 19 years
>= 20 years
<= 30 weeks
> 30 weeks

Reactive
Non-Reactive
Reactive
Non-Reactive

Home delivery
Facility delivery
oxytocin
mesoprostol
ergometrin
Other uterotonics
Still birth rate


24Hrs (1day)
25 - 48 hrs (1 - 2 days)
49 - 72 hrs (2 - 3 days)
73 hrs - 7 days (4 - 7 days)
Caesarean section
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
>= 30 years
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
>= 30 years
Oral contraceptives
Injectables
Implants
IUCD
Vasectomy
Tubal ligation
Others
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
>= 30 years
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
>= 30 years
10 - 14 years
15 - 19 years
02 - PMTCT | Hospital, Health center, Clinic | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 2014; Nehase 2014)
Activity
PMTCT
Number of women tested and know their HIV result during the postpartum period
Number of women with known HIV positive status attending ANC, delivery and postpartum for new pregnancy
Number of new HIV positive women during ANC, L&D and Postpartum
Percentage of HIV-positive pregnant women who received ART to reduce the risk of mother-to child-transmission (MTCT) during pr
Number of HIV positive women who received ART to reduce the risk of mother to child transmission during ANC for the first time
Number of HIV positive Pregnant women who received ART to reduce the risk of mother to child transmission during L&D for the first time
Number of HIV positive lactating women who received ART to reduce the risk of mother to child transmission during PNC for the first time
Number of HIV-positive women who get pregnant while on ART and linked to ANC
Total Number of infants within 12 month received virological test result
Number of HIV exposed infants who received an HIV test 0- 2 months of birth
Positive
03 - EPI | Hospital, Health center, Health post, Clinic | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 2014; Nehase 201
Activity
TD Vaccination
BCG doses opened
BCG doses damaged
BCG doses expired
Rota doses opened
Rota doses damaged
Rota doses expired
Polio doses opened
Polio doses damaged
Polio doses expired
TD doses opened
TD doses damaged
TD doses expired
IPV doses given
IPV doses opened
IPV doses damaged
IPV doses expired
HPV Vaccine wastage rate
HPV doses given
HPV doses opened
HPV doses damaged
HPV doses expired
04.2 - Neonatal and Child Health | Health center, Hospital and clinic | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 20
Activity
Child Health
Treated by ORS only
Treatment outcome of neonates admitted to NICU
Total neonates admitted to NICU
Total neonates discharged from NICU
Recovered
Dead
Transferred
Newborns that received at least one dose of CHX to the cord on the first day after birth
Number of Newborns that received at least one dose of CHX to the cord on the first day after birth
Children aged 0 to 59 months Assessed for developmental milestone
0 to 24 months
24 to 59 months
Children aged 0 to 59 months Assessed for developmental milestone and there status
Developmental Delay
05.2 - Nutrition | Hospital, Health center | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 2014; Nehase 2014)
Activity
Nutrition
0 - 5 months
6 - 23 months
0 - 5 months
6 - 23 months
0 - 5 months
6 - 23 months
6 - 11 months
12 - 59 months
First dose
Second dose
First dose
Second dose
10 - 14 years
15 - 19 years
>= 20 years
MUAC < 23 cm
MUAC >= 23 cm
Pregnant
lactating
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
0 - 5 months
6 - 23 months
24 - 59 Months
Admission and treatment outcome for management of severe acute malnutrition in children under 6-59 Months
10 - 14 years, Male
15 - 19 years, Male
Adolescent and Youth Aged 10-19 screened for nutrition-underweight
10 - 14 years, Male
15 - 19 years, Male
Adolescent and Youth Aged 10-19 screened for nutrition-overweight
10 - 14 years, Male
15 - 19 years, Male
06 - HIV | Hospital, Health center, Clinic | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 2014; Nehase 2014)
Activity
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
New positive
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Known positive
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
Directly assisted
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male

>= 50 years, Female
Unassisted
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Pregnant
Non pregnant
4j= ABC +3TC + DTG
4k= AZT + 3TC + DTG
4h=other first line
5n= AZT + 3TC + DTG
5j=other secondline
4d = AZT+3TC+EFV
4j= ABC +3TC + DTG
4k= AZT + 3TC + DTG
4L= ABC + 3TC + EFV
4h=other first line
5h=ABC + 3TC + EFV
5n= AZT + 3TC + DTG
5j=other secondline
4d = AZT+3TC+EFV
4e= TDF+3TC+EFV
4i= TDF + 3TC + DTG
4j= ABC +3TC + DTG
4k= AZT + 3TC + DTG
4L= ABC + 3TC + EFV
4h=other first line
5g= TDF + 3TC + EFV
5h=ABC + 3TC + EFV
5i=TDF + 3TC+ LPV/r
5n= AZT + 3TC + DTG
5o= TDF + 3TC + DTG
5j=other secondline
4d = AZT+3TC+EFV
4e= TDF+3TC+EFV
4i= TDF + 3TC + DTG
4j= ABC +3TC + DTG
4k= AZT + 3TC + DTG
4L= ABC + 3TC + EFV
4h=other first line
5g= TDF + 3TC + EFV
5h=ABC + 3TC + EFV
5i=TDF + 3TC+ LPV/r
5n= AZT + 3TC + DTG
5o= TDF + 3TC + DTG
5j=other secondline

1d = AZT-3TC-EFV
1e = TDF-3TC-EFV
1g= ABC + 3TC + EFV
1j=TDF + 3TC + DTG
1k= AZT +3TC +DTG
1i = Other specify
2e= AZT+3TC+LPV/r
2f=AZT+3TC+ATV/r
2g= TDF-3TC-LPV/r
2h =TDF-3TC-ATV/r
2l=other secondline
3d=Other thirdline
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
ART retention rate (Percentage of adult and children on ART treatment after 12 month of initation of ARV therap
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
Known on ART
Died
Others
Viral load Suppression (Percentage of ART clients with a suppressed viral load among those with a viral load tes
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
< 1 year, Male
1 - 4 years, Male
5 - 9 years, Male
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female

< 1 year, Male
< 1 year, Female
1 - 4 years, Male
1 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Transferred out
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Died
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
By age and Sex
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
By Client Category
Discordant Couple
By age and Sex
15 - 19 years, Male
20 - 24 years, Male
25 - 29 years, Male
30 - 34 years, Male
35 - 39 years, Male
40 - 44 years, Male
45 - 49 years, Male
>= 50 years, Male
>= 50 years, Female
By Client Category
Discordant Couple
Occupational
Sexual violence
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Total MAM
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Total SAM
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
>= 15 years, Male
< 15 years, Male
>= 15 years, Male
Male
Female
Male
Female
Urethral discharge
Scrotal swelling
Vaginal discharge
Inguinal bubo
Neonatal herpes
10 - 14 years
15 - 19 years
20 - 24 years
25 - 29 years
30 - 49 years
Oral contraceptives
Injectables
Implants
IUCD
Others
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Patients on 6H
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Patients on 3HP
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Patients on 3HR
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Screened by VIA
Screened by HPV DNA
Normal cervix:
15 - 19 years
20 - 24 years
25 - 29 years
30 - 49 years
07 - TB/Leprosy | Hospital, Health center, clinic | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 2014; Nehase 2014)
Activity
Number of bacteriologically confirmed New Pulmonary TB cases detected and enrolled in the reporting period
0 - 4 years, Male
0 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 34 years, Male
35 - 44 years, Male
45 - 54 years, Male
55 - 64 years, Male
>=65 yr, Male
>=65 yr, Female
Number of clinically diagnosed New pulmonary TB cases detected and enrolled in the reporting period by age
0 - 4 years, Male
0 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 34 years, Male
35 - 44 years, Male
45 - 54 years, Male
55 - 64 years, Male
>=65 yr, Male
>=65 yr, Female
Number of clinically diagnosed and bacteriological confirmed new EPTB cases detected and enrolled in the rep
0 - 4 years, Male
0 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 34 years, Male
35 - 44 years, Male
45 - 54 years, Male
55 - 64 years, Male
>=65 yr, Male
>=65 yr, Female
0 - 4 years, Male
0 - 4 years, Female
5 - 9 years, Male
5 - 9 years, Female
10 - 14 years, Male
15 - 19 years, Male
20 - 24 years, Male
25 - 34 years, Male
35 - 44 years, Male
45 - 54 years, Male
55 - 64 years, Male
>=65 yr, Male
>=65 yr, Female
Failed, Male
Failed, Female
Diabetes
Homeless
Refugee
Prisoners
Miners
TB Contacts
Total number of bacteriologically confirmed new Pulmonary TB cases enrolled in cohort (PTB+) in the same month of t
Completed
Cured
Lost to follow-up
Dead
Failed
Not evaluated
Completed
Lost to follow-up
Deaths
Failed
Not evaluated
Completed
Lost to follow-up
Deaths
Failed
Not evaluated
Completed
Cured
Lost to follow-up
Dead
Failed
Not evaluated
Number of cohort TB patients (all forms) who were successfully treated (cured plus completed treatment) who received support fo
Total number of patients who started TB treatment in same reporting month of pervious year and who received any form of treatme
Total number of contacts with index bacteriologically confirmed drug susceptible TB cases during the reportin
0 - 4 years
5 - 14 years
>= 15 years
0 - 4 years
5 - 14 years
>= 15 years
0 - 4 years
5 - 14 years
>= 15 years
0 - 4 years
5 - 14 years
>= 15 years
Number of contacts with index bacteriologically confirmed TB (drug susceptible) cases screened negative for TB
0 - 4 years
5 - 14 years
>= 15 years
Number of contacts screened negative for TB and others eligible and put on TB Preventive Therapy (TPT) in th
0 - 4 years
5 - 14 years
>= 15 years
By Regimen Type
3HP
3RH
6H
0 - 4 years
5 - 14 years
>= 15 years
By Regimen Type
3HP
3RH
6H
TPT completion rate
Number of cohort of individuals that completed TPT treatment among those who started 12 months prior to the
0 - 4 years
5 - 14 years
>= 15 years
By Regimen Type
3HP
3RH
6H
0 - 4 years, Male
0 - 4 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
Number of notified bacteriologically confirmed TB cases evaluated for drug susceptibility testing according to
New
New
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Positive
Negative
Unknown
New
Unknown
Shorter regimen
Longer regimen
Positive
Negative
Unknown
New
Unknown
Short term regimen
Long term
Cured
Completed
Died
Failed
Lost to follow-up
Not evaluated
Cured
Completed
Died
Failed
Lost to follow-up
Not evaluated
Cured
Completed
Died
Failed
Lost to follow-up
Not evaluated
Normal
MAM
SAM
Normal
MAM
SAM
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Total number of new and relapse TB patients registered during the reporting period having a documented HIV ne
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
0 - 4 years, Male
0 - 4 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
0 - 4 years, Male
0 - 4 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
TB_Total Number of tests performed using GeneXpert MTB/RIF/Ultra for MTB detection
MTB Detected Rif Resistance not detected
08.2 - Malaria, NTD, NCD | Hospital, Health center, Clinic | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 2014; Nehase
Activity
< 5 years, Male
< 5 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
< 5 years, Male
< 5 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
< 5 years, Male
< 5 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
Cured
Defaulted
Failed
Dead
Referred
Positive
Negative
< 5 years, Male
< 5 years, Female
5 - 14 years, Male
>= 15 years, Male
>= 15 years, Female
Cured
Defaulted
Failed
Dead
Referred
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
< 15 years, Male
>= 15 years, Male
< 15 years, Male
< 15 years, Female
>= 15 years, Male
>= 15 years, Female
Hypertension
18 - 29 years, Male
30 - 39 years, Male
40 - 69 years, Male
>=70 years, Male
>=70 years, Female
Raised BP
Normal BP
18 - 29 years, Male
30 - 39 years, Male
40 - 69 years, Male
>=70 years, Male
>=70 years, Female
Previously in care
Controlled
Uncontrolled
Lost to follow-up
Died
Transferred out
Not evaluated
40 - 59 Years, Male
60 - 74 Years, Male
With Statin
Without Statin
40 - 59 Years, Male
60 - 74 Years, Male
Diabetes mellitus
< 40 years, Male
< 40 years, Female
>= 40 years, Male
>= 40 years, Female
Raised blood sugar
Normal blood sugar
Type I
Type II
Gestational DM
< 15 years, Male
< 15 years, Female
15 - 29 years, Male
30 - 39 years, Male
>= 40 years, Male
>= 40 years, Female
Previously in care
Treatment outcome for cohort of patient registered for diabetes treatment six months prior to the reporting peri
Controlled
Uncontrolled
Lost to follow-up
Died
Transferred out
Not evaluated
< 15 years, Male
< 15 years, Female
15 - 29 years, Male
30 - 39 years, Male
>= 40 years, Male
>= 40 years, Female
Screened by VIA
Screened by HPV DNA
Negative
Suspicious cancerous lesion
Women age 30 - 49 years who have been screened for cervical Ca HPV/DNA screening result
Positive
Negative
Eligible women who received treatment for cervical lesion
Crayotherapy
LEEP
Thermal Abrasion/Thermocoagulation
Women screened for cervical lesion 1 year after treatment follow up by Screening type
Screened by VIA
Screened by HPV DNA
Women screened for cervical lesion 1 year after treatment follow up VIA screening result
Negative
09.2 - Medical services | Health center | Monthly (Hidar 2015; Tikemet 2015; Meskerem 2015; Hamle 2014; Nehase 2014)
Activity
< 5 years, Male
< 5 years, Female
5 - 10 years, Male
11 - 19 years, Male
20 - 29 years, Male
30 - 45 years, Male
46 - 65 years, Male
>= 66 years, Male
>= 66 years, Female
Bed occupancy rate
Referral-out rate
Emergency referral
Referral-ins
Emergency referral
Ambulance service utilization for emergency referral
Pre-facility
Between facility
Trauma
Burn & Poisoning
Others
Admission rate
< 24 hours
>= 24 hours
from blood bank
Vehicle occupant
Motor cyclist
Pedestrian
Others
Pentavalent vaccine
Oxytocine inj
Iron + folic acid
TTC eye ointment
RHZE/RH
TDF/3TC/DTG
Amlodipine tablet
Frusamide tablets
Metformin tablet
Normal Saline 0.9%
40% glucose
Omeprazole capsule
Clients with 100% prescribed drugs filled
Number of clients who received 100% of prescribed drugs
et 2015; Meskerem 2015; Hamle 2014; Nehase 2014)
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCUKumbi PHCU
Sokoru PHCU Total
2131 1842 1447 1718 2025 2103 11266

818 782 810 567 503 550 4030
1 1
65 6 50 83 43 41 288
164 135 190 132 118 141 880
229 400 250 164 158 223 1424
360 241 320 188 184 144 1437
1313 1060 637 1151 1522 1553 7236
5 5
33 18 48 31 62 192
177 137 125 260 209 343 1251
587 456 248 389 536 588 2804
516 467 246 454 746 555 2984
2128 1770 1446 1629 1934 2103 11010
815 710 810 534 480 550 3899
182 127 104 23 60 76 572
359 451 580 391 288 411 2480
272 107 126 117 131 62 815
2 25 3 1 1 32
1313 1060 636 1095 1454 1553 7111

330 98 74 41 117 48 708
771 962 530 791 1134 1194 5382
206 31 203 199 276 915
6 1 60 4 35 106
45 84 28 10 122 289
5 1 19 25
11 26 16 3 36 92
8 41 11 6 57 123
21 17 1 10 49
4 2 6
4 1 5
1 1
4 38 33 15 61 151
319 447 493 565 432 465 2721

175 298 284 238 341 227 1563
25 26 93 31 67 242
119 149 183 234 60 171 916
319 447 493 565 432 465 2721
23 44 143 91 72 373
296 447 449 422 341 393 2348
240 319 344 205 331 207 1646

10 39 49
37 20 58 47 29 191
193 319 324 108 284 178 1406
230 319 344 205 331 217 1646
73 184 64 4 87 412
157 135 344 141 327 130 1234
226 226
245 447 493 565 432 465 2647
114 114
245 447 493 451 432 465 2533
63 63
194 361 493 565 432 402 2447
114 1 115
194 361 493 451 431 402 2332
283 369 342 477 416 400 2287

79 79
79 79
283 369 342 477 416 323 2210

283 369 342 477 416 320 2207
3 3
8.4 15 23.4
4 6 10
283 407 375 473 416 394 2348
283 369 342 473 416 310 2193

283 290 274 403 336 400 1986
283 290 274 382 336 400 1965
3 3
5 5
13 13
7 7
45 54 18 21 76 46 260
20 48 18 13 31 23 153
1 1 2
3 3 3 3 12 16 40
5 15 11 4 9 4 48
5 20 4 3 8 1 41
7 10 3 1 1 22
25 6 8 45 23 107
3 2 12 3 20
9 4 15 6 34
8 1 1 9 8 27
5 5 1 9 6 26
50 54 18 21 71 46 260
50 54 18 21 71 46 260
31 38 18 37 39 163
2 3 2 7
11 8 5 9 19 52
18 10 2 28 18 76
17 11 28
6 3 28 173 63 30 303
2 1 3
6 3 28 173 61 29 300
157 264 228 992 318 116 2075
mle 2014; Nehase 2014)
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
0 4 1 8 0 1 14
326 441 428 579 432 465 2671

326 399 394 579 432 465 2595
42 34 76
1 1
d-transmission (MTCT) during pregnancy, L&D and PNC
g ANC for the first time 1 1
sion during L&D for the first time
ion during PNC for the first time
1 1
1 1
1 1
2015; Hamle 2014; Nehase 2014)
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
88 191 279
68 191 259
20 20
491 412 512 687 390 476 2968
351 404 480 679 456 510 2880
339 411 478 664 450 506 2848
328 406 480 679 453 510 2856
341 409 478 664 450 506 2848
363 407 483 679 453 510 2895
336 389 478 664 450 506 2823
330 392 476 666 456 506 2826
343 412 480 679 447 510 2871
331 406 476 659 432 506 2810
328 389 468 659 423 506 2773
310 408 468 659 423 506 2774
399 389 383 564 360 484 2579
339 350 428 668 447 507 2739
7 7
onth interval from the first dose
302 502 241 440 440 476 2401

235 356 138 423 327 443 1922
28 145 125 344 17 97 756
16 3 40 12 41 112
3 10 1 34 48
-62.6 0 -62.6
88 180 268
70 180 250
33.8 11.1 6.1 19.3 51 33.9 155.2

398 458 590 721 421 476 3064
601 515 628 893 860 720 4217
1.4 0 0 0 -1.1 0 0.3

1046 1196 1126 1997 1347 1522 8234
1061 1196 1126 1997 1332 1522 8234
5.9 3.7 2 2.3 6 2.3 22.2

1073 1196 1033 1997 1347 1428 8074
1136 1242 1054 2043 1433 1462 8370
2 2
2 2
1.1 0 0 0.67 -1.1 0 0.67
697 805 968 1338 893 1016 5717
705 805 968 1347 883 1016 5724
7.4 6.2 4.1 5.9 16.1 10.6 50.3

1026 1196 1046 1882 1347 1529 8026
1108 1275 1091 2000 1605 1710 8789
7.6 6.5 2.2 8.2 19.1 9.9 53.5
714 781 886 1225 793 1014 5413
773 835 906 1335 960 1125 5934
10 10
10 10
5 4.2 2.7 4.2 3.3 3.2 22.6
627 1066 677 1188 793 1326 5677
660 1113 696 1240 820 1370 5899
12.1 13.1 4.9 12.7 19.1 16.4 78.3

394 391 546 666 452 506 2955
448 450 574 763 559 605 3399
100 100
1 1
015; Meskerem 2015; Hamle 2014; Nehase 2014)
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
588 340 518 1064 829 339 3678

121 273 118 185 134 831
11 1 12
11 65 36 5 19 136
110 208 71 180 114 683
542 576 551 944 842 435 3890
542 576 551 944 842 435 3890
57 209 205 102 163 7 743
15 4 2 21
15 4 2 21
15 4 2 21
0 0 0 0 0 0 0
53 150 333 536

53 150 333 536
340 365 655 106 1466
240 202 339 23 804
100 163 316 83 662
240 287 655 1468 1 2651
1 1
1 1
240 287 653 1468 1 2649
2014; Nehase 2014)
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
220 369 349 382 499 395 2214
8013 9773 7997 11487 9015 9746 56031

852 2388 930 912 1262 1178 7522
7161 7385 7067 10575 7753 8568 48509
97 68 615 38 43 25 886
3 14 12 3 32
94 54 603 35 43 25 854
27 19 265 16 18 21 366
4 4 2 10
27 15 261 14 18 21 356
1209 2709 3229 4138 1325 3761 16371

410 905 477 1157 464 798 4211
799 1804 2752 2981 861 2963 12160
1209 2709 3229 4138 1325 3761 16371
869 2709 3192 4138 1004 3323 15235
340 37 321 438 1136
872 1624 1027 2307 630 3251 9711

584 1583 947 2241 630 2910 8895
288 41 80 66 341 816
129 555 738 371 10 218 2021
261 651 551 737 452 553 3205

2 2
28 56 167 91 88 430
233 649 495 570 361 465 2773
4085 1118 1395 2548 1770 3578 14494

123 2 14 47 8 33 227
3962 1116 1381 2501 1762 3545 14267
4005 1009 1689 2545 1577 3575 14400
1632 754 859 1305 1040 1553 7143
2373 255 830 1240 537 2022 7257
14608 17577 12565 21058 17524 23356 106688

292 2163 235 279 50 228 3247
4498 5497 4285 6625 6362 8132 35399
9818 9917 8045 14154 11112 14996 68042
2254 70 1125 47 50 76 3622
4 3 4 11
1181 27 583 28 31 25 1875
1069 40 542 19 15 51 1736
92 12 201 24 27 33 389
8 8
24 7 140 2 18 16 207
68 5 61 14 9 17 174
9 10 8 6 217 250
2 7 3 157 169
7 3 5 6 60 81
25 24 2 51
11 19 1 31
14 5 1 20
7 19 13 39
4 15 11 30
3 4 2 9
2 5 12 19
2 5 9 16
3 3
18 18
15 15
3 3
3 291 294
44 44
2 111 113
1 136 137
16 658 24 217 36 951

9 20 8 37
3 11 22 21 8 18 83
1 1 2
10 10
3 3
3 17 26 27 24 35 132
3 17 28 31 8 34 121
7 19 19 19 64
7 17 21 26 71
8 10 18
10 9 21 26 66
1 1
1 1
12 12
7 7
7 11 15 26 59
431 300 204 155 1090

426 96 75 79 676
128 19 147
118 46 16 4 184
86 8 8 102
94 50 32 67 243
5 86 75 166
1 21 22 44
1 25 35 61
2 11 13 26
1 29 5 35
204 43 1 248
50 12 62
90 13 1 104
64 10 74
8 8
2014; Nehase 2014)
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
1441 575 1359 1014 926 1596 6911
7 7
4 10 14
2 3 7 12
1 12 13
3 3 2 16 24
13 1 12 35 61
31 12 40 4 60 147
73 15 58 156 157 86 545
124 5 133 3 113 378
400 70 237 196 264 196 1363
63 5 226 1 102 397
225 163 170 239 295 164 1256
75 13 87 1 94 270
253 132 182 155 99 246 1067
58 11 48 1 51 169
98 89 99 102 43 53 484
2 15 17 99 65 40 238
14 7 21 23 2 234 301
1 9 11 20 21 62
1 11 7 18 37
6 8 13 1 17 45
1 4 1 1 14 21
1 4 5
1 1
1 1 2
1 1
1 1
2 2
187 187
1179 493 1189 1013 926 1407 6207

1 5 6
0 0 0 0 0 1 1
2 2
1 1
1 1
10 10
6 6
4 4
4 4
2 2
2 2
3 3
1 1
2 2
20 20
8 8
12 12
46 46
16 16
30 30
2 2
2 2
47 47
12 12
35 35
2 2
2 2
36 36
12 12
24 24
12 12
5 5
7 7
16 16
5 5
11 11
9 9
8 8
1 1
2 2
2 2
11 11
9 9
1 1
1 1
4 4
4 4
352 352
72 72
8 8
95 95
74 74
8 8
95 95
14 14
4 4
2 2
2 2
2 2
2 2
2 2
5 5
1 1
1 1
1 1
1 1
1 1
ferred out (net current cohort) 279 279

1 1
1 1
1 1
2 2
8 8
2 2
2 2
2 2
2 2
2 2
2 2
7 7
12 12
12 12
16 16
1 1
29 29
14 14
35 35
35 35
12 12
24 24
24 24
5 5
5 5
7 7
5 5
11 11
5 5
5 5
55 55
8 8
8 8
7 7
12 12
5 5
3 3
8 8
4 4
n the reporting period 67 67
10 10
3 3
9 9
18 18
11 11
10 10
6 6
e reporting period
82 82
1 1
3 3
2 2
6 6
2 2
2 2
1 1
3 3
21 21
29 29
5 5
7 7
120 120
10 10
14 14
28 28
56 56
4 4
8 8
12 12
12 12
r supplementary food
143 143
14 14
22 22
23 23
84 84
ggregated by Age, Sex and Pregnancy)
by age, sex and pregnancy status)

17 17
8 8
9 9
17 17
5 5
5 5
7 7
d of modern family planning by age 282 282
14 14
93 93
175 175
d of modern family planning by method 227 227
55 55
164 164
8 8
44 44
3 3
9 9
8 8
24 24
39 39
3 3
7 7
8 8
21 21
reporting period
3 3
3 3
full course of therapy
57 18 75
57 18 75
57 23 80
11 11
9 9
57 3 60
; Hamle 2014; Nehase 2014)
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
12.2 38.9 2.4 24.3 9.7 19.5 107

3 8 1 3 3 5 23
1 1 2
1 2 3
1 1 1 3
1 1 2
1 1
1 1 2
1 1 2
1 1 2
3 2 5
1 1
1 5 3 9
1 1
2 2
2 2
2 2
1 1
1 1
1 3 4 3 11
1 1
1 1 2
1 1
1 1 2
1 1
1 1
1 1
1 1
1 1
1 1
1 1
2 3 5
3 3
2 2
4 2 1 1 4 12
6 2 1 2 2 4 17
3 3
3 2 1 2 2 4 14
month of the previous EFY 2 1 2 2 7

2 1 5 1 2 11
2 1 5 1 2 11
2 2 4 1 9
1 2 5 1 9
1 2 5 1 9
2 1 1 6 10
who received support fo 2 2 4
eived any form of treatme 2 3 2 7
agnosis or initiation of TB treatment. in the reporti 1 1
11 2 19 10 7 22 71
5 2 3 10
3 13 1 11 28
3 2 4 9 7 8 33
4 2 35 22 63
3 3
1 14 11 26
3 2 21 8 34
2 12 3 17
4 3 7
2 8 10
4 9 24 5 7 3 52
1 16 3 20
3 9 8 5 7 32
6 9 24 1 22 62
5 3 8
1 16 1 11 29
9 8 8 25
1 9 16 1 14 41
1 9 4 1 14 29
12 12
7 9 16
7 7
9 9
1 9 10
1 9 10
5 5
5 5
6 6
5 5
1 1
g a WHO recommended rapid tests (GeneXpert and others) 2 2
1 1
1 1
1 2 5 1 3 12
1 2 1 1 3 8
4 4
1 2 5 8
1 2 5 8
0 1 0 0 1 0 2
revious year (12 month earlier)
e month of the previous year (12 month earlier)

ame month of the previous year (12 month earlier)
24 months earlier.
4 months earlier.
d-line anti-TB treatment regimen 36 months earlier.
mented HIV positive test result 1 1

1 1
4 2 8 3 3 20
2 2 5 1 10
2 3 2 3 10
1 1
1 1
2 2
2 2
6 6
6 6
1 1
1 1
1 2 48 8 8 67
1 1 47 4 53
1 1 8 4 14
1 4 6 8 19
2 3 4 9
1 2 3 4 10
2 2
2 2
rem 2015; Hamle 2014; Nehase 2014)
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
288 175 408 3947 1346 1592 7756
13 16 474 86 201 790
31 1 25 552 93 215 917
48 4 74 669 162 147 1104
47 5 84 720 110 133 1099
83 120 125 718 575 438 2059
66 45 84 814 320 458 1787
28 7 41 543 281 138 1038
35 13 7 55
1 2 40 10 9 62
5 8 110 51 17 191
1 4 82 17 16 120
19 6 18 169 159 46 417
3 9 107 31 43 193
1 83 16 100
27 19 24 20 16 35 141
36 36
36 36
2 1 2 6 1 0 12
5 3 3 28 39
1 1 1 13 16
4 2 2 15 23
57 57
21 21
36 36
167 1197 652 109 822 4831 7778

3 90 50 1 26 368 538
2 101 36 1 33 451 624
25 153 29 25 88 867 1187
24 172 64 1 96 1001 1358
23 252 113 41 223 820 1472
79 274 150 20 251 724 1498
9 74 95 10 48 237 473
2 81 115 10 57 363 628
165 1197 495 109 822 3024 5812
16 15 12 2 17 72 134
149 1182 483 107 805 2952 5678
16 15 12 2 17 1300 1362
3 1 10 1111 1125
13 14 2 2 17 189 237
16 15 7 2 17 136 193
4 4
1 4 5
10 10
1 1 1 40 43
6 7 2 7 45 67
1 6 3 7 17 34
8 1 3 1 7 20
1 9 10
60 13 41 62 17 147 340
60 11 7 17 18 113
2 34 62 129 227
8 13 55 6 18 228 328
8 16 35 6 18 388 471
8 13 35 6 18 388 468
2 2
1 1
1 1
1 1
1 1
1 1
12 13 157 179 361

16 18 34
6 5 11 49 71
4 4 58 41 107
2 4 72 71 149
13 13 54 91 171
2 2 1 32 37
11 11 53 59 134
2 2 1 60 65
2 2 1 60 65
2 2 2 1 80 87
2 2 57 61
2 1 23 26
2 2 79 1 63 147
6 6
15 3 18
20 6 26
35 7 42
9 8 17
2 2 1 24 29
9 9
2 2 1 257 262
2 2 1 247 252
10 10
7 1 1 5 4 113 131
7 1 1 5 4 113 131
7 1 1 5 4 113 131
eporting period by age and sex 1 3 2 12 18

1 1
1 1 2
2 2
1 1 1 10 13
584 321 905

438 321 759
146 146
432 291 723
430 291 721
1 1
1 1
84 84
84 84
84 84
84 84
014; Nehase 2014)
Natri PHCU
Gebjiro PHCU
Baso PHCU
Deneba PHCU
Kumbi PHCU
Sokoru PHCU Total
13792 33973 20941 44290 32206 18383 163585
1526 2225 2570 4993 8359 1463 21136
2165 2718 2644 6163 9157 1685 24532
641 1215 1208 1724 813 858 6459
849 916 780 2451 1104 1297 7397
607 1170 1175 2225 1010 1199 7386
448 3059 1071 2915 940 1001 9434
966 892 950 2830 1614 1238 8490
1432 1707 1061 4567 2559 1403 12729
1127 991 2183 4202 2195 1620 12318

610 1898 1661 2413 1101 1027 8710
473 2853 848 2861 1134 1815 9984
1575 10524 1747 954 238 950 15988

5870 7620 6787 29472 12171 12773 74693
39 50 72 205 98 79 543
6 6 6 34 15 13 80
39 40 20 98 98 65 360
32 33 36 142 50 54 347
0 17 18 17.8 100 71.3 224.1
98 90 72 256 56 183 755

73 76 31 174 11 62 427
25 14 41 82 45 121 328
68 68 39 256 6 142 579

45 60 19 174 32 330
23 8 20 82 6 110 249
71 69 51 205 6 183 585

21 43 19 135 97 315
50 26 32 70 6 86 270
68 68 43 234 6 183 602

61 60 43 178 6 160 508
7 8 56 23 94
93 89 45 243 10 188 668
68 68 39 210 6 183 574
58 60 27 124 6 151 426
5 1 34 4 44
2 6 4 21 19 52
2 1 3
3 2 5 31 8 49
53 10 109 172
53 158 109 320
8 13 75 50 89 235
7 50 105 171 12 345

3 36 8 2 49
4 9 52 3 8 76
17 69 2 88
41 91 132
4 4 5 5 5 4 27
4 5 5 5 5 4 28
4 5 5 5 5 4 28
4 5 5 5 5 4 28
4 5 5 5 5 4 28
4 5 5 5 5 4 28
3 5 5 5 5 4 27
4 4 5 5 5 4 27
4 5 5 4 5 4 27
4 5 5 5 5 4 28
4 4 4 5 5 4 26
4 4 3 3 5 4 23
4 5 5 5 5 4 28
3 4 3 4 5 4 23
3 5 5 4 5 4 26
4 4 5 4 5 4 26
4 5 4 5 5 3 26
4 5 5 4 5 4 27
4 5 5 5 5 4 28
4 5 4 5 5 4 27
4 3 4 4 5 4 24
4 4 5 5 5 4 27
4 4 5 5 5 4 27
4 4 3 5 5 4 25
4 3 3 5 5 4 24
98.9 100 58.5 100 82.4 102 541.8
1505 7350 2257 11684 11109 13020 46925
1521 7350 3861 11684 13479 12759 50654
4456 4647 3059 21848 12769 13020 59799

4558 6403 3861 21932 12769 13020 62543
100.5 100 79.7 100 100 100 580.2
3255 7550 3201 17459 41548 13007 86020
3240 7550 4017 17459 41548 13007 86821
6 6 6 7 12 7 44
95 85.8 87.5 93.1 79.2 93.8 534.4
95 90.8 85.8 93.8 90 93.8 549.2
6 6 6 6 13 7 44
95 91.7 85 88.1 80.4 90.7 530.9
95 92.5 89.2 93.8 90 91.4 551.9
1 1 1 1 1 1 6
95 95 90 95 90 95 560
95 95 90 95 90 90 555

5month DHIS

Uploaded by

Copyright:

Available Formats

5month DHIS

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

5month DHIS

Uploaded by

Copyright:

Available Formats

01.

RMH Reproductive and Maternal Health

RMH_FP_IPImmediate Postpartum Contraceptive Acceptance (IPPFP)

RMH_FP_L Premature Removal of Long term family planning methods (PRLAFP)

MAT_ANC1 Antenatal Care (ANC) coverage 鈥

MAT_ANC4 Antenatal care (ANC) coverage 鈥

MAT_ANC8 Antenatal Care (ANC) coverage 鈥

RMH_ANC_Pregnant women attending antenatal care tested for syphilis

RMH_L&D_ Births attended by skilled health personnel

MAT_EPNC.Early postnatal care coverage

RMH_L&D_ Caesarean section

MAT_IMD Proportion of maternal death(institutional)

HIV_TX_CUChildren currently on ART aged 5-9 yr on by regimen type

750 363 416 470 425 365 2789

486 190 150 312 298 278 1714

9.9 14.3 24.2

242 74 95 145 66 73 695

160 75 96 128 74 100 633

83 75 133 134 81 111 617

6 month interval from the first dose

16.4 18 13.6 18.5 42.8 39.2 148.5

13.4 4.2 4 2.4 7.6 3.5 35.1

15 5 7.1 10 17.3 14.8 69.2

2.8 7.3 4 6.9 21.9 13.7 56.6

18.3 11.8 12.7 10.7 21 20.7 95.2

186 1187 1373

1472 1917 1465 1697 1948 870 9369

223 552 1457 452 245 365 3294

834 211 261 162 487 521 2476

1270 679 1104 323 2001 3137 8514

244 105 349

utic or supplementary food

disaggregated by Age, Sex and Pregnancy)

ated by age, sex and pregnancy status)

method of modern family planning by age 54 54

n the reporting period

ted a full course of therapy

reporting period 60.8 12.2 73

ng period by age and se 2 2

ame month of the previous EFY

uring the reporting Month by age

ned negative for TB in the reporting period

herapy (TPT) in the reporting period by Age Group

ting according to national policy during the reporting month

(12 month earlier)

same month of the previous year (12 month earlier)

men 24 months earlier.

men 24 months earlier.

econd-line anti-TB treatment regimen 36 months earlier.

documented HIV positive test result

documented HIV negative test result

the reporting period 1 1 2 79 83

the reporting period by age and sex 1 1

305 235 89 783 383 184 1979

1504 135 1021 233 94 231 3218

RMH_FP_IPImmediate Postpartum Contraceptive Acceptance (IPPFP)

RMH_FP_L Premature Removal of Long term family planning methods (PRLAFP)

MAT_ANC1Antenatal Care (ANC) coverage 鈥

MAT_ANC4Antenatal care (ANC) coverage 鈥

MAT_ANC8Antenatal Care (ANC) coverage 鈥